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Abstract: 
 The use of stereoselective aminohydrolases (acylases) in kinetic resolutions is 
a commonly employed industrial route to both L- and D- α-amino acids from N-
acetylated-DL-starting materials. However, a flaw in this process is the need for 
repeated racemisation steps of the non-desired enantiomer to achieve yields >50%. A 
solution to this drawback would be a dynamic kinetic resolution driven by an in situ 
racemisation step that would allow the yield to approach 100% (Figure 1). 
 
Figure 1. A proposed NAAAR/acylase coupled dynamic kinetic resolution of an enantiopure 
amino acid.  
A cheap and “green” catalyst for this racemisation would be an enzyme such 
as N-acyl amino acid racemase (NAAAR) from the actinobacteria Amycolatopsis sp. 
Ts-1-60. This enzyme requires no organic cofactor, is stable at high temperatures 
(~60°C) and importantly, shows no racemase activity toward free amino acids. 
Unfortunately, the activity of NAAAR with N-acetyl substrates is low and reported 
to suffer from inhibition above substrate concentrations of 50 mM, prohibiting its use 
in NAAAR/acylase coupled dynamic kinetic resolutions under industrial conditions. 
In an attempt to remove these limitations, directed evolution has been applied 
to the Amycolatopsis Ts-1-60 NAAAR to engineer a variant enzyme with increased 
activity towards N-acetyl substrates. An improved variant NAAAR may allow for a 
commercial NAAAR/acylase coupled dynamic resolution process. Directed 
evolution has proven to be a highly versatile and successful tool for protein 
engineering. However, the ability to screen for improved variants is often technically 
difficult or time consuming and in the case of NAAAR this is especially true as the 
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substrate and product are simply enantiomers of an N-acetyl amino acid. To 
overcome this, an enantioselective genetic selection system has been employed to 
allow the screening of mutagenic NAAAR libraries. After several rounds of 
selection, a NAAAR variant (NAAAR G291D F323Y) has been isolated with 
increased racemase activity towards a range of synthetically useful N-acetyl 
substrates. This enzyme has been over-expressed, purified and its characteristics 
compared to the wild-type and other variants discovered during the evolution 
process. NAAAR G291D F323Y has been crystallised to 2.71 Å allowing a 
molecular basis for the increase in catalytic activity to be proposed.  
Coupling of this enzyme with a stereoselective acylase has been used to 
produce enantiopure amino acids in >99% yield, twice the inherent 50% maximum 
yield of acylase based resolutions. Early results suggest this NAAAR variant has the 
potential to be employed on a multi kilogram scale for the economical production of 
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1.1, Enzymes as biocatalysts:  
Enzymes have been used for several thousand years to carry out simple 
chemical reactions (biotransformations), for example the fermentation of ethanol 
from sugar by Saccharomyces cerevisiae (baker’s yeast)
[1]
. The science behind these 
processes was of course a mystery to our ancestors, but today we have the knowhow 
and ability to use enzymes to carry out a number of chemically exotic and diverse 
biotransformations. In the previous century an improved understanding of both 
enzymology and recombinant protein expression has allowed biocatalysis to become 
an established branch of chemical synthetic techniques
[2-7]
. It is generally viewed as a 
“greener” alternative to traditional chemocatalysis due to the mild conditions 
required for many enzymatic reactions, and this no doubt fuels a large amount of the 
interest that exists in the field
[8, 9]
. Chemical feed stocks (both organic and metallic) 
are dwindling and biocatalysis may help to alleviate some of the demands on these 
resources
[10-12]
. However, biocatalysis often struggles to match chemical means in 
terms of cost, as it is still relatively expensive to develop an effective biocatalyst. For 
this reason, biocatalysis is mostly used in the realm of pharmaceutical and fine 
chemicals where the low volume/high value adage exists
[13]
. Yet, there are 
exceptions, such as the synthesis of acrylamides from acrylonitriles by Nitrile 




Figure 2. Nitrile hydratase mediated hydrolysis of acrylonitriles to generate acrylamide.  
This biocatalytic route to acrylamides proved to be cheaper, more environmentally 
friendly, and resulted in an improved yield and purity of final product compared to 
the previous chemo-catalytic route
[15]
. NHase is only one of a number of commonly 
used biocatalysts, most of which belong to distinct enzyme classifications dependent 
on their chemistry. Directed evolution and protein engineering will no doubt help to 
improve the range of available biocatalysts and possibly overcome the inherent 
problems (low substrate range, activity and stability) limiting their application
[16-18]
. 
This PhD project seeks to develop an economic process to α-amino acids 
which are useful intermediates in the pharmaceutical and fine chemical industries. To 
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introduce the subject, examples of reaction types and enzymes that are relevant to the 
industrial production of these building blocks are given below.  
1.2, Types of enantioselective biocatalytic reactions: 
In the field of biocatalysis, there are three general reaction types that can be 
used to synthesise enantio-pure α-amino acids – kinetics resolutions, dynamic kinetic 
resolution/de-symmetrisations, and asymmetric synthesis reactions. 
1.2.1, Kinetic resolutions: 
 Kinetic resolutions (KRs) are employed to resolve a racemic starting material 
into a single enantiomer in a 50% yield. The process can be operated such that the 
desired product is formed during the biotransformation, or that the biocatalyst only 
transforms (removes) the unwanted enantiomer leaving the desired product un-
reacted. In either case, only a 50% yield can be achieved. A typical (and appropriate) 
example of this process would be the use of an enantioselectivity acylase to de-
protect a racemic N-acyl amino acid (Figure 3). In these reactions, the relative rates of 
reaction with each enantiomer need to be significantly different to allow for the 
resolution to proceed with high e.e. If cost allows, it may be possible to racemise or 
recycle the ‘off’ enantiomer and repeat the biotransformation to increase the yield 
above 50%, however the process needs to be repeated 7 times to reach a theoretical 
yield of 99% making this un-attractive unless the substrate is expensive or in low 
supply. 
 
Figure 3. The kinetic resolution of a D-amino acid from racemic N-acetyl-amino acid starting 
material with a D-amino hydrolase. 
1.2.2, Dynamic kinetic resolutions/de-symmetrisations: 
The second type of biocatalytic reaction is an improved form of the KR 
which allows for yields greater than 50% to be achieved in a single pot reaction.  
Dynamic kinetic resolutions (DKRs) employ a racemising agent selective for the 
substrate (either chemical or enzymatic) to racemise the ‘off’ enantiomer allowing 
for it to be continually converted to desired product. Unlike substrate recycling 
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which can be performed once a KR has reached its 50% yield end point, the 
racemisation is done continually, in situ (Figure 4A). The term DKR is applied to 
resolutions in which the product is formed as the reaction proceeds, allowing the 
unreacted starting material to be racemised. A form on DKR in which the racemic 
starting material is converted to a single enantiomer of that material is called a de-
symmetrisation. Here, an enzyme is used to transform one enantiomer, and this 
molecule then chemically converted back to chiral starting materials. As a result, a 
single enantiomer constantly undergoes racemisation leading to a decrease in its 
concentration until it has been completely removed (Figure 4B). Both processes can 
lead to a theoretical 100% conversion and 100% e.e. During a DKR, a chemical 
transformation takes place that involves either bond breaking or bond making, 
whereas during de-symmetrisation the starting material undergoes no net chemical 
change other than stereoinversion. 
 
Figure 4. A) The dynamic kinetic resolution of a D-amino acid by in situ racemisation of an N-
acetyl amino acid and hydrolysis by a D-amino hydrolase. B) De-symmetrisation of a chiral 
amino acid to generate a D-amino acid in 100% yield and e.e. with an L-amino acid oxidase and 
a chemical reduction step. 
1.2.3, Asymmetric synthesis: 
The final reaction involves the biotransformation of a prochiral starting 
material to give an enantiopure product. An example of this type of reaction would 
be the reductive amination of a keto acid by an oxidoreductase to give an enantiopure 
amino acid (Figure 5). Such reactions suffer from the need for an amine donor in 
stoichiometric amounts relative to the substrate which increases the overall cost. 
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Figure 5. Asymmetric synthesis of a D-amino acid using a D-amino acid oxidase by reductive 
aminiation of a keto acid. 
Often, any of these three possible reaction types can be used to generate an 
enantiopure amino acid, and the decision on which route to take inevitably comes 
down to substrate availability/cost, and of course the availability of a biocatalyst 
capable of the desired transformation. The list of possible biocatalysts is ever 
expanding; however there are several class of enzyme which make up the bulk of 
those that can be applied to the production of α-amino acids. A list of these classes 
and brief examples are given below. 
1.3, Nitrilase (EC 3.5.5.1) 
 Nitrilases (Nitrile aminohydrolase, NIase) convert nitriles into carboxylic 
acids with high enantio- and regio-specificity (Figure 6A)
[19, 20]
. They can be used to 
hydrolyse N-acetylated aminonitriles to N-acetylated amino acids with high yield and 
e.e. in a DKR process due to the self-racemisation of N-acylated aminonitriles. 





Figure 6. A) NIase hydrolysis of a nitrile to a carboxylic acid. B) NIase hydrolysis of an N-
acetylated aryl-aminonitrile to yield an enantiopure N-acetyl-D-amino acid. This could then be 
de-protected by a D-acylase to yield the free amino acid. 
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1.4, Amino acid ammonia lyase (EC 4.3.1.x) 
 Amino acid ammonia lyases carry out the addition of ammonia to an α,β-
unsaturated carboxylic acid to yield an enantio-pure amino acid
[22, 23]
. This class of 
enzyme was first employed in 1960 for the production of L-aspartic acid from 
fumaric acid by Japanese company Tanabe Seiyaku
[24]
. Common amino acid lysases 
include aspartic acid ammonia lyase (Aspartase), phenylalanine ammonia lyase 





Figure 7. Amino acid lyases: A) aspartic acid ammonia lyase. B) phenylalanine ammonia lyase. 
C) histidine ammonia lyase. D) methyl-aspartic acid ammonia lyase. 
1.5, Lipase (EC 3.1.1.3)  
Lipases can be used for the kinetic resolution of carboxylic acids, secondary 
alcohols and primary amines
[29]
. They are one of the most versatile and well used 
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biocatalysts due to their high regio- and enantio- selectivity. These enzymes also 
have a high tolerance to organic solvent making them especially appealing for 
organic synthetic use
[30]
. The lipase reaction is reversible with both ester hydrolysis 
and trans-esterification reactions being catalysed (Figure 8A). The reaction 
equilibrium can be pushed towards either product by selection of the solvent
[2]
. Using 
lipases, amino acids can be resolved from DL-amino acids to give an amino acid ester 
and an α-amino acid (Figure 8B)
[31, 32]
.  
1.5.1, Dynamic kinetic resolution of amino acid derivatives using lipase and 
a chemocatalyst: 
Using a combination of chemocatalysis and lipases, DKRs of DL-amino acid 
amides have been carried out
[33]
. In this process the lipase is employed as the 
resolving agent, and a Palladium catalyst as the racemisation agent (Figure 8C). 
Hydrolysis of both amides would yield an enantio-pure amino acid in >99% 
theoretical yield and e.e.  
 
Figure 8. A) Kinetic resolution of an ester by hydrolysis. B) Kinetic resolution of L-
phenylalanine from DL-phenylalanine ethyl ester. C) Combined chemo/biocatalytic DKR of 
enantiopure amino acid amides.  
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1.6, Amino acid oxidases (L-specific EC 1.4.3.2, D-specific EC 1.4.3.3) 
Amino acid oxidases (AAOs) catalyse the stereoselective oxidative 
deamination of amino acids to their corresponding keto acid releasing ammonia as a 
side product (Figure 9A)
[34-36]
. Both L- and D- AAOs use flavin adenine dinucleotide 





Figure 9. A) The oxidative deamination of an L-amino acid by L-AAO to yield a D-amino acid. 
B) Flavin oxidised and reduced forms. 
1.6.1, Desymmetrisation using AAO: 
AAOs have been used to carry out the deracemisation of chiral amino acids 
by interrupting the hydrolysis with a mild chemical reducing agent
[40]
. Under the 
correct conditions, the prochiral imino acid is reduced to regenerate the racemic 
starting material. This reduction is typically carried out using NaBH3(CN), amine-
borane complexes or catalytic transfer hydrogenation, which allow reduction under 
conditions that are compatible with optimal enzyme activity (i.e. at neutral pH)
[36]
. 
This selective-oxidation/non-selective reduction gives rise to a cycle which will 
eventually leave only the enantiomer on which the AAO is un-reactive. Catalase (EC 
1.1.1.6) can be incorporated into this reaction to remove the potent H2O2 oxidant, 
arising as a by-product of cofactor recycling (Figure 10A)
[41]
.  
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1.6.2, Use of D-AAO in production of 7-aminocephalosporanic acid: 
This D-AAO/Catalase system is employed in the industrial production of 7-
aminocephalosporanic acid (7-ACA), a key intermediate in the synthesis of semi-
synthetic penicillins, from cephalosporin C (Figure 10B)
[39, 42-44]
. A third enzyme, 
Glutaryl acylase (GAC, EC 3.5.1.93), hydrolyses the non-lactam amide bond in α-





Figure 10. A) The deracemisation/ de-symmetrisation of amino acids using D-AAO. B) 
Production of 7-ACA from Cephalosporin C with D-AAO/Catalase/GAC. 
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1.7, Amino acid dehydrogenases (L-specific EC 1.4.1.5, D-specific EC 
1.5.5.1) 
Amino acid dehydrogenases (AADs) catalyse the oxidation of amino acids to 
their corresponding keto acids releasing ammonia as a side product in a similar 
fashion to AAOs (Figure 11A)
[46]
. The difference being that as ADDs use 
nicotinamide adenine dinucleotide (NAD
+
), instead of the flavin cofactor used by 
AAOs, they do not generate hydrogen peroxide. ADDs are frequently used in the 
asymmetric synthesis of L-amino acids, but they can also be used in the resolution of 




Figure 11. A) Comparison of amino acid oxidases (AAO) and amino acid dehydrogenases 
(AAD). B) The kinetic resolution of D-phenylalanine by L-AAD. 
To date, all known AADs have been L-enantioselective; however a novel D-
enantioselective AAD has been developed by protein engineering
[48]
. The 
dehydrogenase reaction is reversible and can be operated in reverse (synthesis 
direction) to perform asymmetric synthesis of enantiopure amino acids from 
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prochiral keto acids. The thermodynamics of this process favour the formation of the 
aminated product promoting high yields of the desired amino acid
[46]
.  
1.7.1, Use of L-ADD in the asymmetric synthesis of L-tert-leucine: 
An established AAD process run in this manner is used to generate L-tert-
leucine from the corresponding keto acid, trimethylpyruvic acid
[49]
. Leucine 
dehydrogenase (LeuDH, EC 1.4.1.9) is used in this process along with Formate 
dehydrogenase (ForDH, EC 1.2.1.43) which is used to recycle the expensive oxidised 
NAD
+
 co-factor back to its reduced form (Figure 12).  
 
Figure 12. The asymmetric synthesis of L-tert-leucine from trimethylpyruvic acid by LeuDH and 
a ForDH NADH recycling system. 
1.7.2, Use of L-ADD in the kinetic resolution of D-tert-leucine: 
D-tert-leucine can be accessed by carrying out a kinetic resolution of DL-tert-
leucine again using LeuDH. However, as explained, the oxidative deamination of L-
tert-leucine is a non-favourable reaction and must be driven with the use of 




Figure 13. The kinetic resolution of D-tert-leucine from DL-tert-leucine with LeuDH. 
1.8, Transaminases (EC 2.6.1.x) 
Transaminases catalyse the transfer of an amino group from an amine donor 
to a keto acid in a pyridoxal-5’-phosphate (PLP) dependent reaction (Figure 14A)
[51, 
52]
. The reverse reaction, using pyridoxal-5’-amine (PMP) as a cofactor, can be 
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referred to as an aminotransferase reaction. Transaminases can have both excellent 
regio- and enantio-selectivity, with both (R)- and (S)- transaminases being 
available
[53]
. Their regioselectivity has led to them being split into two types; α-
Transaminases which are active on α-amine of amino acids and ω-Transaminases 
which are active on a non-α-amine in an amino acid, such as Orthinine transaminase 
(OTA, EC 2.6.1.13), or amino compounds which do not contain a carboxylic acid
[54]
.  
1.8.1, Kinetic resolutions using Transaminases: 
The enantioselectivity of transaminases makes them ideal for the resolution 
of racemic amines; however, the need for at least stoichiometric quantities of the 
amine acceptor drives up the cost of these processes. Kinetic resolutions can be 
driven towards the product by use of an amine acceptor that will become the product 
for another enzyme, for example pyruvate can act as an amine acceptor to yield L-
alanine which will then feed into the L-AAO pathway and then be oxidised back to 
pyruvate
[55]
. Using this method, only catalytic amounts of amine acceptor are 
required (Figure 14B). 
1.8.2, Asymmetric synthesis using Transaminases: 
When used in the synthesis direction (prochiral keto acid to amine product) 
enantiopure amines can be readily generated
[56, 57]
. This leads to a situation in which 
both enantiomers of an amine can be generated with a single enantioselective 
transaminase, either by kinetic resolution, or asymmetric synthesis
[55]
. Careful 
selection of the amino/keto donor can help to drive the synthesis direction reaction to 
completion, for instance the use of isopropylamine as an amino donor will generate 
acetone as the keto product which will be removed from the equilibrium by 
evaporation
[18]
. Another approach is to generate a keto product which becomes the 
substrate for a second enzyme, for instance, the use of alanine as the amine donor 
will generate pyruvate as the keto product. This can then be removed from the 
reaction equilibrium by Pyruvate dehydrogenase (PDH, EC 1.2.4.1)) which converts 
it to acetyl-CoA, however this approach introduces added complexity in the need for 
source of CoA (very expensive) and a Glucose dehydrogenase (GDH, EC 1.1.99.10) 
NAD
+
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Figure 14, A) Transamination and aminotransferase reactions catalysed by an α-Transaminase 
and PLP/PMP. B) The kinetic resolution of a D-amino acid from DL-amino acid and asymmetric 
synthesis of the L-amino acid from the keto acid, both catalysed by the same L-selective α-
Transaminase.  
1.9, The Hydantoinase process 
The Hydantoinase process utilises a Hydantoinase (Dihydropyrimidinase) (L-
specific EC 3.5.2.2 / D-specific EC 3.5.2.3) and Carbamoylase (L-specific EC 
3.5.1.77 / D-specific EC 3.5.1.87), to resolve a cyclic, racemic hydantoin into an 
enantiopure amino acid via a multi-step process (Figure 15)
[59, 60]
. The use of a 
Hydantoin racemase (EC 5.1.99.5) or suitable reaction conditions (> pH 8.0) allows 
this to be a DKR process
[61]
. The cyclic hydantoin is first stereoselectively 
hydrolysed to give the N-carbamoyl-amino acid, which is then hydrolysed again by 
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an N-carbamoylase, (Figure 15). This process is used commercially to produce L- and 










modified Hydantoinase process that incorporates NAAAR has also been reported
[66]
. 
In this work, an engineered Hydantoinase with increased L-selectivity (although not 
entirely specific) was used to resolve DL-homophenylalanylhydantoin (DL-HPAH) to 
N-carbamoyl-L-homophenylalanine (N-carb-L-HPA), which was then converted to L-
homophenylalanine (L-HPA) by an N-L-carbamoylase. By incorporating NAAAR 
(from Deinococcus radiodurans), the low enantioselectivity of the Hydantoinase was 
overcome by racemisation of any N-carb-D-HPA to the N-carb-L-HPA, so that it 
could then be a substrate for the highly L-enantioselective N-Carbamoylase. 
Inclusion of NAAAR increased yield of L-HPA from 60% to 90%.  
 
Figure 15. The hydantoinase process for resolution of both L- and D- amino acids. 
1.10, Amidases (EC 3.5.x.x) 
Amidases (also referred to as aminohydrolases or acylases) catalyse the 
hydrolysis of a amide bond to generate a amine and carboxylic acid, one of which is 
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usualy chiral (Figure 16)
[67]
. They are commonly used in the resolution of α-amino 
acids as both amino acid amides and N-acylated amino acids can be resolved. 
 
Figure 16. The amide hydrolysis reaction catalysed by an amidase. 
1.10.1, The use of amidases (acylases) in the production of semi-synthetic 
penicillins:  
Penicillin G and penicillin V amidases (PGA/PVA, EC 3.5.1.11) are two of 
the most commonly used industrial amidases
[68-70]
. They are commonly referred to as 
Penicillin acylases. Although the product from these processes is not an α-amino acid 
they are fine examples of acylase based processes and warrant discussion here. PGA 
is used in the production of (+)-6-aminopenicillanic acid (6-APA) and 7-amino-3-
deacetoxy cephalosporanic acid (7-ADCA), key intermediates in synthesis of 
numerous semi-synthetic penicillins
[71-73]
 (Figure 17A and Figure 17B). Another key β-
lactam intermediate, 7-ACA, is produced using a separate acylase (GAC) and D-
AAO (See section 1.4.2)
[45]
. Although not economical, ampicillin can be synthesised 
via the condensation of D-phenylglycine amide (or methyl ester) and 6-APA
[74, 75]
. In 
this case, the carboxylic acid is added as the amide/ester derivative which first forms 
an enzyme-acyl intermediate. This can either undergo hydrolysis to yield D-
phenylglycine, or aminolysis with 6-APA to yield ampicillin (Figure 17C). The 
hydrolysis of D-phenylglycine amide (from the acyl intermediate, generating the free 
amino acid) occurs more slowly than aminolysis but still has a detrimental effect on 
product yield. 
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Figure 17. A) The acylase hydrolysis of penicillins to yield 6-APA B) The acylase hydrolysis of 
penicillins to yield 7-ADCA C) The acylase mediated synthesis of ampicillin via initial D-
phenylglycine-enzyme (acyl-enzyme) intermediate formation, followed by condensation with 6-
APA to yield the desired semi-synthetic ampicillin.  
1.10.2, The use of amidases to resolve DL-amino acid amides: 
Amidases can also be used to resolve DL-amino acid amides, in which case 
the carboxylic acid is the chiral product. The recent discovery that α-amino-ε-
caprolactam racemase (ACL, EC 5.1.1.15) can racemise amino acid amides has led 
to the possibility of this process being implemented as a DKR (Figure 18A)
[76, 77]
. 
ACL racemase was originally used in combination with an L-ACL hydrolase to 
resolve DL-ACL to L-lysine (Figure 18B)
[78]
.  
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Figure 18. A) An amidase/ACL racemase DKR of a D-amino acid. B) L-ACL hydrolase/ACL 
racemase DKR of α-amino-ε-caprolactam to produce L-lysine.  
1.10.3, The use of acylases in the kinetic resolutions of N-acyl-DL-amino 
acids: 
Amidases (acylases) are key enzymes used in the resolution of N-acylated 
amino acids
[79-81]
. This process generates a waste carboxylic acid and chiral amine 
(amino acid)
[82]
. Their high activity and broad substrate tolerance, coupled with their 
excellent enantioselectivity makes them ideal biocatalysts. The original amidase 
enzymes were purified from mammalian sources such as porcine kidney, however 
many bacterial examples are known today, including an L-acylase from 
Thermococcus litoralis and D-acylase from Alcaligenes denitrificans, both of which 
are used industrially
[83-88]
. However, a flaw with these acylase based resolutions is 
that as the starting material is often chemically synthesised, it is racemic, resulting in 




Figure 19. The resolution of an α-amino acid using an L-acylase. 
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The waste enantiomer can be recycled by chemical racemisation, and the resolution 
repeated, but as this needs to be performed seven times to approach a theoretical 
yield of 99%, it is more likely that this enantiomer will be discarded. This problem 
has not hindered the acylase process becoming a well-established route to many L- 




1.10.4, The dynamic kinetic resolution of N-acyl-DL-amino acids using an 
acylase and a racemase: 
An obvious improvement in this process would be an in situ racemisation 
step that would be specific for the N-acyl substrate and leave the free amino acid 
product in high e.e.
[89]
. A commercial N-acyl amino acid racemase is available (Rac 
101, Biocatalytics), but this enzyme has several problems associated with it, such as 
poor activity towards the desired N-acetyl substrates and low thermostability. These 
observations are not surprising considering that Rac101 is a Proline racemase (ProR, 
EC 5.1.1.4) from Clostridium sticklandii (ATCC 12662), a non-thermophilic 
bacterium
[90]
. Many patents have been granted describing NAAAR enzymes and 
processes involving their use, but no enzyme has yet been disclosed that is effective 
economically under industrial conditions (for examples, see patents EP 1074628 B1, 
US 6372459, EP 0304021 B1, and US 7629154). If an industrially practical NAAAR 
could be developed it would allow acylase based processes to become even more 
useful and may allow for novel, cheaper routes that can compete with the established 
methods mentioned above. 
1.11, Aims of this project: 
The aim of this project is to investigate and develop possible industrial 
NAAAR biocatalysts that will allow the acylase kinetic resolutions of N-acetyl-DL-
amino acids to become efficient DKRs (Figure 20).  
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Figure 20. A NAAAR/acylase coupled dynamic kinetic resolution.  
There are successful literature examples of NAAAR/acylase DKRs being 
utilised to produce enantiopure amino acids from N-acetylated racemic starting 
materials, but these also highlight the problems with low activity and substrate 
inhibition associated with NAAAR
[91, 92]
. The reported substrate inhibition above 50 
mM would limit processes to less than 10 g L
-1
 for an average N-acetyl amino acid 
which is not cost effective and well short of the ideal 50 g L
-1[82]
. To address these 
problems, a directed evolution approach was proposed in order to attempt to increase 
NAAAR activity towards a range of industrially relevant N-acetyl-amino acids at 
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2.1, Discovery of NAAAR: 
NAAAR activity was first reported by Toukyama et al in Streptomyces 
atratus Y-53 after screening of ~49,000 bacterial, actinomycetes, fungal and yeast 
strains
[91, 93-95]
. Further screening revealed a series of NAAAR enzymes from 
Amycolatopsis sp., all of which share >90% homology with each other
[96, 97]
. Of these 
enzymes, NAAAR from Amycolatopsis Ts-1-60 (Am. Ts-1-60) has the highest 
reported activity on N-acetyl derivatised substrates; however it is also reported to 
suffer from substrate inhibition above 50 mM. This inhibition is also described for a 
less active NAAAR homolog from Amycolatopsis azurea, but not in Amycolatopsis 
orientalis subsp. lurida. None of these enzymes have the required levels of activity 
that would justify the cost of their inclusion in an industrial process. Several other 
bacteria have been found to contain NAAAR enzymes, two of which, Thermophilus 
thermus, and Deinococcus radiodurans, have been crystallised, along with Am. Ts-1-
60
[98-100]
. There are literature examples of NAAAR/acylase coupled DKRs being 
employed to produce enantiopure amino acids such as L-/D-methionine and L-
homophenylalanine, however, there have been no published examples of this process 
applied at large scale
[91, 92]
. As a result, NAAAR is often neglected in literature 
reviews dealing with industrial enzymes, understandably replaced with more 
effective and commonly used biocatalysts. Despite this, Am. Ts-1-60 NAAAR has 
been well studied by Gerlt et al, due to it being a member of the enolase 
superfamily
[101-106]
. NAAAR was found to be a promiscuous enzyme catalysing both 
the afore mentioned racemase reaction and the dehydration of 2-hydroxy-6-succinyl-
2,4-cyclohexadiene carboxylate (2-HSCHC) to give o-succinylbenzoate (OSB). The 
o-succinylbenzoate synthase (OSBS, EC 4.2.1.113) reaction was found to be 10 fold 
faster than the N-acetyl racemase reaction, leading to the NAAAR protein being 
reassigned as an OSBS with low levels of promiscuous NAAAR activity. 
Furthermore, it was found that NAAAR exhibited high activity (on par with its 
OSBS activity) towards N-succinyl-amino acids, leading to the NAAAR protein 
being re-labelled again as a bi-functional enzyme with both OSBS and N-succinyl 
amino acid racemase (NSAAR) activity. In this work, the OSBS/NSAAR enzyme is 
referred to as an N-acetyl amino acid racemase (NAAAR).  
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2.2, Enolase superfamily: 
Within the enolase superfamily, NAAAR is part of the muconate lactonising 
enzyme (MLE) sub-group
[103]
. This superfamily contains >1000 individual enzymes, 
all of which are structurally homologous, but display highly divergent sequences and 
mechanisms
[107]
. In terms of mechanism, each member of the enolase superfamily 
catalyses an initial proton abstraction from an α-carbon to generate an enediol 
intermediate, from which differing reactions can occur (Figure 21)
[102]
. This 
superfamily has been studied as the paradigm example of divergent enzyme 
evolution. It is thought that a progenitor gene, which had the ability to carry out the 
abstraction of an α-proton, has undergone gene duplication numerous times, and each 
time a novel advantageous function has been evolved for this new protein which 
required an initial proton abstraction. After many years of evolution, this process has 




Figure 21. Initial proton abstraction step to form the enediol intermediate. 
The substrates on which the enolase superfamily act is vast, ranging from amino 
acids and sugars to unsaturated carboxylic acids, however all substrates contain an 
essential carboxylate group to facilitate enediol formation
[110]
. The chemistry carried 
out by enolase enzymes is equally varied, with examples including lactone ring 
formation by Muconate lactonizing enzyme (MLE, EC 5.5.1.1), carbon-carbon 
double bond formation by enolase (EC 4.2.1.11) and β-ammonia elimination by -
methylaspartate ammonia lyase (MAL, EC 4.3.1.12))
[111-113]
. An overview of each 
enolase subgroup and the nature of the reactions contained within these groups can 
be seen below
[114]
 (Figure 23). The initial reaction step of all enolase superfamily 
reactions forms a prochiral enediol intermediate by abstraction of the α-proton. The 
substrate on which this occurs, and the resulting chemistry that is carried out on the 
intermediate, is determined by the amino acid residues located on the N-terminal 
strands on seven of the eight β-sheets that make up the central (/)7-barrel
[115]
 
(Table 1).  
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Table 1. Identities of amino acid residues located on the N-terminal ends of β2- β8 strands. 
Including Mandalate Racemase (MR, EC 5.1.2.2), dTDP-glucose 4,6-dehydratase (GlucD, EC 
4.2.1.46), and Mannonate dehydratase (ManD, EC 4.2.1.8). 
 Sub-group β2 β2 β4 β5 β6 β7 β8 
Enolase E D E D K H K 
MAL H D E D K - - 
MLE KxK D E D K - E/DXD/G 
MR Kx(KRHDY) D E E D H E 
GlucD KxK D E N D H D 
ManD R D E E R H E 
The enediol intermediate is stabilised by three conserved acidic residues that interact 
through a Mg
2+
 ion complexed between the carboxylates of the amino acids and 
substrate. Once this common intermediate is formed, structural variations between 
the enolase superfamily enzymes partition the enediol intermediate down differing 
reaction pathways to give various products. Mutations within the β-sheet terminal 
residues have been shown to interchange the activities of enolase enzymes. OSBS 
activity was imparted to both E. coli MLE II and Pseudomonas sp. P51 L-Ala-D/L-
Glu epimerase (AEE, EC 4.2.1.-) by the installation of single E323G and D297G 
mutations respectively
[116-118]
. These characteristics point towards the enolase 
superfamily active site having a degree of “plasticity”, i.e. it is very susceptible to 
changes in substrate preference and reaction pathway through single mutations. This 
would make it suited to evolution, and especially divergent evolution where a single 
mutation in a duplicated gene can quickly generate a novel activity which provides a 
selective growth advantage. Several publications discuss the evolution of structure 
and function of α/β-barrel enzymes, with some advocating evolution from an ancient 
single progenitor and others claiming many progenitor genes have converged on this 
ideal protein fold (Figure 22)
[114, 119, 120]
. The α/β-barrel is clearly a stable protein 
configuration, as ~10% of all solved protein structures make use of it. The various 
cofactors employed by α/β-barrel enzymes (simple divalent cations, ribonucleotides 
and flavins), coupled with the vast range of functions catalysed within the barrel and 
the low sequence homology, would most likely suggest that convergent evolution has 
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driven separate progenitors towards this fold
[121]
. It is still unclear whether several 
ancestral enzymes fell into this thermodynamically favourable conformation 
independently of each other, or whether a single gene gave rise to every present day 
α/β-barrel gene. High homologies between the two halves of the α/β-barrels involved 
in histidine biosynthesis suggest that the eight strands of the barrel may have 
originated as two separate four stranded half barrels which have fused together
[122]
. 
The exact evolutionary history of this fold cannot be traced (proteins and DNA do 
not fossilise), and genomics/structural studies have not yet confirmed either scenario.  
 
Figure 22. A typical β/α-barrel protein fold. Figure generated from published NAAAR: N-
acetyl-L-methinoine structure, PDB:1SJA
[100]
. The active site would be found between the yellow 
β-strands. 
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Figure 23. Examples of the paradigm reaction found within each subgroup. 
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2.3, N-acetyl amino acid racemase (NAAAR): 
NAAAR belongs to the MLE subgroup along with MLE and AEE
[103, 123]
. Of 
interest, this small group of three enzymes catalyse a considerable variety of 
chemical transformations (Figure 24).  
 
Figure 24. Reactions catalysed by MLE enolase superfamily subgroup. 
The MLE subgroup of enzymes performs lactone ring formation, dehydration, and 
racemisation/epimerisation on structurally diverse substrates. Although the MLE and 
OSBS reaction substrates have very different structures, there is a clear similarity 
between those of the AEE and NAAAR reactions. However, there is only 22% 
sequence identity between putative Amycolatopsis mediterranei U32 NAAAR and 
AEE (See section 6.22.2 for alignment). This is a common trait within the enolase 
superfamily; they are structurally similar but differ greatly in terms of catalytic 
mechanism and sequence. Whether NAAAR also has substantial AEE activity has 
not yet been determined, however low activity (<10% of that compared to racemase 
activity towards N-acetyl-L-methionine) has been reported with L-Ala-L-Met from 
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Am. Ts-1-60 NAAAR
[95]
. This would support the thinking that although these 
enzymes operate on related substrates via similar mechanisms, they have evolved 
separately to carry out different roles within the cell. 
2.3.1, Biological role of NAAAR: 
The main biological role of the promiscuous NAAAR protein is almost 
certainly o-succinylbenzoate synthase activity, as all NAAAR/OSBS enzymes, 
regardless of the host strain, carry out this reaction (the 3rd step in the biosynthesis 
of menaquinone, vitamin K12, from chorismate)
[103]
. It is only in certain bacteria that 
the OSBS protein also has promiscuous NAAAR activity; in E. coli for instance, 
OSBS has no detectable NAAAR activity
[100, 103]
. When the OSBS protein does 
possess racemase activity, it is largely in extremophillic bacteria, such as 
Thermophilus thermus, Deinococcus radiodurans, and Geobacillus kaustophilus
[98, 
99, 124, 125]
. NAAAR from G. kaustophilus has been suggested to operate as a bi-
functional enzyme playing a role in two biosynthetic pathways (moonlighting)
[106]
. In 
this bacterium, menC (the gene encoding OSBS) is not found in the usual 
menaquinone biosynthetic operon, but as part of a small, three gene, D-amino acid 
detoxification operon. Here, an N-succinyl-D-amino acid transferase/ N-succinyl 
amino acid racemase/ N-succinyl-L-amino acid hydrolase (“L-succinylase”) pathway 
irreversibly converts D-amino acids to their L-enantiomers. In A. mediterranei U32, 
the only Amycolatopsis bacteria with a fully sequenced genome, the gene 
corresponding to OSBS is again found out-with the usual menaquinone biosynthesis 
operon, and downstream of a hypothetical D-amino acid acylase and a hypothetical 
member of the N-acyltransferase (NAT) superfamily. These two genes, along with 
NAAAR, may be part of an L-amino acid racemase pathway. Given that D-glutamate 
and D-alanine are essential components of peptidoglycan, NAAAR may play a role 
in the synthesis of these un-natural amino acids before they are incorporated into the 
peptidoglycan monomers to be transported to the periplasm
[126]
. The G. kaustophilus 
pathway appears to involve inversion of D- to L-, whereas the A. mediterranei U32 
performs this in the other direction, suggesting that in these cases NAAAR has been 
employed in two very different biological routes, a D-amino acid biosynthesis 
pathway, and a D-amino acid de-toxification pathway. Both of these require stereo-
inversion to achieve different goals, so although the enzymes have evolved the same 
chemical activity, their roles within their host organisms may be different. 
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2.3.2, Substrate specificity: 
NAAAR exhibits a large preference for N-succinyl-containing substrates (2-




Table 2. Published kinetic parameters for Am. Ts-1-60 NAAAR. 
Substrate kcat (s
-1





2-SHCHC 120 0.48 2.5x10
5 
N-succinyl-L-methionine 110 5.9 1.8x10
4 
N-succinyl-D-methionine 110 6.5 1.7x10
4 
N-acetyl-L-methionine 6.4 11.0 5.9x10
2 
N-acetyl-D-methionine 4.8 9.8 4.9x10
2 
Upon examination of the Am. Ts-1-60 NAAAR: N-succinyl-methionine complex X-
ray crystal structure (PBD code: 1SJC) published by Gerlt et al, key interactions are 
observed that are thought to contribute to this substrate preference
[100]
. These are 
hydrogen bonding interactions between the G291 backbone carbonyl and the 
substrate amide, the S135 hydroxyl and substrate carbonyl, and finally, the R299 
guanidinium group and the succinyl carboxylate via two structural H2O molecules 
(Figure 25). 
 
Figure 25. NAAAR enzyme interactions with N-succinyl-D-methionine highlighting the acyl-











N-succinyl-D-methionine  R299 
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In contrast, all of these interactions are absent in the NAAAR: N-acetyl-L methionine 
complex structure (PDB code: 1SJA). In fact, apart from the common magnesium: 
substrate carboxylate interaction, there are no other obvious protein:ligand contacts 
that would explain substrate specificity. NAAAR generally shows a preference for L-
enantiomers over D-, with activity being generally ~30% higher with the former 
substrate, although for certain amino acids, phenylalanine, leucine, and alanine this is 
reversed
[95]
. Low activity (50 times lower than the N-acetyl-methionine equivalent) 
has been reported with N-carbamoyl-methionine
[124, 127]
. NAAAR shows activity 
towards a wide range of amino acids, with highest activity exhibited towards those 
that are hydrophobic in nature. Activity appears to be especially low (100 fold less) 
with charged amino acids such as glutamate, aspartate, and arginine
[106]
.  
2.3.3, Protein structure: 
 Am.Ts-1-60 NAAAR is an octameric enzyme in solution, but hexameric and 
tetrameric isozymes have also been isolated from Streptomyces atratus Y-53 and G. 
kaustophilus respectively
[95, 125]
. The E. coli NAAAR homologue, OSBS, is a 
monomeric enzyme
[100, 128]
. Like all enolase enzymes, NAAAR has a (/)7-barrel 
fold, a derivative of the common (/)8-barrel protein fold, with each monomer 
containing two domains; an α+β N/C-terminal capping/lid domain (Figure 26, 
coloured red, M1-C132, G336-S368) and substrate binding (/)7 barrel domain 
(coloured yellow, G133-A335). The domains are connected by a flexible hinge 
which allows the enzyme to close around the substrate. The capping domian has 
three roles in activity and structure. Firstly, it is responsible for amino acid substrate 
specificity
[99, 105]
. Secondly, extra residues (K85-K100 and A120-S129) found within 
the lid region that are not found in the monomeric E. coli OSBS are thought to be 
responsible for the higher state of oligomerization
[100]
. Thirdly, the capping region 
closes down on the substrate, sequestering it from the solvent, removing solvent 
effects and allowing for maximal interaction between the basic lysine and the α-
proton
[98]
. As the pKa of an α-proton adjacent to a carboxylic acid is between 22 and 
25, a substantial energy barrier must be overcome by the enzyme to facilitate the 
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Figure 26. The Am.Ts-1-60 NAAAR monomer, with the α+β N/C-terminal lid/capping region 




2.3.4, Reaction mechanism: 
Three acidic amino acids (D189, E214, and D239) and a H2O molecule bind the 
substrate via a Mg
2+
, and two lysines (K163 and K263) carry out the proton 
abstraction/re-protonation responsible for racemisation
[100, 101]
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Figure 27. The interactions between Am. Ts-1-60 NAAAR residues D189, E214, and D239 and 
Mg
2+
 (green cross) and H2O (red cross). Catalytic K163 and K263 residues and N-acetyl-L-
methionine are also shown. Figure generated from 1SJA
[100]
. 
In NAAAR, as with all enolase enzymes, the initial step is proton abstraction to 
generate an enediol intermediate, however as there is no further chemistry possible 
on the N-acyl enediol intermediate (for example loss of water or ammonia), the 
reaction effectively stalls and goes in reverse to regenerate the initial amino acid 
substrate. If the abstraction and subsequent re-protonation are carried out by differing 
lysine residues, then stereo-inversion around the α-carbon occurs, allowing for 
racemisation of the N-acyl amino acid substrate (Figure 28). 
 
Figure 28. The mechanism of NAAAR-catalysed racemisation of N-acyl-amino acids. 
The arrangement of these two lysine residues is such that they sit on either side of the 
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assigned stereoselective roles in the enzyme mechanism. As K163 can only de-
protonate N-acyl-L-amino acids this is labelled the “L-specific base” and K263 the 
“D-specific base”. It has been reported that replacement of these lysines with 
arginine/serine/alanine removes all activity confirming they are essential for enzyme 
turn-over
[101]
. No racemase activity is displayed towards the free amino acid 
(essential for the proposed industrial application), indicating that an N-acyl group is 
crucial and that the electron withdrawing nature of this group promotes abstraction of 
the proton at the α-carbon
[96]
. Metal chelators such as ethylenediaminetetraacetic acid 
(EDTA) are known to inhibit NAAAR activity, highlighting the requirement for a 
divalent cation
[93]
. Methyl ester amino acid substrates show no activity, again likely 






 is the natural cation for 















2.4, Amino acid racemases in nature: 
2.4.1, Role of D-amino acids in nature: 
Although cell biology is based almost exclusively on L-amino acid chemistry, 
D-amino acids do serve a purpose in bacterial cells, for example, D-alanine and D-
glutamate form essential components of bacterial peptidoglycan, and D-
phenylalanine is incorporated in the peptide antibiotic Gramicidin S
[130, 131]
. Given 
that there are no known de novo D-amino acid synthesis pathways in nature, the need 
for amino acid racemases is obvious
[132]
. The use of D-amino acids has likely arisen 
after evolution of the L-amino acid biosynthetic pathways, because if this was not the 
case, the equivalent D-amino acids pathways would also surely exist. It is possible 
that the use of D-amino acids has evolved to impart resistance to L-amino acid 
specific proteases found within competing bacterial populations. In the case of 
peptidoglycan this is in the form of a defence mechanism, whereas Gramicidin S, and 
other D-amino acid containing antibiotic peptides, have been evolved as a toxin that 
other bacteria cannot degrade
[133-135]
. This would also suggest that the use of D-amino 
acids for defence/attack arose after evolution of L-amino acid chemistry within 
bacteria. As many amino acid synthetic pathways are multi-step and inter-connected, 
nature has decided to use a racemase to synthesise the D-enantiomer, following 
synthesis of the L-enantiomer
[136]
. Bacteria that have made this evolutionary step and 
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use this novel D-amino acid building block, give themselves an evolutionary 
advantage over their competing neighbours.  
2.4.2, Mechanisms of amino acid racemases: 
There are two mechanisms for amino acid racemisation that have been 
evolved by bacteria, the first of which generates a prochiral planar sp
2
 hybridised 
carbon centre via an enolate, and the second, which generates an sp
3
 hybridised 
carbanion. The most widespread mechanism involves the use of a PLP cofactor to 
generate this sp
3
 hybridised carbanion. Examples of four bacterial racemases which 
use these mechanisms are given below. 
2.4.1.1, Alanine racemase: 
 Alanine racemase (Alr, EC 5.1.1.1) from Bacillus stearothermophilus, a 
well-known and studied amino acid racemase uses PLP to generate a carbanion that 
allows racemisation (Figure 29)
[137]
. Alr initiates racemisation by formation of a 
substrate external aldimine with a transaldimination between the α-amino group of 
the L-alanine substrate, and the ε-amino group of K39 bound to PLP. A concerted 
proton abstraction by Y285 from the α-carbon and donation to the substrate 
carboxylate generates the carbanion. This is followed by a further proton abstraction 
by K39 from the substrate carboxylic acid, followed by donation of a proton to the 
carbanion. The location of Y285 and K39 on opposite sides of the α-carbon permit 
this process to carry out racemisation of the substrate. K39 then reforms the PLP-
internal aldimine via another transaldimination and releases the free amino acid 
product, D-alanine.  
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Figure 29. The proposed mechanism of the PLP dependent Alanine racemase.  
2.4.1.2 Glutamate/Aspartate racemase: 
Glutamate racemase (MurI, EC 5.1.1.3) uses a cofactor-free mechanism to 
generate a carbanion, with a pair of cysteines performing the acid/base chemistry
[138, 
139]
. This mechanism is also found in Aspartate racemase (AspR, EC 5.1.1.13)
[140]
. 
Two cysteine residues act as stereospecific acid/bases to first abstract and then re-
protonate the α-proton of the glutamate or aspartate substrate. X-ray crystal structure 
data would suggest that MurI operates similar to Alr, with the racemisation 





. Although there have been mutational studies, and the 
crystal structure solved, the exact roles of other amino acids within the MurI/AspR 
active site have not yet been fully elucidated. 
 
Figure 30. The proposed mechanism of Glutamate racemase via a carbanion. 
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2.4.1.3 Proline racemase: 
Proline racemase (ProR, EC 5.1.1.4) can be called an N-acyl amino acid 
racemase due to proline being an imino acid
[90]
. ProR uses two cysteines in the same 
manner as MurI/AspR, with X-ray structural evidence suggesting that an sp
3
 





Figure 31. The proposed mechanism of Proline racemase via a carbanion. 
2.4.1.4 Phenylalanine racemase: 
A unique ATP-dependent Phenylalanine racemase (GrsA, EC 5.1.1.11) has 
also been discovered from Bacillus brevis in which racemisation proceeds via a 
thioester enolate
[144, 145]
. As opposed to Alr, MurI/AspR, and ProR which are 
individual enzymes, GrsA is part of gramicidin S synthetase, a multi-subunit and 
domain non-ribosomal peptide synthase (NRPS). Gramicidin S is an antibiotic 
containing two pentapeptides (valine-orthinine-leucine-D-phenylalanine-proline) 
joined in a cyclic form via two valine-proline peptide bonds. The gramicidin S 
synthase is comprised of two subunits, GrsA responsible for racemisation and 
peptide synthesis initiation with D-phenylalanine, and GrsB which then carries out 
the peptide elongation. Phenylalanine racemisation is carried out by GrsA in an ATP 
dependent manner via three domains; an adenylation domain, a thiolation domain, 
and an epimerisation domain (Figure 32).  
- 36 - 
   
Figure 32. The proposed mechanism of ATP-dependent racemisation of L-phenylalanine by 
GrsA via a thioester enolate.  
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The adenylation domain activates L-phenylalanine by forming the Phe-AMP 
ester, which can then form a thioester with the phosphopantetheinyl arm of the 
thiolation domain. Abstraction of the α-proton is then carried out by a basic residue 
on the epimerisation domain to generate the planar sp
2
 enolate. Racemisation occurs 
by re-protonation on the opposite side of the intermediate α-carbon. The next subunit 
in this process, a condensation domain within GrsB, transfers D-phenylalanine from 
the thioester on to proline to form a di-peptide. This step is specific for the D-
enantiomer of phenylalanine. Subsequent peptide elongation and cyclisation gives 
the Gramicidin S product
[146]
.  
2.4.3, “Evolvability” of NAAAR: 
These mechanisms show that nature has devised methods to synthesise D-
amino acids by racemisation of their L-enantiomers, and that evolution has selected 
these bacteria through a process of survival of the fittest. This forms the basis of the 
evolutionary pressure utilised in this work, however, it is the racemisation of D-
amino acids to the L- enantiomer that is the selective pressure. Bacteria that evolve 
this ability faster than others will be able to outgrow their neighbours allowing for 
identification by their increased colony size in an auxotrophic host (SET21, see 
section 3.6). The “evolvability” of the enolase superfamily and (/)8 barrel proteins 
suggests that NAAAR should be open to the changes needed to generate increased N-
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3.1, Directed evolution: 
At first, enzymes appear to be ideal catalysts for many chemical synthetic 
steps due to their excellent chemo-, regio- and enantio- selectivity
[53]
. However, the 
conditions under which a particular enzyme operates, and the substrates which it 
accepts, are not always compatible with those a chemist wishes to use, leading to 
enzymes often being far from ideal biocatalytic tools. Recently methodologies have 
been developed that allow for novel enzymes with improved catalytic properties to 
be generated. This process of mutagenesis and screening of generated variants in 
hope of discovering mutations that cause improved properties has been termed 
“Directed Evolution”. 
For an enzyme to form part of a successful biotransformation process, it must 
catalyse the reaction fast enough to give high yields of product in a reasonable time 
frame, possess the correct reaction specificity, be stable under the bioprocess 
conditions and be amenable to production at high volumes (fermentation) and 
subsequent downstream processing
[147]
. The enzyme may have to function under 
conditions that facilitate substrate/product stability, for instance, non-native 
temperature (<30°C or >37°C), non-neutral pH or in reaction media containing 
organic solvent
[148, 149]
. These requirements can cause problems as enzymes tend to 
display their highest activities on a very narrow substrate range and are typically only 
active in aqueous media at physiological pH and temperature
[150, 151]
. This situation 
has arisen because evolution has often selected their design towards immense 
specificity at the cost of multiple activities and broad substrate range
[152]
. The 
preference for mild reaction conditions is due to evolutionary pressure having been 
exerted under physiological conditions, as opposed to 50°C in 25% MeOH. As a 
result of these selective requirements, there are, with possibly only a few exceptions, 
such as lipases, no enzymes that can be used to carry out general reactions on a wide 
range of substrates under harsh chemical conditions
[29]
. The highly selective nature 
of enzymes has long been known and was described as being like a “key and lock” 
by Emil Fischer in 1894
[153]
. This is especially true when considering enzymes in 
biocatalytic reactions, as often a high number of keys  must be tested to find one that 
fits the desired lock. The highly specific nature of enzymes is one of the major 
considerations when evaluating enzymes for use in synthetic reactions. When a 
reaction is being tested with a natural substrate or a molecule closely related to a 
natural substrate, screening can generally be performed directly with this compound. 
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For instance, screening for a leucine amino acid racemase operating at 37°C would 
involve testing this reaction using L-leucine and a variety of amino acid racemases. 
Once a positive hit has been discovered, if any characteristic of the enzyme is 
deemed unsuitable, attempts could then be made to tailor the enzyme using a directed 
evolution approach
[154]
. In more complicated scenarios, when there is less chance of 
a natural enzyme being compatible with a synthetic substrate or reaction conditions, 
such as screening for a tert-leucine amino acid racemase operating at 60°C, it may be 
necessary to initially screen under mild conditions using a natural substrate (L-
leucine) that is structurally similar to the desired un-natural substrate, before 
optimising activity towards tert-leucine using directed evolution. In this way it may 
be possible to engineer thermostability into a protein which displays the desired 
specificity. Another approach would be to begin with thermostable amino acid 
racemases and screen these enzymes for activity towards tert-leucine/leucine. As an 
example of this approach, a novel Cytochrome P450 propane monooxygenase was 
engineered from a Long chain fatty acid (C12-C18) monooxygenase (EC 1.14.15.3) 
from Bacillus megaterium
[155, 156]
. Initial screening and directed evolution used an 
intermediate octane substrate, as the wild-type (WT) enzyme had no measurable 
activity towards the desired propane substrate. Octane was utilised for five rounds of 
screening, after which a novel propane active variant was generated. Eight further 
rounds of screening with propane increased the kcat with the C3 substrate from 0 to 
450 min
-1
. Using directed evolution, enzymes that are close to the requirements for 
industrial biocatalysts can be improved upon to generate novel processes that can 
compete or even replace the present day chemocatalytic routes
[17]
. 
3.2, Generating variant libraries: 
Successful directed evolution generally requires mutagenic libraries 
containing thousands to millions of randomly mutated genes to be synthesised and 
screened effectively
[16, 157]
. Much smaller libraries may also be used where mutations 
are limited to a small number of amino acid positions in the target enzyme. The level 
of screening is therefore influenced by how well the mutagenesis can been 
rationalised, with minimal screening required for more focused libraries in which key 
catalytic, or substrate binding residues have been targeted
[158]
. When very little is 
known about the structure of an enzyme, i.e. only an amino acid sequence with no 
crystal structure or homology model, the screening effort can be vast, with every 
amino acid (except the ATG start codon) open to mutagenesis. For a hypothetical 
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300 amino acid protein; a single random amino acid change equates to 6x10
3
 
possible enzyme sequences, two changes generates 1.2x10
5
 possible variants and 
three mutations gives rise to 2.4x10
6 
possible variants. As a rule, to attain 95% 
confidence that all possible variant sequences have been screened following a 
mutation protocol calibrated to introduce one mutation per gene copy, three times the 
number of possible mutated gene sequences must be screened. Thus, 1.8x10
4
 
colonies would need to be screened to have 95% confidence of having fully mutated 
and screened every base in a 300 amino acid protein
[159]
. Accordingly, these numbers 
quickly become too large to reasonably screen using a typical high throughput 
HPLC/GC-MS assay. In some cases, supported by the ever growing level of bio-
informatics available, it is possible to cut screening down to much more reasonable 
numbers by focusing on residues that are likely to be involved in substrate 
binding/catalysis
[160]
. A single amino acid position located within the active site can 
be substituted with all other 19 amino acids and screened with 95% amino acid 
mutation coverage on a single 96 well plate
[158]
. If a quick screening assay is 
available; for instance a two minute HPLC run, this screening can be accomplished 
in under four hours. The random mutagenic gene libraries needed for directed 
evolution can be created by a variety of differing in vivo and in vitro methods
[161, 162]
. 
A brief description of the main techniques used for this is discussed below. 
3.2.1, In vivo mutagenesis: 
3.2.1.1, E. coli mutator strains: 
In vivo mutagenesis involves mutating a recombinant plasmid that harbours 
the gene of interest while it is being propagated by a cell. This is often accomplished 
in an E. coli mutator strain, such as XL1-Red (Stratagene)
[163]
. This strain is deficient 
in three major DNA repair mechanisms; mutS (deficient in error-prone mismatch 
repair), mutD (deficient in 3’- to 5’-exonuclease of DNA polymerase III) and mutT 
(unable to hydrolyse 8-oxo-dGTP). These allow for the XL1-Red’s natural 
mutagenesis rate to increase ~5000 fold above WT E. coli
[164]
. A difficulty in 
working with this strain is that introduced mutations are not restricted solely to the 
gene of interest. Mutations will accumulate in both the plasmid backbone, and the 
host’s genomic DNA. As a result, potential libraries must be constantly isolated and 
fresh XL1-Red re-transformed with this library. Any potential mutation which 
increases enzymatic activity must also be cloned into a fresh vector backbone to rule 
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out origin of replication (ori)/promoter driven increases in expression, and thus non-
specific activity. Although, any mutations in the ori/promoter region that increases 
expression would likely be interesting and may be of some use in an expression 
plasmid. The XL1-Red strain provides a simple method to generate mutagenic 
libraries, but more sophisticated methodologies that require less time and labour are 
readily available.  
3.2.1.2, In vivo chemical mutagenesis: 
In vivo mutagenesis can also be carried out using chemical mutagens such as 
ethyl methanesulfonate (EMS), however, this process is not suited to selectively 
mutating a gene of interest; it is much more suited to wide spread mutagenesis of an 
entire genome
[165]
. To carry out specific mutagenesis of a gene, a much higher degree 
of mutagenic control is needed. This can be easily and quickly achieved with several 
in vitro techniques.  
3.2.2, In vitro mutagenesis: 
In vitro techniques form the work horse for most directed evolution projects. 
Their main advantage is that mutagenesis can be limited to the gene of interest. They 
are performed outside of a living cell and give rise to the phrase “test tube 
evolution”, another term used for directed evolution. Most of these techniques are in 
the form of PCR based protocols, although it is possible to carry out in vitro 
mutagenesis using chemical mutagens.  
3.2.2.1, Error prone PCR: 
Error prone PCR (epPCR) is one of the most used, safest, and simplest 
methods for in vitro mutagenesis
[166]
. Taq based PCRs can be made error prone by 
including Mn
2+
 in the reaction buffer in place of Mg
2+
 or by using synthetic dNTPS 
to incorporate mutations (8-oxo-dGTP and 2’-deoxy-p-nucleoside-5’-triphosphate 
(dPTP))
[167, 168]
. These steps cause point mutations throughout the PCR product 
(gene) that can then be cloned into a non-mutated vector and evaluated for activity in 
an appropriate screening system. Error prone PCRs using Taq appear simple and 
cheap, but there are issues with the bias of mutations it provides
[169, 170]
. This skewed 
bias can be overcome by using a commercial epPCR kit, such as the genemorph II 
(Stratagene). Genemorph II uses two enzymes (the one Taq under mutagenic 
conditions, the other a proprietary error prone polymerase) with opposite biases to 
provide a balanced mutagenic spectrum. The overall mutagenic rate can be 
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controlled by altering the number of PCR cycles and the concentration of initial 
template. This gives different levels of amplification and as a result, varying levels of 
mutagenesis. PCR products generated with this combination of error prone 
polymerases should possess a high variety of mutations
[169]
. The random introduction 
of point mutations would at first glance appear to be an ideal method for generating 
mutations within proteins, however, this method fails to account for the complexity 
of the DNA genetic code
[170]
. When a single base is mutated, there is only around a 
50% chance of this giving rise to a useful, chemically altered amino acid. The other 
possibilities of introducing a destabilising amino acid (glycine/proline), introducing a 
stop codon, or causing no amino acid mutation are just as likely. A major step 
forward would be made if methodologies were developed that enabled the quick and 
simple mutation of two or three base runs randomly throughout a gene. A complex 
approach for this has been developed (RID, random insertion and deletion) but it is 
technically challenging requiring multiple ligations
[171]
.  
The beauty of genetic code is that vast amounts of information can be stored 
using only four “letters of the alphabet” – A,G,T and C
[172]
. Nature has achieved this 
by introducing degeneracy by means of sixty-four codons (3 bp “words”) that allow 
for twenty proteinogenic amino acids and three stop codons to be encoded solely by 
these four bases. However, this degeneracy makes the process of mutagenesis 
intrinsically difficult, as multiple, related DNA sequences encode the very same or 
highly related amino acids. For instance, the final base on many codons can be 
changed without fear of changing the encoded amino acid. Due to this effect, DNA 
mutations are not guaranteed to result in amino acid changes, e.g. the codons GGC 
and GGG both encode glycine in E. coli
[173]
. As a result, certain amino acids require 
higher levels of mutagenesis than others for specific changes, such as lysine (AAA, 
or AAG), which requires three mutations to become cysteine (TGT, or TGC). In 
other cases, only one mutation is required, such as valine (GTT, GTC, GTA, or 
GTG) to alanine (GCT, GCC, GCA, or GCG). If an error prone PCR is carried out 
with three random bp mutations per kb, there is only a 0.00000000074 % chance a 
specific K→C mutation compared to 0.3 % chance for a specific A→V. The genetic 
code appears to have evolved in such a way that when mutations within an amino 
acid sequence do occur, they are most likely to introduce changes wherein the 
chemistry is changed very little, for instance alanine to valine, or aspartate to 
glutamate
[174]
. The problem of limited mutagenesis due to codon degeneracy affects 
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any mutagenic technique which introduces single random point mutations into a 
gene. 
3.2.2.2, In vitro recombination: 
An excellent mutagenic technique based on biological mutagenesis is that of 
in vitro recombination, or “DNA shuffling”
[175-177]
. During cell meiosis, the 
chromosomal DNA can undergo crossover events which result in recombination 
within the genes contained on those chromosomes
[178]
. This process is essential to 
allow for sexually reproducing organisms to exchange genetic material without the 
accumulation of deleterious mutations. The nature of this process has been simulated 
in a test tube by using homologous genes which now act as the chromosomes to be 
recombined. The natural recombinases that carry out the chromosomal exchange 
process have been replaced by endonucleases and a DNA polymerase
[175]
. The in 
vitro process involves digesting homologous genes into 10 to 50 bp strands with a 
non-specific Deoxyribonuclease (DNase, EC 3.1.21.1) and then assembling these 
randomly back together with a DNA polymerase (Figure 33). How well this 
reconstruction occurs depends largely on how much conserved sequence identity 




Figure 33. Digestion and random reconstruction methodology of DNA shuffling. 
Using this method, point mutations should be kept to minimum level
[180]
. However, if 
desired, point mutations can be deliberately introduced into the process by using an 
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error prone polymerase, such as Taq with Mn
2+
 for the PCR reconstruction
[181]
. 
When point mutations are kept to a minimum, essential motifs within the sequence 
should be maintained i.e. conserved catalytic residues are not removed and structural 
motifs are in general left untouched. DNA shuffling was first reported in 1994 by 
Stemmer et al
[175, 176]
. Here, in vitro recombination was used to shuffle several TEM-
1 β-lactamases and the reconstructed genes screened for improved resistance to 
cefotaxime. Three rounds of recombination resulted in a variant enzyme that 
increased resistance of an E. coli host by 32,000 fold. A similar effort using epPCR 
generated only a 16 fold improvement in resistance. 
3.2.2.3, Saturation mutagenesis: 
 A third PCR based method used in directed evolution is that of saturation 
mutagenesis
[182, 183]
. This method is similar to epPCR, in that a PCR product is 
generated with point mutations, but very different in that the mutagenesis is 
controlled and selected for during the primer design process. Unlike epPCR, 
saturation mutagenesis does not suffer from limitations due to the degeneracy of the 
genetic code; instead it embraces it and uses only three point mutations to introduce 
20 different possible amino acid mutations at a single position within the protein. 
Ideally, the process should be guided by initial epPCR/XL1-Red mutagenesis that 
has highlighted a residue as having an effect on the desired enzyme property being 
evolved, or by identifying suspected active site/substrate binding residues from either 
a solved structure or a homology model. Using this semi-rational methodology, a 
single amino acid can be mutated to all other amino acids in a single step; this 
generates a small library containing 20 variant enzymes which can be sufficiently 
screened with 95% sequence coverage on a 96 well plate
[158]
. Saturation mutagenesis 
is carried out by performing a high fidelity PCR with a specifically designed primer 
than contains a degenerate codon in place of the amino acid codon to be mutated. 
The degenerate codon is typically of the form NNK, where N = A/T/G/C and K = 
T/G, which allows combinations of all 20 possible amino acid codons
[184]
. By using 
K as the 3
rd
 base in the codon instead of N, the requirement for screening is halved as 
only 32 codons are encoded, but these still allow for a full mutagenic coverage (all 
20 amino acids). The PCR can be carried out in a site directed mutagenesis manner 
with complementary degenerate primers (with the reverse primer containing a 
complementary 5’-MNN-3’ degenerate codon) or as a conventional PCR with a 
single degenerate primer and non-degenerate primer located elsewhere in the 
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gene/plasmid. In the latter case, a megaprimer is generated that can then be 





Figure 34. Saturation mutagenesis methodology using DpnI to digest the parental template. 
Careful design of the primer(s) used can allow for a high degree of control over the 
mutagenesis process, for instance two amino acids can be simultaneously mutated by 
including two degenerate codons in a single primer. This approach is limited to 
amino acids that can be encoded on one primer
[185]
. Another approach which is of 
more use when the targeted residues are further apart is to use two degenerate 
primers to generate a megaprimer which spans two separate locations within the 
gene. In theory, another degenerate codon containing primer could then be used to 
extend this megaprimer allowing for three degenerate codons in a single PCR 
product. However, the chances of the final PCR product showing a full mutagenic 
spectrum at all three positions are low and the complexity of the generated library 
- 47 - 
becomes so great that effective screening becomes a major problem. When two 
positions are mutated using NNK degeneracy instead of only one, the number of 
clones that need to be screened for 95% coverage jumps from 94, to 3,066
[158]
. If this 
were increased to three codons, 98,163 clones would be required for effective 
screening. These numbers apply to the NNK degenerate codon, however, other 
degenerate codons can be used that limit the numbers of possible amino acids and 
thus reduce the number of clones possible. The most common reduced amino acid 
alphabet degenerate codon is NDT, where D = A/T/G, which encodes for twelve 
codons and twelve amino acids (Arg, Asn, Asp, Gly, His, Ile, Leu, Phe, Ser, Tyr, and 
Val)
[188]
. All amino acid chemical properties (acidic, basic, non-polar aliphatic, 
aromatic, and polar) are represented within these twelve amino acids. As there are 
only twelve codons available, the number of clones required for adequate screening 
drop dramatically. One amino acid mutated requires only 34 clones screened, two 
requires 430, and three requires 5,175. These relatively low numbers make the NDT 
degenerate codon a good option when screening libraries with more than one 
degenerate codon. For complete screening, any position which returns a positive 
response can then be saturated with a single NNK to investigate the eight non-
represented amino acids. Although NNK and NDT are the most common, and useful 
degenerate codons, any degenerate codon can be used if it can be selected in such a 
way that only the desired amino acids are represented
[189]
. For instance NTN can 
only encode five non-polar aliphatic and aromatic residues, and VAN, where V = 
A/G/C, would specify six acidic, basic and polar residues. Using degenerate codons 
in this manner provides very tight control over the mutations introduced but is 
primarily of use when trying to limit screening to reasonable numbers with multiple 
degenerate codons, and is vulnerable to the degree by which desirable mutations (i.e. 
making a position of interest acidic will have the desired effect) can be predicted 
with a reasonable level of confidence.  
3.2.2.4, Iterative Saturation mutagenesis: 
Saturation mutagenesis is widely applied in an iterative form
[160, 184, 188]
. In 
this method, several sites (single or double amino acids) are mutated in separate 
libraries and the best performing variant from each library is re-mutated using the 
other targeted sites. In this way, four hypothetical sites - A/B/C/D, would all undergo 
saturation mutagenesis to give four separate libraries
[190]
. If the best performing 
variant was found in site A, this would then be saturated at positions B/C/D to give 
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three further libraries. Again the best variant (e.g. from library B containing the 
previous A library mutation), is used for mutagenesis at C/D giving two libraries. 
The process is repeated until an optimised variant has been found for all four sites 
(Figure 35). Screening in this way allows for four sites to be mutated with screening 
of ten libraries each containing only 100 colonies with 95% mutagenic coverage. 
Screening these sites in one library would not be realistically feasible – if 
mutagenesis could somehow be limited to the twelve bases of interest, >3x10
6
 clones 
would need to be assayed. At any stage in the A→B→C→D process, any position 
can then be re-screened with relative ease to include further library diversity in the 
screen, and would only require screening of an extra 100 colonies per site. This 
method drastically cuts down on the total number of colonies needed to be screened 
and has been termed combinatorial active site saturation testing (CASTing)
[160, 191]
. 
Of course, to saturate the active site efficiently, the amino acids that make it up must 
be known, which often requires a solved crystal structure of the protein of interest or 
a high homology model, which is not always immediately available.  
 
Figure 35. Iterative screening of four saturation positions (A, B, C, and D). 
ABCD 
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3.2.2.5, Chemical mutagenesis:  
A less common method for in vitro mutation is that of chemical 
mutagenesis
[192]
. However this approach has been used very successfully in the past 
for generating libraries with a high variety of mutations
[193]
. Several compounds are 
available which can be applied directly to DNA that will induce point mutations 
(mutagens). Examples of these mutagens are ethyl methanesulfonate (EMS), nitrous 






Figure 36. Mis-match effects of chemical mutagen mutagenesis. 
EMS introduces point mutations by alkylating the keto group of guanine so that it 
can now mismatch base pair with thymine. This alkylation can cause G/C→A/T 
transitions (substitution of purine → purine or pyrimidine → pyrimidine) during 
DNA replication. Other alkylating agents such as methyl methanesulfonate or 
dimethylsulfonate can also be used, and in general they have similar mutagenic 
properties to EMS. HNO2 carries out oxidative deamination of both adenine and 
- 50 - 
cytosine to introduce G/C→T/A transversions (substitution of purine → pyrimidine 
or vice versa) during DNA replication. The deamination of adenine and cytosine 
generates hypoxanthine and uracil respectively. Guanine also undergoes deamination 
to xanthine but as this can still pair with cytosine as the usual Watson-Crick base 
pairing still occurs. NH2OH reacts preferentially with cytosine to give N
4
-
hydroxycytosine which can mismatch with adenine to give G/C→T/A transitions. 
Nowadays these compounds are more likely to be used by those carrying out 
mutagenesis in model organisms than isolated DNA as PCR techniques provide a 
much safer (mutagens are highly toxic), convenient and controllable method for 
carrying out DNA mutagenesis
[195]
.  
3.2.3, Mutagenic library construction: 
In vitro mutagenesis is often performed on an isolated gene to avoid 
mutations to the plasmid backbone, but this causes issues as the mutated PCR 
product must now be incorporated into an appropriate vector by means of ligation, or 
another method to allow screening. Ligations can be frustratingly low in their 
efficiency even when cloning a homogenous PCR product into a vector, and 
compatible restriction sites must also be found when multiple genes are being 
shuffled
[196]
. A more efficient method for vector construction is to use a PCR process 
in which the mutated gene product is used as a megaprimer around which, the rest of 
the vector is then reconstructed (MEGAWHOP)
[186]
. This method uses the same 
principles as site directed mutagenesis but with a mutagenic gene megaprimer 
instead of a small mutated primer
[197]
. A DpnI digest of the resulting PCR gives a 
library of mutated vectors; however, like most PCR reactions, optimisation is needed 
for best results. For successful vector construction, any polymerase used for this step 
must have high fidelity and possess no A’ overhang extension or strand displacement 
activity. Taq meets none of these requirements; whereas polymerases such Pfu turbo 
and pfx platinum match them all, making them ideal polymerases for most mutagenic 
library work ups. 
3.3, Selecting and screening variant libraries:  
To increase the likelihood of directed evolution being successful, sampling 
high volumes of sequence space with ease must be possible. This can be done in two 
ways, either by in vivo selection/screening methods, or in vitro high throughput 
screening. In vivo selection can be used to evaluate library sizes in the millions using 
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genetically modified bacterial cell lines which rely on the evolved reaction to provide 
an essential compound for life or remove a toxic one. Using in vivo screening, 
libraries of >10
4
 c.f.u. can be screened on an agar plate using a visual indicator of 
enzyme turnover. Using in vitro screening, multiples of 96 well plates can be 
screened with almost analytical accuracy 
3.3.1, In vivo selection/screens techniques: 
3.3.1.1, In vivo selection: 
In vivo assays can be in the form of either a genetic selection or high 
throughput screening – the difference being that in a selection method, poorly 
performing variants should be removed from the background by host death, whereas 
in a screening approach, even catalytically dead variants will be assayed. In vivo 
selection methods can be used to screen vast libraries and typically give a life/death 
or growth/no growth assay in which an increase in the desired characteristic helps the 
host bacteria to survive and/or possibly out-grow its competitors
[198]
. In vivo 
selections can suffer from a lack of quantification that means potential hits often 
need to be re-screened using more accurate analytical methods such as HPLC/GC-
MS. They can be used as an initial screen to remove redundant sequences with no 
activity and subsequently cut down on the variants that need screened in vitro
[199]
. 
The major advantage of in vivo selection is that the size of libraries that can be 
screened is in the millions
[200]
. An classic example of in vivo selection is evolving 
resistance to an antibiotic – for instance Stemmers evolution of cefotaxime resistance 
using DNA shuffling (See section 3.2.2.2)
[175]
. In vivo selection in auxotrophic 
bacteria can be a very powerful process if a suitable auxotroph can be engineered 
that is complemented by product of the reaction of interest. Kagamiyama et al have 
utilised an E. coli strain deficient in a Branched-chain amino acid aminotransferase 
(BcaT, EC 2.6.1.42) required for the final stage of L-valine, L-leucine, and L-
isoleucine biosynthesis to increase the branched-chain substrate acceptance of 
Aspartate aminotransferase (AspTA, EC 2.6.1.1). The strain was transformed with an 
AspTA mutagenic library and grown on minimal media supplemented with 2-
oxovaline, L-leucine, and L-isoleucine. Repeated selection of the fastest growing 
colonies, i.e. those that could transaminate 2-oxovaline effectively, revealed a variant 
AspTA with 10
5
 fold increase in activity towards branched-chain amino acids 
compared to the WT
[201]
. In vivo selections can be difficult to devise as the internal 
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chemical pathways of bacteria are complicated and inter-connected, with many 
“escape routes” to any applied selection being possible. 
3.3.1.2, In vivo screening: 
In vivo screening utilises a visual assay to indicate improvements in enzyme 
activity
[202]
. This may be relatively straightforward if the product can be directly 
detected (e.g. coloured products) or can be fed easily into a coupled enzyme assay 
which gives a coloured response. For instance, the synthesis of a D-amino acid can 
be detected in a bacterial colony on an agar plate using a combination of D-amino 
acid oxidase (D-AAO, EC 1.4.33) and Horseradish peroxidase (HRP, EC 1.11.1.7). 
The D-amino acid is oxidised to the keto acid by D-AAO releasing H2O2 which HRP 
uses to oxidise a redox indicator added to the agar giving a coloured colony
[203]
. As 
D-amino acids are not found in E. coli at high concentrations, any colony possessing 
the ability to produce these (from an appropriate substrate) will be coloured more so 
than its neighbours and should be easily identified.  
3.3.2, In vitro screening techniques: 
 In vitro screening ideally takes place in 96 or even 384 well plates and uses 
an optical assay (UV/visible/fluorescence) to measure enzyme activity
[204]
. This 
process begins with small scale growth of colonies containing variants in 96/384 well 
plates followed by enzyme expression, cell lysis and clarification. The cell free 
extract (CFE) can be used as source of enzyme activity to test for improved variants. 
This has the added advantage that it screens for soluble/folded protein as well as 
activity
[205]
. Detection of enzyme turnover can be carried out by any number of 
chemical assays, and this step depends entirely of the nature of the substrate/product 
and any organic cofactor used. Examples of possible assays included using D/L-
AAO/HRP, or by measuring the rate of NADPH/NADP oxidation by a decrease in 
absorbance at 340 nm
[206-208]
. Often, coupled enzyme systems are used to cause a 
measurable change, such as the use of Pyruvate kinase (PK, EC 2.7.1.40) and Lactate 
dehydrogenase (LDH, EC 1.1.1.27) to measure ATP hydrolysis. Here, the hydrolysis 
of ATP triggers the reduction of NAD
+
 which can be monitored by an absorbance 
increase at 340 nm
[209]
. In these assays, care must be taken to ensure that the rate 
limiting step is the reaction being investigated to allow for increases in this step to be 
measured accurately. Once an effective in vitro screen has been developed, multiple 
96/384 well plates can be screened rapidly with the use of a liquid handling robot and 
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a plate reader. If a coupled UV/vis/fluorescence assay cannot be adequately designed 
for a given reaction, a high throughput HPLC/GC-MS/LC-MS assay can be used 
instead. However, these are less than ideal for high-throughput screening as even 
with a quick two minute sample/detection time, a 96 well plate will still require three 
hours for full analysis, and given the requirement for high-purity samples, extra 
liquid handling steps may be required beforehand. One clear advantage of in vitro 
screening over in vivo techniques is that they can be carried out in semi-quantitative 
manner, whereas in vivo methods are more qualitative but higher throughput.  
3.3.3, Fluorescence assisted cell sorting: 
Fluorescence assisted cell sorting (FACS) matches the sensitivity of in vitro 
screening with the throughput of in vivo selection is Fluorescence-activated cell 
sorting (FACS)
[210, 211]
. This method allows for high cell densities (>10
7
 cells) to the 
screened (sorted) depending on the fluorescence of individual cells. If an assay can 
be developed in which the product is fluorescent, the reaction can be directly assayed 
and hits physically separated from the non-hits. FACS can also be applied as a 
life/death assay in which a living cell activates a fluorescent dye, whereas a dead cell 
does not. In this situation the reaction being evolved must generate either a required 
metabolite due to a desired reaction (e.g. novel activity on the desired non-natural 
substrate) or a toxin if the reaction is undesired (e.g. activity on the non-desired 
natural substrate)
[212]
. Ideally, both these selective pressures are applied at the same 
time otherwise non-active enzymes would be selected as false positives due lack of 
toxin release. FACS appears to be an attractive way to perform directed evolution, 
but it is hindered by the requirement for a fluorescent product/life death assay and 
access to an expensive and mechanically complicated fluorescence-activated cell 
sorter.  
3.4, Computer aided directed evolution: 
Computational de novo design of novel enzymes to carry out required 
reactions efficiently would be the pinnacle of protein engineering
[213]
. Although 
whether this constitutes directed evolution is debatable, the end goal is the same, 
with a computer now conducting in silico screening of hypothetical mutations and 
protein folds to find an ideal arrangement of amino acids. The use of in silico tools to 
identify biocatalysts by sequence analysis has already been shown, the next step 
would be the de novo design of such enzymes
[214]
. The timeframe in which this will 
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become routine (if at all) is difficult to judge as our understanding of how protein 
sequence dictates folding and activity is poor
[215, 216]
. Dywer et al infamously claimed 
to have designed a de novo enzyme capable of triose phosphate isomerase activity. 
However, it was later discovered that a low level E. coli Triose phosphate isomerase 
(TIM, EC 5.3.1.1) contaminant was in actual fact responsible for the observed 
activity
[217, 218]
. The contaminating TIM was believed to have been co-purified during 
the nickel resin step, at a concentration which gave the appearance of low level 
activity from a novel enzyme. This is unsurprising given the high catalytic efficiency 
of TIM and highlights the need for effectively “nullified” background reactions in 
purification hosts when performing this type of experiment
[219]
. The recently reported 
computational design of enzymes capable of catalysing a Kemp elimination (Kemp 
eliminase) and a Diels-Alder reaction (Diels-Alderase) has shown that this field of 
protein engineering can develop enzymes not only carrying out the required 
chemistry, also entirely novel enzymatic reactions (Figure 37A and Figure 37B) 
[220, 221]
. 
Whether the Diels-Alder reaction is used by nature or is truly novel is still an 
unsolved question, although evidence would suggest that fungal Lovastatin 
nonaketide synthase (LNS, EC 2.3.1.161) may perform an intra-molecular Diels-
Alder reaction
[222, 223]
. Certainly, the engineered intermolecular Diels-Alderase would 
appear to be novel. Some of the earliest directed evolution work using catalytic 
antibodies did succeed in developing proteins that could carry out the Deils-Alderase 
reaction but they were exceptionally poor and this approach is no longer in use
[224]
. 
At present, in silico designed enzymes invariably suffer from hindered activity that is 
several orders of magnitude lower than those of their naturally evolved counter-parts, 
but by using directed evolution, improvements can be made in the designed protein. 
The catalytic efficiency of a Kemp eliminase was improved over 200 fold by directed 
evolution after an initial in silico design. The possibility of bespoke enzymes 
carrying out custom reactions may not ever be truly realised due to the complicated 
nature of enzyme design, but so far, impressive steps have been made towards this 
goal.  
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Figure 37. Novel enzymatic chemistry designed in silico. A) Kemp elimination catalysed by an 
enzymatic base, and stabilised by an enzyme H bond donor. B) Intermolecular Diels-Alder 
activity exhibited by designed enzyme with H-bond donor and acceptor stabilisation.  
3.5, Directed evolution of a Sitagliptin transaminase: 
 The directed evolution of a transaminase biocatalyst for the production of 
sitagliptin, developed by Codexis and Merck, is an extremely elegant example of 
evolution being used to overcome the inherent failings of a possible industrial 
biocatalyst
[18, 225]
. The biocatalytic synthesis replaced an asymmetric hydrogenation 
using a Rhodium catalyst at 250 psi. Along with a cleaner and cheaper route to the 
desired product, the % e.e. was increased from 97% to >99.9%, and the yield 
increased from 82% to 91% (Figure 38). 
- 56 - 
 
Figure 38. The chemo- and bio- catalytic routes to sitagliptin. 
This work is marked for several reasons, such as the evolution of not just activity on 
a novel substrate but also constant engineering of the protein stability towards the 
final required process conditions. The WT enzyme was stable under the mild 
conditions of 5% DMSO at 22°C, pH 7.5 in the presence of 0.5 M 2-propyl amine 
(the amine donor in the reaction) whereas after eleven rounds of evolution, it was 
stable at 50% DMSO at 45°C, pH 8.5 in the presence of 1 M 2-propyl amine. Each of 
these parameters was increased gradually with each round of screening to allow for 
the final protein to be industrially useful. Directed evolution was performed on a PLP 
dependent transaminase (ATA-117) from Arthrobacter sp. that had previously been 
shown to carry out (R)-specific reductive aminations of small methyl and cyclic 
ketones
[226]
. A major problem that had to be overcome was the traditional large 
pocket/small pocket substrate specificity of transaminases
[227, 228]
. The two R group 
pockets within the enzyme active site limit the substrate range to those that can fit 
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into these spaces. Prositagliptin, the substrate for this biocatalyst, clearly falls out 
with the small substituent/pocket requirement (Figure 39). The large pocket was first 
optimised using a methyl ketone prositagliptin analogue. After this was achieved, 
screening was performed with tri-fluoro benzyl substituted prositagliptin to open up 
the second, small pocket to accommodate this group.  
 
Figure 39. Screening approach used to bypass the large pocket/small pocket binding 
characteristics of transaminases. 
The screening in this work made use of HPLC and LC-MS in vitro screening and 
involved screening of only 10,000 clones due to semi-rational mutagenesis based on 
a homology model of ATA-117. Attempting to optimise both pockets at once would 
have required a substantially higher level of screening. The work shows that effective 
industrial biocatalysts can be engineered that not only rival, but out perform their 
equivalent chemo-catalytic routes. 
3.6, Directed evolution of NAAAR: 
To allow directed evolution of NAAAR, bacteria will be grown in conditions 
where selective pressure will favour those that can racemise N-acetyl amino acids. 
To apply this selective pressure, a double knockout bacterial host (SET21) will be 
used allowing for in vivo selection of large random libraries generated with 
epCPR
[229]
. High-throughput screening using Chiral HPLC will also be used to 
screen focused saturation mutagenesis libraries of mutation hotspots. The SET21 
strain was developed by Dr Sylvain Royer and highlighted a NAAAR enzyme 
containing a G291E mutation that is believed to improve NAAAR activity. The 
SET21 strain is deficient in the de novo L-methionine pathway (from L-homoserine), 
via a Cystathionine-γ-synthase knockout (MetB, EC 2.5.1.48), and a D-methionine 
racemisation pathway by means of a D-amino acid dehydrogenase knockout (DadA, 
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EC 1.4.99.1)[230-234]. These knockouts were achieved using the published PCR 
product gene knockout method of Datsenko et al
[235]
. The gene encoding MetB was 
replaced with a chloramphenicol resistance marker and the gene encoding DadA was 
deleted. Deletions removed any chance of reversion to the WT genotype, and 
insertion of an antibiotic resistance marker allowed for strain selection. These genetic 
modifications limit SET21 growth to conditions in which either L-methionine or N-
acetyl-L-methionine (the strain has endogenous aminohydrolases capable of 
hydrolysing N-acetyl-L-methionine) are available, for instance LB media. When 
grown on minimal media, L-methionine must be provided to allow SET21 growth. 
This can be done via chemical complementation with L-methionine/N-acetyl-L-
methionine, or via genetic complementation using recombinant NAAAR to racemise 
N-acetyl-D-methionine added to the growth media, which can then be used by the 
strain to facilitate growth (Figure 40). Importantly, SET21 cannot grow on D-
methionine and neither can NAAAR racemise this amino acid.  
 
Figure 40. Disabled L-methionine biosynthesis and genetic NAAAR complementation. 
By creating a system is which NAAAR turnover is the rate limiting step for strain 
growth, NAAAR variants will be effectively assayed in vivo and those with the 
highest activity should outgrow their neighbours. This dependence on NAAAR 
activity will allow for directed evolution to be applied, and the resulting variants 
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“I’m simply saying that life, uh….. finds a way” 
Dr Ian Malcolm (Jurrasic Park) 
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4.1, Directed evolution of Amycolatopsis Ts-1-60 NAAAR: 
Directed evolution allows for new functions to be introduced, or the 
improvement of existing ones, in an enzyme/protein
[236]
. Using this technique, the 
promiscuous N-acetyl amino acid racemase activity of NAAAR from Am. Ts-1-60 
has been enhanced. This process involved using the SET21 host to screen variant 
NAAAR plasmid libraries for mutations that caused desirable characteristics.  
4.2, SET21 microbiology: 
4.2.1, SET21 host growth conditions: 
Before screening of variant libraries could be performed, it was necessary to 
become familiar with the SET21 host and the microbiology techniques required for 
its use. The growth requirements for the host (with, and without NAAAR present) 
were confirmed with growth of SET21(DE3) expressing either empty pET20b or 
pET20b NAAAR WT on minimal media containing either L-methionine, D-
methionine, N-acetyl-L-methionine, or N-acetyl-D-methionine (all 2.5 mM). As 
expected, and shown by Dr Royer, the SET21 cell line requires a source of L-
methionine for growth (Figure 41). SET21(DE3) transformed with pET20b did not 
grow when streaked on D-methionine or N-acetyl-D-methionine, whereas growth was 
confluent on media containing L-methionine and N-acetyl-L-methionine. Growth on 
N-acetyl-L-methionine confirms that this host possess an L-acylase capable of 
hydrolysis of N-acetyl-L-methionine to the release the free amino acid. SET21(DE3) 
expressing NAAAR from pET20b NAAAR WT again showed no growth on media 
containing D-methionine and confluent growth on N-acetyl-L-methionine/L-
methionine. Importantly, these cells were now capable of growth on N-acetyl-D-
methionine due to NAAAR racemising this to the L-enantiomer. No growth was 
observed with either host on D-methionine confirming the requirement for D-
methionine to be N-acetylated for enzymatic racemisation.   
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Figure 41. Growth conditions of SET21(DE3) with pET20b = (-) and pET20b NAAAR = (+). A = 
L-methionine, B = D-methionine, C = N-acetyl-L-methionine, D = N-acetyl-D-methionine. 
Bacterial growth is stained with 2,3,5-Triphenyltetrazolium chloride redox indicator giving 
bactreia a dark contrast on the light agar plate. 
4.2.2, Improved expression system for screening: 
For saturation mutagenesis of G293, NAAAR was expressed in the SET21 
(non DE3) host using a pTTQ18 plasmid, driven by a tac promoter
[237]
. This strong 
promoter is a hybrid of the separate lac and trp promoters used for recombinant 
protein expression. The promoter is followed downstream by the lac operator and as 
the plasmid also contains the lacI
Q
 gene, protein expression is very tightly regulated. 
The addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) is required to 
overcome the lacI
Q
 repression and allow protein expression. This system had proven 
to be effective in the past with discovery that a G293E mutation in NAAAR 
increases activity, and was used with success in saturation mutagenesis of G293 (See 
section 3.2.2). However, it gave non-reproducible growth during early stages of 
testing. Difficulties were encountered as when the SET21 host was transformed with 
pTTQ18 NAAAR WT and spread on M9 minimal media containing N-acetyl-D-
methionine (2.5 mM) and IPTG (1 mM), the resulting colonies would show a 
considerable variation in size. In comparison, SET21(DE3) transformed with 
pET20b NAAAR WT and spread on Davis minimal agar (DMA) containing 2.5 mM 
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Figure 42. Growth characteristics of SET21 pTTQ18 NAAAR WT and SET21(DE3) pET20b 
NAAAR WT. SET21 pTTQ18 grown on M9 minimal agar supplemented with 1 mM IPTG and 
2.5 mM N-acetyl-D-methionine. SET21(DE3) pET20b NAAAR WT grown on DMA 
supplemented with 2.5 mM N-acetyl-D-methionine. Uniform colony size with pET20b compared 
to variable colony size with pTTQ18. 
This variation in size was attributed to the requirement for IPTG to induce expression 
of NAAAR in the pTTQ18 plasmid to facilitate growth. The concentration of IPTG 
in any given cell is related to the number of active lactose permeases available for 
uptake of IPTG and is controlled by stochastic fluctuations in protein expression
[238, 
239]
. Higher numbers of lactose permeases gives higher levels of expression, and vice 
versa. Further variation in the exact cellular inducer levels can arise due to Lactose 
permease expression/activity being passed on to daughter cells by asymmetric 
cellular division and other pre-induction genetic/phenotypic dispositions. Given that 
the rate of SET21 growth is dependent on NAAAR activity; any cells which happen 
to have higher levels of NAAAR expression than background will outgrow their 
neighbours. Further to this, cells which undergo IPTG induced expression do so 
under enormous metabolic burden compared to those that do not
[240]
. A combination 
of effects may lead to the differing colony sizes observed with SET21 expressing a 
single NAAAR enzyme from the pTTQ18 plasmid on minimal media containing 
IPTG (Figure 42). It should be noted that although cell size of any given 
SET21/NAAAR population varied, in general, SET21 cells expressing NAAAR 
G293E were larger than those expressing NAAAR WT. To remove the variation in 
colony size arising from IPTG effects, the gene encoding the NAAAR protein was 
cloned into the multiple cloning site of pET20b via the NdeI and HindIII sites. The 
cloning of this IPTG independent, NAAAR expression plasmid was performed by 
amplification of NAAAR WT gene from pTTQ18 NAAAR WT using primers 
NAAAR NdeI F that encoded an N-terminal NdeI site and NAAAR HindIII R that 
encoded a C-terminal HindIII site. As the native start codon for Am. Ts-1-60 
SET21 pTTQ18 NAAAR WT:       SET21(DE3) pET20b NAAAR WT: 
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NAAAR (GTG) is retained in the pTTQ18 plasmid, this was mutated to ATG to 
allow better expression in E. coli. The restriction sites are shown below in bold, with 
the mutation underlined:  
 NAAAR NdeI F 5’-CAT ATG AAA CTC AGC GGT GTG GAA CTG-3’ 
 NAAAR HindIII R 5’-AAG CTT CTA CGA ACC GAT CCA-3’ 
The PCR product containing the NAAAR gene was gel extracted and ligated into the 
pGEM T-easy cloning vector. From here, the plasmid was digested with NdeI and 
HindIII before ligation into pET20b digested with the same enzymes. The sequence 
of the pET20b NAAAR WT clone (4715 bp) was confirmed by sequencing (gene 
only). This was repeated with the NAAAR G293E gene to generate pET20b 
NAAAR G291E. In going from pTTQ18 to pET20b, an EcoRI restriction site from a 
previous cloning step was removed from the 5’ end of the sequence between bases 4 
and 10. This step removed two non-native amino acids (Glu-Phe) from the translated 
protein sequence and accounts for the discrepancy in numbering between G293 in 
pTTQ18 and G291 in pET20b. This plasmid allows expression of native NAAAR 
from the strong T7 promoter but does not require the addition of IPTG to do so. To 
allow the use of the T7 promoter, the SET21 host was made DE3 lysogenic using a 
commercial kit and the manufacturer’s instructions (Merck). The constitutively 
(“leaky”) expression from pET20b occurs because there is no lac operator 
downstream of the T7 promoter to repress expression. IPTG is not required for 
expression of the T7 RNA polymerase from the SET21 chromosome (derived from 
BW23115) as the host is lacI
+[241]
. The switch from pTTQ18 to pET20b gave a 
marked decrease in the deviation of colony size between SET21(DE3) colonies, with 
almost all colonies appearing to be the same diameter (Figure 41).  
4.2.3, Minimal media: 
 The media used for SET selection was also modified from the original M9 
minimal media previously used by Dr Royer. This media required M9 salts, MgSO4, 
Glucose, CaCl2, and CoCl2 solutions to be separately prepared and sterilised
[242]
. 
These solutions were then quickly added to Agar Number 1, before being aliquoted 
into sterile Petri dishes. The process was open to contamination due to the number of 
components that had to be added. During early SET21 testing a large number of 
contaminations (bacterial growth on D-methionine/N-acetyl-D-methionine/no 
methionine) were encountered. In an attempt to remove these, the minimal media 
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being used was changed from M9 to Davis minimal media
[243]
. Similar to M9, Davis 
minimal media is a potassium phosphate buffered solution (pH 7.0) containing 
various compounds (magnesium sulphate, ammonium sulphate, glucose and sodium 
citrate) that can be assimilated by bacteria into all the components required for life. 
The media is available as a commercial broth or agar making its preparation a simple 
task with less chance of contamination or formulation mistakes. Contaminations did 
decrease as SET21 testing progressed but whether this was due to the change in 
media or improved microbiological techniques is unclear.  
4.2.4, SET21(DE3) competency: 
To perform effective directed evolution using the SET21 selection host, it 
was important to ensure that large numbers of plasmids could be screened on a 
relatively small number of agar plates. This required SET21 cells that were highly 
competent allowing for maximal screening per transformation. Initial attempts at 
making competent SET21 cells involved using the standard CaCl2 technique
[244]
. 
This involved back diluting an SET21 overnight culture to an OD600 of 0.1 in 100 
mL of LB broth (30 μg mL
-1
 chloramphenicol) and allowing this to grow with 
agitation at 37°C until the OD600 reached 0.5. After an hour on ice, the cells were 
harvested by centrifugation and treated with 100 mM CaCl2. The final volume (~2 
mL) was stored as 200 μL aliquots. A single aliquot would be frozen and then 
defrosted to check cell competency. This involved transforming the SET21 aliquot 
via the standard heat shock method with 0.01 ng of pUC18 (Invitrogen) and 
spreading serial dilutions of this on LB agar (100 μg mL
-1
 ampicillin). Five μL was 
then streaked on separate DMA plates containing N-acetyl-D-methionine, or L-
methionine to check for contaminations. No antibiotics were added to these plates. 




 c.f.u. per μg pUC18 could 
be regularly attained. These values were deemed far too low for effective screening. 
As electroporation is known to generate much higher cell competencies than the 
CaCl2 heat shock method previously used, focus switched to this technique
[245]
. The 
SET21 host was made electro-competent by culturing SET21 overnight at 37°C in 
LB broth lacking NaCl (30 μg mL
-1
 chloramphenicol) and sub-culturing back to an 
OD600 of 0.1 in to 100 mL of the same media. The procedure was based on that 
reported by Shi et al
[246]
. Once these cells had reached an OD600 of 0.5, they were 
harvested by centrifugation and washed twice with 25 mL ice cold ddH2O (followed 
by 10 mL of 20% glycerol), and finally centrifuged and re-suspended (gentle 
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swirling for all resuspension steps) in 1 mL of ice cold 20% glycerol, 150 mM 
trehalose. The final OD600 of this 1 mL sample was ~100. This was stored as 50 μL 
aliquots, and was tested for both competency with 0.01 ng pUC18 (Invitrogen) and 





 c.f.u. per μg pUC18 could be regularly attained, with occasional values 
>1x10
10
 c.f.u. per μg pUC18 being measured. The inclusion of NaCl in the growth 
media was found to drop competency to ~1x10
7
 c.f.u. per μg pUC18. Keeping the 
cells below 4°C was believed to be of key importance. Although no studies were 
performed to address the importance of trehalose in the final re-suspension stage, 
literature evidence suggests it acts as a biological stabiliser of both protein and lipids 
and is most likely an important component for obtaining high competencies. It is 
often included in bacterial freeze drying formulations to help protect the integrity of 
cellular membranes, and is possibility performing a similar role here given the high 




Throughout this project, various means of mutagenesis have been used for 
both rational and random mutagenesis. Most of these techniques involved standard 
directed evolution PCR methods. 
4.3.1, Site directed mutagenesis (SDM) of G293E: 
To characterise the novel NAAAR G293E enzyme discovered by Dr Royer, it 
was first necessary to mutate the WT sequence to incorporate the g874a DNA 
mutation required for this amino acid change (the original pTTQ18 NAAAR G293E 
plasmid cloned by Dr Sylvain Royer was not available). The WT glycine codon 
(GGG) was mutated to an E. coli glutamic acid codon (GAG) using the standard 
SDM approach with primers G293E for and G293E rev
[249, 250]
. The mutation is 
shown below in bold. 
G293E for: 5’-GG TGC GGC GAG ATG ATC GAG ACC G -3’ 
G293E rev: 5’-CC GGT CTC GAT CAT CTC GCC GAC-3’ 
The mutagenesis was performed on the pTTQ18 NAAAR WT plasmid. Successful 
variants were compared to WT in the SET21 host and found to increase the rate of 
growth. The increase in growth rate was measured by colony size, judged by eye, on 
DMA plates containing 2.5 mM N-acetyl-D-methionine. 
- 67 - 
4.3.2, Saturation mutagenesis of G293: 
A standard approach in directed evolution is to saturate a position highlighted 
by XL1-Red/epPCR with all other amino acid possibilities. This was performed at 
position G293 in pTTQ18 NAAAR WT using an NNK degenerate codon encoding 
all 20 proteinogenic amino acids
[158]
. 
4.3.2.1, PCR amplification of NAAAR G293x mutagenic library: 
Saturation mutagenesis of G293 was performed on pTTQ18 NAAAR WT 




G293x for: 5’-C CCG GTG TGG TGG TGC GGC NNK ATG-3’ 
G293x rev: 5’-CC GGT CTC GAT CAT MNN GCC G-3’ 
The PCR was performed with Pfu turbo and the product digested for 5 hours with 
DpnI at 37°C to remove WT template. DpnI was then inactivated by incubation at 
80°C for 20 minutes in a PCR thermal cycler followed by gentle cooling to room 
temperature and centrifugation. Inactivation of DNA binding proteins was thought to 
help increase transformation efficiency.  
4.3.2.2, Screening of NAAAR G293x mutagenic library: 
The DpnI digested product was briefly centrifuged before 2 μL was used to 
transform 50 μL of electrocompetent SET21 cells. An ethanol precipitation of the 
digested product was tested, however this was found to decrease transformation 
efficiency by 50%. Transformed cells were incubated at 37°C for one hour with 
agitation and then washed three times in sterile ddH2O to remove all exogenous 
sources of L-methionine. To screen the mutagenic library, 95% of the washed cells 
were spread on a DMA plate (2.5 mM N-acetyl-D-methionine, 30 μg mL
-1
 
chloramphenicol, 100 μg mL
-1
 ampicillin, 1 mM IPTG) with the remaining 5% 
spread on an LB agar plate (30 μg mL
-1
 chloramphenicol, 100 μg mL
-1
 ampicillin). 
This LB agar plate was used to check cloning and transformation efficiency. After 24 
hours incubation at 37°C, forty colonies were visible on the DMA plate. The four 
largest of these were re-streaked on replica DMA to isolate single colonies. After 24 
hours growth, three of these streaks had grown better than the WT. The plasmid 
DNA from the three faster growing colonies was isolated and sequenced to reveal a 
single mutation common to all plasmid samples. The WT glycine codon had been 
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mutated from GGG to GAT, corresponding to aspartic acid
[250]
. As an NNK codon 
was used for saturation mutagenesis, this is the only aspartic acid codon available. A 
repeated round of screening under the same conditions generated only glutamic acid 
variants (from WT). All variants isolated from screening of G293 were found to 
contain either glutamic or aspartic acid, and SET21 hosts expressing these variant 
NAAARs grew faster than hosts expressing the WT. When the growth rates of the 
two variants were compared, it was observed that G293D grew slightly faster than 
G293E. An interesting observation from his process is that although the initial XL1-
Red screen (performed by Dr Sylvain Royer) was able to generate NAAAR G293E 
as an enzyme with improved activity; it would have been highly unlikely for it to 
create a G293D variant within a single round of screening. The reason for this is that 
the chances of WT being mutated to G293E are roughly 1 in 3000 (as there are 1104 
base pairs, with 3 possible base substitutions per base, only one of which, GGG to 
GAG, gives glutamic acid), whereas the chances of WT being mutated to G293D are 
roughly 1 in 4,500,000 (roughly 1 in 3000 to generate GAG, then 1 in 1500 to 
generate either GAT or GAC after that initial GAG mutation). These numbers show 
the importance of saturation mutagenesis as a means to ensure that as much of the 
useful protein sequence space is tested as possible during directed evolution.  
4.3.2.3, Structural analysis of G293E/D mutations: 
The G293E and G293D mutations share functional overlap as they both 
introduce a carboxylate group. This suggests that this functional group is of key 
importance in increasing NAAAR activity. In the WT NAAAR:N-succinyl-L-
methionine crystal structure (PDB code: 1SJC) the peptidic carbonyl of G293 (G291 
in the native form and PDB structure) forms a H-bonding interaction with the N-
succinyl amide forming part of the N-acyl binding pocket
[100]
. This interaction does 
not appear to occur in the WT:N-acetyl-L-methionine structure (PDB code: 1SJA) as 
there is distance of 3.8 Ǻ between these groups (Figure 43). The introduced glutamic 
and aspartic acid side groups may reposition the peptidic carbonyl to allow this 
interaction, or they may enter into the active site themselves and H-bond with the 
substrate amide. The conservation of the carboxylate group would suggest that this 
functionality is essential for whatever role these mutations play in increasing 
enzymatic activity. 
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Figure 43. Location of G291 in NAAAR active site. Catalytic residues K163, K263, D189, E214, 




4.3.3, Error prone PCR (epPCR) of NAAAR G291D: 
After the success of saturation mutagenesis at position G293, a more random 
approach was taken for the next round of mutagenesis. At this stage screening was 
also switched from the pTTQ18/SET21 system to the improved 
pET20b/SET21(DE3). Error prone PCR can be accomplished by modification of a 
standard PCR, for instance, over inclusion of a single base in the dTNP mix, or 
swapping the usual Taq polymerase Mg
2+
 cofactor to Mn
2+
, however these 
approaches tend to give a limited mutation spectrum that is not conductive to 
effective epPCR
[161]
. In order to achieve a varied mutational spectrum, a commercial 
kit (Genemorph II, Stratagene) was used. This kit uses a combination of Taq and a 
proprietary error prone polymerase that has been engineered to have the opposite 
mutational spectrum to that of Taq polymerase. As a result, this kit gives a mutagenic 
product with a balanced spectrum containing an equal distribution of transitions and 
transversions. Another useful feature of this commercial kit is that the level of 
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occur. This can be achieved by changing either the initial template concentration or 
the number of amplification cycles. The more the product is amplified (i.e. less 
template or more thermal cycles), the higher the overall mutagenesis rate of the final 
PCR product. The Genemorph II kit claims to allows mutagenic rates of up to 16 bps 
per 1 kbp (although higher rates would be possible), however high rates like this are 
of little use for effective directed evolution, as any enzyme containing this number of 
random mutations will likely suffer from multiple deleterious changes in 
function/structure. Mutagenesis should ideally be a stepwise process with ~1 amino 
acid change being screened per round. Another key reason for this is that the effort 
required to screen a single amino acid mutation in a 300 residue protein is relatively 
small (6000 clones), whereas two amino acids in parallel requires a substantial 
increase in screening (120,000 clones). Serial mutagenesis of two positions would 
require only 12,000 clones. A drawback of this approach is that pairs of synergistic 
mutations may be missed. 
4.3.3.1, Amplification of NAAAR G291D mutagenic library with epPCR: 
 A mutagenic pET20b G291D NAAAR library was constructed using primers 
pET20b Fm and pET20b Rm. These primers terminate on the 3’ end with either the 
ATG start codon or CTA stop codon limiting mutagenesis to residues 2 – 368 of the 
NAAAR protein. The start and stop codons are shown in bold and restriction sites 
underlined below. 
pET20b Fm 5’-GTT TAA CTT TAA GAA GGA GAT ATA CAT ATG-3’ 
pET20b Rm 5’-GTG CTC GAG TGC GGC CGC AAG CTT CTA-3’ 
The NAAAR G291D gene was amplified using an initial template (i.e. the NAAAR 
gene) concentration of 100 ng and cycled 25 times. According to the manufacturer’s 
specification, these conditions should generate between 0 - 4.5 mutations/kb. The 
amount of template is given as the amount of the actual gene, for instance, pET20b 
NAAAR G291D is roughly 5000 bp, of which 1100 bp are NAAAR template, 
therefore in a reaction containing 500 ng of total plasmid, 20% of this (100 ng) is the 
NAAAR template. Two μL of the epPCR product was then used as the template in a 
second, high fidelity PCR (Pfu) which is required to generate the >300 ng of PCR 
product needed for incorporation into the pET20b vector via a megaprimer of whole 
plasmid PCR (MEGAWHOP)
[186, 197]
. Also, as the epPCR product is relatively 
expensive to produce (£15/reaction), it makes sense to re-amplify this so it can be 
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used numerous times, and allow optimisation of the MEGAWHOP process. 
MEGAWHOP eliminates the need for a ligation that can severely limit the 
effectiveness of library construction. The MEGAWHOP works much like SDM; 
however, it uses a ~1100 bp gene as a mutagenic primer pair. Extension from the 3’ 
end re-constructs the vector backbone once the gene has annealed at the correct 
position. The product of this process is a mutagenic nicked plasmid library that can 
be used to transform the SET21(DE3) host for selection. The conditions for the 
MEGAWHOP PCR were optimised to maximise the number of c.f.u. after 
SET21(DE3) electroporation. The optimum conditions were found to be 100 ng of 
pET20b NAAAR template and at least 300 ng of megaprimer. This was found to be a 
crucial parameter as MEGAWHOP efficiency dropped dramatically below 300 ng. 
The optimal number of thermal cycles was found to be 25 and increasing this caused 
no improvement in the number of c.f.u. After 35 cycles, the number of c.f.u. 
decreased. SET21(DE3) (at least 1x10
8
 c.f.u. per μg pUC18) electroporated with the 
MEGAWHOP PCR product under optimum conditions were estimated to contain 
approximately 10,000 c.f.u. (5% spread on an LB agar gave approximately 500 
c.f.u.).  To check that the mutagenic spectrum of this epPCR was unbiased, the DpnI 
digested MEGAWHOP product was used to transform DH5α and the plasmid DNA 
isolated. Four plasmids were sequenced to determine the mutagenic spectrum of the 
epPCR mutagenic library (Table 3).  
Table 3. Variants sequenced from pET20b G291D NAAAR error prone PCR library. 
Colony Mutations  
1 t629c (L210P) 
2 g144t (silent), g642a (silent), a1061c (E353A) 
3 c963g (E321D) 
4 Parental template 
Sequencing of these plasmids indicated that a good mutagenic spectrum had been 
achieved. The mutations corresponded to 40% transitions (C↔T, A↔G): 60% 
transversions (T↔AG, C↔AG, A↔TC, G↔CT) and CG→N (40%): AT→N (60%). 
The library contained on average 1.2 DNA mutations per sequenced gene (1104 bp), 
or 0.75 amino acid mutations per enzyme (368 residues).  
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4.3.3.2, Screening of pET20b G291D NAAAR mutagenic library: 
 To screen this library for improved variant NAAARs, five aliquots of 
SET21(DE3) were each electroporated with 2 μL of DpnI digested MEGAWHOP 
PCR product constructed from the above epPCR product. The cells were incubated at 
37°C for 1 hour with agitation before being washed three times with 1 mL of sterile 
ddH2O. The five aliquots were each resuspended in a final volume of 100 μL ddH2O, 
of which 5 μL were spread on an LB agar plate (30 μg mL
-1 
chloramphenicol, 100 μg 
mL
-1
 ampicillin) and the remaining 95 μL was spread on a DMA plate (30 μg mL
-1 
chloramphenicol, 100 μg mL
-1
 ampicillin, 500 μM N-acetyl-D-methionine). After 16 
hours growth at 37°C, the number of colonies on each of the five LB agar plates was 
approximately counted and this value used to judge the number of c.f.u. thought to 
have been screened. This was estimated to be in the region of around 35,000-40,000 
c.f.u. in total from the five plates. After 48 hours growth, three colonies were judged 
by eye to have out grown their immediate neighbours. These three colonies were re-
streaked onto a single replica DMA plate and a single colony (from each streak) from 
this plate used to inoculate 5 mL of LB broth (30 μg mL
-1 
chloramphenicol, 100 μg 
mL
-1
 ampicillin). The plasmid DNA was isolated from these three colonies and 
sequenced (Table 4).  
Table 4. Mutations found within fast growing NAAAR colonies. 
Colony Mutations  
1 c598t (P200S), t968a (F323Y) 
2 t968a (F323Y) 
3 a148t (M50L), g1065t (silent) 
An initial assay of activity of these variant NAAARs was conducted using a liquid 
growth assay in Davis minimal broth (DMB). DMB is identical to DMA, but in 
liquid form, allowing for OD600 measurements to be read and a quantitative value for 
growth attributed to each SET21 colony/NAAAR variant. This approach was 
investigated as it proved very difficult to measure colony size accurately as they 
tended to be only 1-2 mm in diameter. The liquid growth assay was performed by 
taking 1 mL of an LB broth (100 μg mL
-1
 ampicillin) overnight culture of 
SET21(DE3) expressing each NAAAR variant and harvesting the cells with 
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centrifugation. The cell pellet was then washed three times with 0.22 μm filtered 
ddH2O. The washed cell suspension was then diluted in DMB (30 μg mL
-1 
chloramphenicol, 100 μg mL
-1
 ampicillin, 500 μM N-acetyl-D-methionine) to an 
OD600 of ~0.15. The cultures (5 mL) were then incubated at 37°C with agitation and 
the increase in OD600 measured every hour. A standard of SET21(DE3) expressing 
NAAAR G291D was included along with a control containing no source of 
methionine to rule out non-methionine auxotroph contaminations. Typically, there 
was no OD600 change during the first 5 hours, after which differing rates of growth 
were observed for SET21(DE3) hosts expressing each NAAAR variant (Table 5). 
After 24 hours, all cultures had reached a maximum OD600 of ~0.9. Addition of 
further N-acetyl-D-methionine after this point did not result in an increase in OD600. 
4.3.3.3, Liquid growth assay of NAAAR G291D P200S F323Y, NAAAR G291D F323Y, 
and NAAAR G291D M50L variants: 
To overcome the low sensitivity of the solid agar screen, a liquid screening 
assay was developed to quantify the rate of culture growth. The high number of false 
positives encountered highlighted the need for an improved quantitative screening 
method. Attempts were made at using a plate reader to carry out this work but it was 
found to be impossible to measure NAAAR dependent growth with the plate reader 
available. An effective setup was found that allowed reproducible growth using 5 mL 
cultures of minimal media incubated at 37°C on a flask shaker. The OD600 was 
measured using a spectrophotometer at set time points (Table 5). 
Table 5. Comparison of growth characteristics for SET21 complemented with differing NAAAR 
variants. 
NAAAR variant Initial OD600 OD600 (8 hours later) OD600 increase 
G291D 0.16 ± 0.01 0.18 ± 0.04 0.02 
G291D M50L 0.14 ± 0.01 0.36 ± 0.01 0.22 
G291D F323Y P200S 0.16 ± 0.01 0.24 ± 0.02 0.08 
G291D F323Y 0.16 ± 0.01 0.49 ± 0.01 0.33 
All three variant NAAARs were found to increase the growth rate of the 
SET21(DE3) host compared to the parental NAAAR G291D template. The largest 
- 74 - 
increase in growth came from the F323Y mutation, with M50L also providing a 
marked increase. Interestingly, the F323Y mutation was isolated in two independent 
colonies; the other also containing the P200S mutation. From the growth data, it 
would appear that F323Y is a beneficial mutation increasing SET21 growth, whereas 
P200S is deleterious. Given this, the P200S mutation was quickly discarded as an 
adverse mutation that had only been highlighted due to its occurrence in the same 
plasmid as the F323Y mutation. 
4.3.3.4, Structural analysis of M50L, P200S, and F323Y mutations: 
Analysis of the X-ray crystal structure of NAAAR WT complexed with N-
acetyl-methionine (PDB code: 1SJA, substrate modelled as the L-enantiomer) gave 
an indication of what possible role the of M50L, P200S, and F323Y mutations may 
be playing
[100]
. Both M50L and F323Y are found in two separate substrate binding 
pockets; M50L appears to be located in the substrate side group binding pocket and 
F323Y appears to contribute to the N-acyl binding pocket along with G291D. The 
deleterious P200S was located on an outer α-helix, ~25 Å away from the substrate 
(α-carbon to α-carbon) and clearly played no direct role in the active site. The 
presence of proline in an α-helix often leads to kinks or bends, and in the WT X-ray 
crystal structure there is a distinct kink before P200
[251]
. This kink may help to 
position D189, a key catalytic residue involved in Mg
2+
 binding, within 2.5 Å of the 
metal cofactor. The removal of this kink may have pulled D189 into an unfavourable 
position causing a decrease in enzyme efficiency by altering the Mg
2+
 binding site 
(Figure 44). 
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Figure 44. Location of P200 and its proximity to the Mg
2+
 binding site in NAAAR WT. NAAAR 
backbone shown as green ribbon. Figure generated from 1SJA
[100]
. 
Several encouraging observations were made for the F323Y mutation. Firstly it was 
present in two independent colonies that were not daughters from phenotypic 
outgrowth (due to the occurrence of P200S in only one of these). It appeared to 
increase the activity sufficiently in the presence of a likely deleterious mutation to 
allow an increase in SET21 growth. And thirdly, there was a clear chemical rational 
of how this mutation could influence substrate binding. The mutation from 
phenylalanine to tyrosine is a relatively small mutation structurally; however, there is 
a rather marked change in the chemistry once the introduced hydroxyl is considered. 
The hydroxyl can now provide an H-bond donor which could possibly interact with 
the substrate acetyl carbonyl. Given that in the WT structure the para-carbon of the 
phenylalanine ring resides only 5.8 Å from the C atom of this carbonyl, this is a 
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Figure 45. The position of F323 and substrate carbonyl group in NAAAR WT X-ray crystal 
structure. Catalytic residues, along with G291 also shown. Figure generated from 1SJA
[100]
. 
Although the F323Y mutation is novel to the Am. Ts-1-60 NAAAR, in other bacteria 
such, as G. kaustophilus, the equivalent 323 position of NAAAR is already a 
tyrosine
[252]
. It may be that the next step in the natural evolution of Am. Ts-1-60 
NAAAR towards increased N-acyl amino acid racemase activity would have been 
the F323Y mutation.  
M50L is located in the amino acid substrate binding pocket, close to the lid 
domain of the NAAAR monomer (Figure 46). The binding pocket consists of seven 
residues which surround the amino acid side group (F19, F23, Q26, M50, Y55, I292, 
and M293). The mutation of methionine to leucine is likely to affect the sterics of the 
binding pocket more than any chemical interactions as both amino acids are 
hydrophobic in nature. The distance between the terminal methyl groups of both 
M50 and substrate is only 3.1 Å. The M50L mutation may open up extra space 
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4.3.4, Saturation mutagenesis of F323: 
Saturation mutagenesis was carried out at position F323 to see if the F323Y 
mutation was most active amino acid at this position. This work was carried out 
using high-throughput HPLC screening to compare this process to the SET21 genetic 
selection. 
4.3.4.1, PCR amplification of NAAAR F323x mutagenic library: 
 Saturation mutagenesis of F323 was performed by creating a megaprimer 
from pET20b NAAAR G291D using primers pET20b Fm and F323x rev. This 
megaprimer was incorporated into pET20b NAAAR G291D using a MEGAWHOP 
PCR. The degenerate MNN (reverse complement of NNK) codon shown in bold, and 
the NdeI restriction site underlined below. 
pET20b Fm: 5’- GTT TAA CTT TAA GAA GGA GAT ATA CAT ATG -3’ 
F323x rev: 5’- GGT TTT GTG MNN CCG GTC C -3’ 
The PCR megaprimer product (~1100 bp) was gel purified and used in a 
MEGAWHOP PCR using pET20b NAAAR G291D as a template. The PCR was 
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remove the parental template. DpnI was then inactivated by incubation at 80°C for 
20 minutes in a PCR thermal cycler followed by gentle cooling to room temperature.  
4.3.4.2, High-throughput screening of NAAAR F323x mutagenic library: 
The DpnI digested NAAAR G291D F323x MEGAWHOP PCR product was 
used to transform BL21(DE3) competent cells and 96 of the resulting transformants 
(from several hundred) were picked into two 48 deep well plates. Each well 
contained 700 μL LB broth (100 μg mL
-1
 ampicillin). The plates were sealed with 
gas permeable seals and incubated with agitation overnight at 37°C. The cells in each 
well were assayed by adding 10 μL of cell broth to 90 μL of reaction buffer 
containing 100 mM Tris-HCl (pH 8.0), 5 mM CoCl2, and 150 mM N-acetyl-D-
methionine. This was done in a 96 well plate format. This plate was incubated at 
60°C for one hour with agitation before all biotransformations were terminated with 
a 1000 fold dilution with HPLC running buffer (75:25 0.01% TEAA:MeOH). The 
racemisation of N-acetyl-D-methionine was monitored by chiral HPLC. Separation of 
chiral molecules by HPLC can be achieved using two methods. Firstly, a chiral 
stationary phase (CSP) can be used to separate enantiomers by enantioselectively 
retaining one more than the other, thus imparting differing retention profiles on the 
two conformations, or by derivatisation of the analyte with a chiral auxiliary to form 
a pair of diastereomers that can be resolved by RP-HPLC on a non-chiral column
[253]
. 
In the case of primary amines such as amino acids, chiral derivatisation can be 
performed with o-phthaldialdehyde (OPA) and N-acetyl-L-cysteine (NAC)
[254]
. As 
the substrate/products for NAAAR are secondary amines, OPA/NAC derivatisation 
is not possible. To overcome this, a CSP in the form of a Chirobiotic™ T chiral 
column was used. This allowed the effective separation of both N-derivatised and 
free amino acids with no pre-column derivatisation required. The CSP used in this 
column is teicoplanin, an antibiotic glycopeptide (Figure 47)
[255]
. 
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Figure 47. Teicoplanin, the CSP in Chirobiotic T chiral HPLC column. 
The key structural features of this CSP that allow it to separate enantiomers 
are the ionic binding sites (green boxes), the alkyl chain attached to the β-D-
glucosamine ring, and the four inclusion pockets (A, B, C, and D). Along with these, 
there are also π-acceptor/donator and H-bonding sites. The chiral environment of 
these functional groups provides the enantioselectivity required for separation. A 
literature report showing the use of this column to separate N-acetyl-amino acids was 
used as a starting point for optimised analysis conditions
[256]
. The final conditions 
varied very little from those published, with only a 5% increase in methanol required 
to provide a 10 minute HPLC run, monitored at 210 nm, that was sufficient to 
resolve both enantiomers of N-acetyl-methionine and also non-derivatised 
methionine in a single HPLC run. The chiral separation is attained by selective 
retention of the D-enantiomer of both molecules. The mobile phase used for 
separation was a 10 minute isocratic elution of 75:25 0.01% TEAA:MeOH which 
separated N-acetyl-L-methionine and N-acetyl-D-methionine by over 2 minutes. The 
free amino acids also eluted well separated under these conditions (Figure 48). Using 
automated injection and a 10 minute HPLC run, screening of a 96 well plate was 
completed 18 hours.  
Screening of pET20b G291D F323x libraries was carried out by auto-
sampling 20 μL of each 1000 fold diluted biotransformation for HPLC injection. The 
decrease in e.e. was used to measure NAAAR activity. Of the 96 wells tested, three 
had clearly higher levels of racemisation than the rest as judged by the HPLC traces. 
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Sequencing of the plasmid DNA corresponding to these three wells confirmed that 
they all contained a mutation (t968a) corresponding to F323Y. 
 
Figure 48. Injection of N-acetyl-DL-methionine and DL-methionine on a Chirobiotic™ T column 
monitored at 210 nm. Eluted with an isocratic elution of 75:25 (0.01% TEAA: MeOH) at 0.5 ml 
min
-1
. Retention times are 4.5 minutes for N-acetyl-L-methionine, 6.1 minutes for N-acetyl-D-
methionine, 8.5 minutes for L-methionine, and 10.0 minutes for D-methionine. 
High-throughput screening of mutagenic NAAAR libraries proved to be an 
effective method for screening. Although the number of colonies screened (96) is 
considerably lower than the thousands that could be screened using the SET21(DE3) 
selection system, the output of actual enzymatic performance shown in an HPLC 
trace makes it much easier to identify positive hits. Although HPLC screening did 
not highlight a novel mutation, it did select G291D F323Y from a G291D template 
indicating that novel mutations that increase activity can be found using this method. 
HPLC screening gave a much higher sensitivity than the SET21(DE3) selection 
system which although was used successfully in this project, was only able to 
identify two mutations from screening of several thousand variant enzymes. A 
targeted mutagenesis approach in which the amino acids within the active site are 
subjected to iterative saturation mutagenesis (CASTing) and screened using high-
throughput methods would possibly highlight novel mutations missed by the SET21 
selection strain
[160, 188, 190, 191]
. Those mutation missed by the SET21 selection screen 
are those that increase activity, but do not increase activity enough to cause a 
substantial change in the SET21(DE3) phenotype. The difference in agar plate 
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growth between SET21(DE3) expressing NAAAR WT and those expressing 
NAAAR G291D F323Y is relatively small, making positive ‘hit’ identification 
difficult. 
4.4, Cloning, expression, purification and assay of NAAAR: 
To assess the role of the G291E/D, M50L and F323Y mutations, the 
recombinant NAAAR enzymes were over-expressed and purified using a variety of 
chromatographic techniques, allowing for their kinetic and structural 
characterisation. 
4.4.1, Cloning, expression, purification and assay of hexa-histidine tagged 
NAAAR: 
4.4.1.1, Cloning and expression of Hexa-histidine tagged NAAAR: 
Initial attempts to purify NAAAR utilised immobilised metal affinity 
chromatography (IMAC) and expression of NAAAR from pET28a to incorporate an 
N-terminal hexa-histidine tag. The cloning of this plasmid was performed by 
amplification of NAAAR WT gene from pTTQ18 NAAAR WT using primers 
NAAAR NdeI F that encoded a 5’- NdeI site and NAAAR HindIII R that encoded a 3’- 
HindIII site. As the native start codon for Am. Ts-1-60 NAAAR (GTG) is retained in 
the pTTQ18 plasmid, this was mutated to ATG to allow more favourable expression 
in E. coli systems. The restriction sites are shown in bold and the mutation 
underlined below.  
 NAAAR NdeI F 5’-CAT ATG AAA CTC AGC GGT GTG GAA CTG-3’ 
 NAAAR HindIII R 5’-AAG CTT CTA CGA ACC GAT CCA-3’ 
The PCR product containing the NAAAR gene was gel extracted and ligated into the 
pGEM T-easy cloning vector. From here, the plasmid was digested with NdeI and 
HindIII before ligation into pET28a digested with the same enzymes. Sequencing 
confirmed the fidelity of the pET28a NAAAR WT clone (6415 bp). To allow 
expression and characterisation of NAAAR G291E, the NAAAR G293E gene was 
cloned from pTTQ18 NAAAR G293E by the same means. This generated pET28a 
NAAAR G291E. As with pET20b mentioned earlier, on going from pTTQ18 to 
pET28a, G293E becomes G291E. NAAAR WT and NAAAR G291E were over-
expressed in BL21(DE3) for 5 hours with 0.1 mM IPTG at 37°C. Expression was 
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carried out in 5 L of LB broth (30 μg mL
-1
 kanamycin). Cells were harvested with 
centrifugation (4,000 g, 20 mins, 4°C) and stored at -20°C until needed.  
4.4.1.2, Purification of hexa-histidine tagged NAAAR: 
Purification of NAAAR was performed by first re-suspending a BL21(DE3) 
cell pellet expressing NAAAR in 10 mL of lysis buffer (50 mM Tris-HCl (pH 7.5), 
100 mM NaCl, 20 mM imidazole, 1 complete EDTA free mini protease inhibitor 
tablet (Roche)). Once fully re-suspended, the cells were lysed by sonication and the 
CFE clarified by centrifugation (12,000 g, 60 mins, 4°C). The CFE was then filtered 
and incubated for 1 hour with pre-equilibrated Ni:NTA resin (Invitrogen) at 4°C. 
This resin was then loaded into a 1 mL polypropylene column (Qiagen) and washed 
with 40 mL of elution buffer (50 mM Tris-HCl, (pH 7.5), 100 mM NaCl, 20 mM 
imidazole) followed by a stepwise gradient of increasing imidazole concentration. 
The resin was washed with 20 mL of 20 mM, 10 mL of 150 mM and finally, 10 mL 
of 250 mM imidazole. The purification process, which was identical for both WT 
and G291E NAAAR, was monitored by SDS-PAGE analysis (Figure 49). This 
procedure was tested on a pre-packed HisTrap™ FF 1 mL Ni:Sepharose column (GE 
Healthcare) but the final product contained several contaminating proteins. All 
purification steps were performed on ice or at 4°C. 
 
Figure 49. SDS-PAGE analysis of hexa-histidine tagged (A) NAAAR WT and (B) NAAAR 
G291E IMAC purification. M = See Blue Plus2 Marker, 1 = before induction, 2 = after 
induction, 3 = insoluble cell fraction, 4 = cell free extract, 5 = flow through, 6 = 20 mM imidazole 
wash, 7 = 100 mM imidazole elution, 8 = 250 mM imidazole elution. 
Although a large amount of the protein was found in the insoluble cell fraction, there 
was still sufficient NAAAR in the CFE to allow for an effective purification. Due to 
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the high purity of the product (as judged from SDS-PAGE analysis), no further 
purification was performed. This process typically yielded 10 mg L
-1
 growth media 
for both recombinant NAAARs. The 100 mM and 250 mM imidazole fractions 
containing NAAAR were pooled and dialysed three times against 1 L of 50 mM 
Tris-HCl (pH 7.5), 100 mM NaCl, after which, NAAAR concentration was measured 
by the absorbance at 280 nm (Abs280). The following parameters, generated by 
Vector NTi 10 (Invitrogen), were used in calculating concentrations; mass of WT = 





. NAAAR was found to be stable for 3-4 weeks when stored in 20% 
glycerol at -20°C. 
4.4.1.3, In vitro assay of hexa-histidine tagged NAAAR: 
To compare the activities of NAAAR WT and NAAAR G291E, kinetic 
characterisation of these two proteins was carried out using chiral HPLC. Enzyme 
assays were performed by incubating purified histidine tagged NAAAR with 100 μM 
- 20 mM of N-acetyl-D-methionine and N-acetyl-L-methionine. The reaction was 
performed at pH 7.5 in 50 mM Tris-HCl with 5 mM CoCl2 as a cofactor. 100 μL of 
enzyme (0.1 mg) was incubated for three minutes at 37°C in a heat block with 900 
μL reaction mixture containing buffer and substrate. All components were preheated 
to 37°C before mixing. After three minutes, the reaction was terminated and diluted 
by twenty fold in 50 mM HCl. NAAAR was precipitated by three minutes boiling at 
100°C followed by clarification by centrifugation (11,000 g, 3 mins, rt). The 
supernatant was then 0.45 μm filtered before HPLC analysis. To limit the effects of 
formation of methionine sulfoxide and sulfone, the reactions were analysed within 24 
hours. The termination step was attempted with 10 mM EDTA, a known inhibitor of 
NAAAR and other metallo-enzymes, but this was found to co-elute and mask the 
analyte species in the HPLC traces
[95]
. The enzyme kinetic parameters determined 
from these assays are shown below (Table 6). The G291E mutation was expected to 
increase enzyme turnover, however, the results suggested that the G291E variant 
NAAAR is less active than the WT. This was a surprising observation as SET21 
growth studies clearly showed an increase in SET21 growth when the host was 
expressing NAAAR G293E compared to the WT. It should be noted that although 
the Km is lower for the G291E variant, the WT was more active at all substrate 
concentrations tested (100 μM - 20 mM). 
 
- 84 - 





Km (mM) kcat (s
-1
) Km (mM) kcat (s
-1
) 
WT 3.2 ± 0.40 2.15 ± 0.13 1.78 ± 0.25 1.36 ±0.08 
G291E 2.64 ± 0.17 1.39 ± 0.06 1.42 ± 0.2 0.80 ±0.07 
It was thought that as the GGG glycine codon is a rather unfavourable codon for E. 
coli expression and the GAG glutamic acid codon is more favourable, that an 
increase in protein expression could be accountable for the increase in SET21 
growth. This was tested by mutating the rare GGG codon to another, more 
favourable glycine GGC codon
[250]
. When this DNA variant NAAAR was compared 
to WT and G293E, no increase in SET21 growth was observed ruling out the 
possibility that the increase in expression was due to replacement of a rare codon.  
The observed kinetics were slightly lower than those published by Gerlt et al 
under similar conditions (Table 2) and inhibition was observed above 8 mM of both 
substrates compared to the 50 mM that is reported in the literature
[95, 101]
. A literature 
review of enolase enzymes revealed that their β-barrel structure has been noted to 
suffer from mis-folding when expressed with a histidine tag
[258]
. With this in mind, a 
new expression and purification process was developed based on the published 




4.4.2, Cloning, expression, purification and assay of native NAAAR: 
4.4.2.1, Cloning and expression of native NAAAR: 
To allow expression of native NAAAR, the pET20b expression vector was 
used. This vector also allowed for a “gentle” expression without any IPTG as there is 
no lac operator downstream of the T7 promoter. This plasmid had already been 
cloned for use in the SET21(DE3) selection process. The use of a single plasmid for 
both SET21(DE3) selection and protein expression would remove the need for an 
intermediate cloning step between these two processes. Expression from pET20b was 
found to be excellent in a BL21(DE3) host with no IPTG added for induction. 
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Expression was initiated by picking a single BL21(DE3) pET20b NAAAR colony 
into 500 mL LB broth (100 μg mL
-1
 ampicillin). These were left to grow at 37°C for 
24 hours with agitation (Figure 50).  
 
Figure 50. Leaky BL21(DE3) expression from pET20b NAAAR WT over 24 hours. M = L.M.W 
marker, 1 = BL21(DE3) pET20b after 24 hours, 2 = BL21(DE3) pET20b NAAAR WT after 24 
hours. 
Typically, expression was started at 9 am, and cells harvested (4,000 g, 20 mins, 
4°C) 24 hours later allowing for NAAAR purification to be performed with fresh 
cells that had not been frozen. If required, cell pellets were stored at -20°C. 
4.4.2.2, Purification of native NAAAR: 
 NAAAR purification was performed using a combination of ion exchange 
(IEX) and size exclusion chromatography (SEC). This method was identical for all 
NAAAR variants and the WT. As the isoelectric point (pI) of NAAAR is 4.97, the 
monomer has a charge of -13.1 at pH 8.0, hence, anion exchange should allow 
NAAAR to be separated from the less negatively charged background BL21(DE3) 
proteins
[259]
. It was observed during the anion exchange optimisation process that if 
no NaCl was included in the lysis buffer, NAAAR was insoluble. Therefore all lysis 
buffers contained 100 mM NaCl. Three anion exchange columns were tested for their 
capability as an initial purification step; these were a Hi-Load Sepharose Q 26/10 (50 
mL), a Resource Q (6 mL), and a HiPrep FF Q 16/10 (20 mL). All columns were 
equilibrated with 50 mM Tris-HCl (pH 8.0) 100 mM NaCl and elution performed 
with the same buffer containing 1 M NaCl. Although all three of these columns 
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worked well as an initial purification step, there were inherent difficulties with two 
of the columns. The Sepharose Q required dilution of the CFE from 10 mL to 100 
mL and ten separate loadings via a superloop – this step alone took over two hours to 
perform – compared to a single injection for the other two columns. This, and the 
several hours (>12) required for equilibration and elution made using this column a 
long and labour intensive purification. The Resource Q was found to be a very quick 
method for purification of NAAAR, however, as this column has been discontinued 
by the manufacturer, it was rejected as should it ever stop functioning, it would be 
impossible to replace. This decision was made with X-ray crystallography 
particularly in mind. The HiPrep FF Q 16/10 was found to be the best column for the 
purification process with high resolution giving a highly pure NAAAR protein after 
only one purification step. Using this column, NAAAR was found to elute at 300 
mM NaCl (fractions 27 to 34), well separated from both the background E. coli 
proteins (fractions 6 to 25) and DNA (fractions 40 onwards) (Figure 51). 
 
Figure 51. HiPrep FF Q 16/10 chromatogram trace of absorbance at 280 nm. NaCl gradient 
shown as light green trace. NAAAR elutes as a symmetrical peak between fractions 27 and 34. 
Column gradient was 0 to 45% high salt over 9 column volumes (cv), followed by 45 to 100% 
high salt over 3 cv. 
- 87 - 
 
Figure 52. SDS analysis of HiPrep FF Q 16/10 fractions. NAAAR elution shown in lanes 4 + 5. M 
= L.M.W marker, P = insoluble pellet, S = soluble fraction, 1 = fractions 11 – 15, 2 = fractions 16 
– 20, 3 = fractions 21 – 25, 4 = fractions 26 – 30, 5 = fractions 31 – 35, 6 = fractions 36 – 40, 7 = 
fractions 41 – 48. 
Fractions found to be containing a high purity of NAAAR (Figure 52, lanes 4 
+ 5) were pooled and concentrated to 1 mL before loading on to a HiPrep 26/60 
Sephacryl S-300 HR equilibrated with 50 mM Tris-HCl (pH 8.0), 100 mM NaCl. 
The size exclusion step was found to be very effective as a final purification step, 
with NAAAR appearing to be homogeneous by SDS-PAGE analysis. NAAAR 
eluted at 136 mL corresponding to an experimental molecular weight of 310,000 Da, 
which is in good agreement with the theoretical value of ~315,000 Da, confirming 
that NAAAR WT and all variants were octamers (Figure 53). Size exclusion fractions 
were analysed by SDS-PAGE analysis and those containing NAAAR were adjusted 
to 1 mg mL
-1
 for kinetic assays and melting temperature studies, or 8 mg mL
-1
 for 
protein crystallography. The yield of purified NAAAR via this expression and 
purification process was upwards of 50 mg L
-1
 of growth media. NAAAR was stored 
at 4°C and was stable at this temperature for several weeks before a drop in activity 
was observed.  
M     P     S     1      2      3     4     5     6       7 (kDa) 
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Figure 53. HR S-300 chromatogram trace of absorbance at 280 nm. SDS analysis of fractions 13 
+ 14 inset showing homogenous NAAAR. M = L.M.W marker, 1 = fractions 13 + 14 from S-300 
purification. 
 Protein masses were determined using ESI FT ICR MS coupled to a RP-
HPLC (SIRCAMS, The University of Edinburgh) and found to be within 1-2 Da of 
the expected values (Table 7). 
Table 7. Theoretical and experimental masses (average neutral mass) for variant NAAARs. 
Variant Theoretical mass (Da) Experimental mass (Da) 
WT 39,407 39,405 
G291E 39,479 39,478 
G291D 39,465 39,463 
G291D F323Y 39,481 39,480 
4.4.2.3, In vitro assay of native NAAAR: 
 Native NAAAR was assayed in a similar manner to the histidine tagged 
protein, using chiral HPLC with a Chirobiotic™ T column for analysis. Assays were 
performed with various concentrations of N-acetyl-methionine (both enantiomers) 
and N-acetyl-D-phenylalanine at 60°C. Activity was found to be roughly 10% lower 
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at 37°C than at 60°C. Due to the reversible nature of the NAAAR reaction, the 
product instantly becomes the substrate as soon as the reaction begins. For this 
reason, assays were limited to three minutes. Values for kcat are reported at 300 mM 
N-acetyl-methionine (Table 8), and at 10 mM for N-acetyl-D-phenylalanine (Table 9). 




Km (mM) kcat (s
-1
) Km (mM) kcat (s
-1
) 
WT 40 14 ± 1.9 18 20 ± 1.5 
G291E 40 27 ± 2.8 40 48 ± 4.2 
G291D 40 54 ± 3.8 40 80 ± 6.9 
G291D F323Y 50 67 ± 5.5 40 95 ±10.7 
As expected, based on the increase in growth rates observed with SET21 expressing 
these NAAARs, enzyme activity increases on going from WT → G291E → G291D 
→ G291D F323Y. The native NAAAR G291E enzyme was now found to be more 
active than WT as suggested by growth studies. With the most active NAAAR 
G291D F323Y variant, kcat has increased by ~4.7 fold after three rounds of evolution 
for both enantiomers indicating that the mutations are not affecting NAAAR 
enantioselectivity. No decrease in Km was observed after each round of evolution 
suggesting the G291E/D and F323Y mutations are having very little, if any, effect on 
substrate binding.  
NAAAR G291D M50L was purified and assayed as above but the M50L 
mutation was found to increase activity specifically for N-acetyl-DL-methionine. This 
mutation did not increase activity towards N-acetyl-D-phenylalanine above that of 
the WT, and caused a decrease relative to NAAAR G291D. The combination of 
G291D and F323Y was found to nearly double the activity of NAAAR towards N-
acetyl-D-phenylalanine (Table 9). Values of kcat for N-acetyl-D-phenylalanine are 
reported with 10 mM substrate due to substrate solubility issues. 
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) for N-acetyl-D-phenylalanine 
WT 12.32 ± 0.97 
G291D 15.08 ± 0.8 
G291D M50L 13.05 ± 1.3 
G291D F323Y 21.90 ± 1.56 
4.4.2.4, Substrate/product inhibition of NAAAR: 
 It is important that industrial biocatalysts have a high tolerance to substrate 
and product concentration to allow high productivity. In the case of NAAAR, this is 
essential as the acylases to which it will be coupled operate upwards of 500 mM 
substrate. The literature suggests that Am. Ts-1-60 NAAAR, and other Amycolaptosis 
NAAARs suffer from substrate inhibition above 50 mM
[95, 260]
. This would seriously 
hinder their application to industrial processes
[89]
. Inhibition was confirmed by early 
in vitro assays in which no activity was observed above 50 mM N-acetyl-methionine 
with purified NAAAR. The reason for the inhibition was discovered during testing of 
a potential NAAAR variant at 90 mM N-acetyl-D-methionine. All potential variants 
were tested at this concentration to evaluate their impact on substrate inhibition. 
However during this particular experiment, six fold more HEPES buffer was added 
to this substrate concentration than usual. As a result, activity was observed at 90 
mM for the first time. The drop in activity in the non-excess buffered reactions as 
they approached 50 mM confirmed that the observed substrate inhibition was due to 
the lack of buffering at these increasing acidic substrate concentrations (Figure 54). 
Further testing showed that NAAAR WT was active up to tested levels of 300 mM 
N-acetyl-methionine in 100 mM Tris-HCl (pH 8.0) if the substrate was pH adjusted 
to 8.0 before addition to the assay.  
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Figure 54. Inhibition of NAAAR above 50 mM substrate concentration with 50 mM HEPES. 
Activity restored at 90 mM with 300 mM HEPES. 100% activity plotted relative to 10 mM 
substrate. 
4.4.2.3, In vivo assay of native NAAAR as a whole cell biocatalyst: 
In vivo NAAAR assays were also carried out by expressing different NAAAR 
enzymes from pET20b in BL21(DE3) hosts, and then assaying these cells directly for 
NAAAR activity. This assay was performed to mimic the industrial conditions that 
NAAAR is likely to be used in, i.e. to ensure that NAAAR can be used in a whole 
cell biotransformation or as a partially purified enzyme. At this stage, potential 
industrial substrates (N-acetyl-allylglycine and N-acetyl-(4-fluoro)phenylglycine 
were introduced as it was hoped that any evolved NAAAR would be applicable to a 
range of high value, synthetically useful amino acids and not solely methionine. To 
test this, all four NAAAR variants were expressed for 24 hours in BL21(DE3) grown 
at 37°C in LB broth (100 μg mL
-1
 ampicillin) with no IPTG (Figure 55). 
 
Figure 55. BL21(DE3) hosts used for whole cell biotransformations expressing NAAAR WT, 
G291E, G291D, and G291D F323Y. 
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Biotransformations were carried out in sealed 96 well plates with a reaction volume 
of 100 μL. Reaction buffer contained 75 mM substrate (N-acetyl-L-methionine, N-
acetyl-D-methionine, N-acetyl-D-allylglycine, or N-acetyl-D-(4-
flouro)phenylglycine), 100 mM Tris-HCl (pH 8.0), and 5 mM CoCl2. To this buffer, 
10 μL of whole cells were added as a dilution series of 1.0 (no dilution), 0.75, 0.5 
and 0.25. The OD600 of each overnight culture was noted for calculation of specific 
activities (typically ~5.0 for all cultures). The reactions were allowed to proceed for 
1 hour at 60°C with agitation before termination and 1000 fold dilution with HPLC 
running buffer (75:25 0.01% TEAA:MeOH). The conversion of the single 
enantiomer to a corresponding racemate was monitored using chiral HPLC. By using 
the conversion values for each dilution, a rate constant was generated for each 
variant with each substrate. The rate constants for amino acid racemisation (kL and 
kD) have been studied and modelled as a means of determining the age of fossils 
(Figure 56)
[261, 262]
. Rate constants kL and kD can be accurately modelled with first 
order reaction kinetics (FOK) as Eqn (1) for racemisation of L-amino acids, and Eqn 
(2) for the racemisation of D-amino acids where D = proportion of D-enantiomer, and 
L = proportion of L-enantiomer: 
 
Figure 56. Rate constants kL and kD for the racemisation of amino acids. 
















































A linear regression of the FOK transformed D/L or L/D measurements against 
enzyme concentration or time can be used to calculate kL or kD (hour
-1
) by Eqn (3): 
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k LD   
This assumes that kL = kD, which is not case for NAAAR, but as the transformation of 
the data gave good linearity with R
2
 generally >0.95, it was taken to be an accurate 
model for NAAAR racemisation. Enzyme dilutions were used as effective time 
points, i.e. a 0.25 dilution over an hour = 15 minutes with no dilution. This model 
was used to calculate kL and kD for whole cell biocatalysts expressing variant 
NAAARs with N-acetyl-L-methionine, N-acetyl-D-methionine, N-acetyl-D-
allylglycine, and N-acetyl-D-(4-fluoro)phenylglycine. The results are listed below for 





) where calculated using Eqn (4): 
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N-acetyl-L-methionine: 
 
Figure 57. Plot of N-acetyl-L-methionine conversion ((transformed using Eqn (1)) versus 
NAAAR concentration. 
Table 10. Rate constants (calculated with Eqn (3)) and specific activity (calculated with Eqn (4)) 










WT 0.1634 [0.98] 222 ± 14 
G291E 0.2355 [0.95] 321± 11 
G291D 0.2830 [0.98] 385 ± 14 
G291D F323Y 0.5343 [0.99] 728 ± 19 
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N-acetyl-D-methionine: 
 
Figure 58. Plot of N-acetyl-D-methionine conversion ((transformed using Eqn (2)) versus 
NAAAR concentration. 
Table 11. Rate constants (calculated with Eqn (3)) and specific activity (calculated with Eqn (4)) 










WT 0.1600 [0.99] 210 ± 7 
G291E 0.1900 [0.94] 233 ± 4 
G291D 0.2070 [0.97] 282 ± 7 








- 96 - 
N-acetyl-D-allylglycine: 
 
Figure 59. Plot of N-acetyl-D-allylglycine conversion ((transformed using Eqn (2)) versus 
NAAAR concentration. 
Table 12. Rate constants (calculated with Eqn (3)) and specific activity (calculated with Eqn (4)) 










WT 0.1791 [0.85] 236 ± 9 
G291E 0.2904 [0.98] 383 ± 14 
G291D 0.3387 [0.95] 445 ± 9 
G291D F323Y 0.5256 [0.87] 691 ± 14 
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N-acetyl-D-(4-fluoro)phenylglycine: 
 
Figure 60. Plot of N-acetyl-D-(4-fluoro)phenylglycine conversion ((transformed using Eqn (2)) 
versus NAAAR concentration.  
Table 13. Rate constants (calculated with Eqn (3)) and specific activity (calculated with Eqn (4)) 










WT 0.2185 [0.97] 287 ± 47 
G291E 0.3218 [0.99] 395 ± 23 
G291D 0.4914 [0.99] 670 ± 42 
G291D F323Y 0.7878 [0.97] 1441 ± 60 
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 The in vivo racemisation assays complemented the earlier observed in vitro 
results with an increase observed in the rate of racemisation (kL and kD) with each 
round of evolution. NAAAR G291D F323Y exhibited a 3 fold increase with both N-
acetyl-L-methionine and N-acetyl-D-methionine over WT.  
 The increase in kD and specific activity observed for N-acetyl-D-allylglycine 
was very pleasing as it confirmed that the G291E/D and F323Y mutations were not 
specific to N-acetyl-methionine. Again, a threefold increase in activity was observed 
on going from WT to NAAAR G291D F323Y, in line with those measured for N-
acetyl-D-methionine. The activities towards N-acetyl-D-methionine and N-acetyl-D-
allylglycine were effectively equivalent.  
 N-acetyl-D-(4-fluoro)phenylglycine gave a similar trend with racemase 
activity increasing with each improved NAAAR variant. However, in this case there 
was a 5 fold increase in specific activity. Activity towards this substrate was 120% 
higher than that towards N-acetyl-D-allylglycine and N-acetyl-D-methionine. 
Phenylglycines are also known to undergo chemical racemisation easily and this 
likely helps to increase the rate at which NAAAR can racemise these substrates. 
Chemical racemisation can occur under basic conditions due to the low pKa of the α-
proton. However, the increases observed here were not thought to be occurring by 
non-enzymatic racemisation. All HPLC running buffers were acidic (~pH 4.5) to 
ensure that there was no pre- or on-column racemisation. During sample preparation, 
5 M NaOH was used to solubilise hydrophobic amino acids, and this has the 
possibility of introducing a level of non-enzymatic racemisation. However, HPLC 
analysis of reactions containing no racemase, confirmed that racemisation (with all 
substrates) was dependent on the presence of NAAAR.  
 The L-enantiomers of both N-acetyl-allylglycine and N-acetyl-(4-
fluoro)phenylglycine were not available for testing or for use as analytical standards 
for HPLC analysis. However, as the reaction generated a new peak on the chiral 
HPLC trace which became exactly 50% of the total HPLC area (with a decrease of 
50% in the D-enantiomer peak), it is safe to assume that this new peak was the L-
enantiomer – although not isolated and confirmed by NMR or MS. 
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4.4.3, Small scale dynamic kinetic resolutions (DKRs) of N-acetyl-DL-
methionine using NAAAR/L-acylase whole cell biotransformations: 
 The specific activity of BL21(DE3) cells expressing NAAAR G291D F323Y 
has been found to be between three and five fold higher than those expressing the 
WT enzyme. However, the racemisation reaction must be coupled with a 
stereoselective acylase in the form of a DKR to be of industrial use. To test how the 
generated NAAAR variants compared to NAAAR WT in this reaction, small scale 
resolutions of N-acetyl-DL-methionine were carried out to yield enantiopure L-
methionine. This was performed in a BL21(DE3) host expressing NAAAR and an L- 
acylase. All four NAAAR variants were expressed in separate BL21(DE3) hosts in 
LB broth (100 μg mL
-1
 ampicillin) over 24 hours with no IPTG for induction. L-
acylase (Chirotech Technology Ltd) was expressed over 24 hours in auto-induction 
media (100 μg mL
-1
 ampicillin) with no IPTG from a proprietary plasmid
[86]
. 
Resolutions were initiated by adding equal amounts (0.2 OD600 units) of BL21(DE3) 
cells expressing either NAAAR (WT, G291E, G291D, or G291D F323Y) or L-
acylase. The cells were mixed with 30 mM N-acetyl-DL-methionine, 5 mM CoCl2, 50 
mM Tris-HCl (pH 8.0) and incubated at 60°C. Samples were taken for chiral HPLC 
before addition of cells, and then every hour for five hours after addition. All four 
possible substrates/products of the reaction (N-acetyl-L-methionine, N-acetyl-D-
methionine, L-methionine, and D-methionine) are well separated by chiral HPLC 
making it possible to measure the yield and e.e. of the L-methionine product.  
The progress of each resolution is shown below; L-acylase only (Figure 61), 
NAAAR WT/L-acylase (Figure 62), NAAAR G291E/L-acylase (Figure 63), NAAAR 
G291D/L-acylase (Figure 64), and NAAAR G291D F323Y/L-acylase (Figure 65). As 
expected, with no NAAAR present, N-acetyl-D-methionine is not a substrate for the 
L-acylase. Inclusion of NAAAR WT resulted in a 20% conversion of N-acetyl-D-
methionine to L-methionine. NAAAR G291E and NAAAR G291D increases this to 
25% and 40% respectively, however, the L- and D- enantiomers were not being 
‘hydrolysed’ at the same rate, i.e. khydrolysis
 
> kracemisation. When NAAAR G291D 
F323Y was added to the reaction conversion increased to 62% with both the 
conversion of N-acetyl-L-methionine and N-acetyl-D-methionine occurring at 
equivalent rates implying khydrolysis ≤ kracemisation. This would suggest that the reaction 
is running as an effective DKR
[263]
. No D-methionine was observed during chiral 
HPLC analysis indicating the e.e. of L-methionine in all reactions was >99%. 
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KR with L-acylase




























Figure 61. KR of N-acetyl-DL-methionine using L-acylase to yield L-methionine.  
DKR with L-acylase/NAAAR wild-type




























Figure 62. DKR of N-acetyl-DL-methionine using L-acylase/NAAAR WT to yield L-methionine. 
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DKR with L-acylase/NAAAR G291E




























Figure 63. DKR of N-acetyl-DL-methionine using L-acylase/NAAAR G291E to yield L-
methionine. 
 
DKR with L-acylase/NAAAR G291D




























Figure 64. DKR of N-acetyl-DL-methionine using L-acylase/NAAAR G291D to yield L-
methionine. 
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DKR with L-acylase/NAAAR G291D F323Y




























Figure 65. DKR of N-acetyl-DL-methionine using L-acylase/NAAAR G291D F323Y to yield L-
methionine. 
4.5, Structural biology of NAAAR G291D F323Y: 
To determine the chemical roles of the G291D and F323Y mutations, 
NAAAR G291D F323Y was crystallised in collaboration with Dr Gideon Grogan at 
the York Structural Biology Laboratory (YSBL), The University of York. The 
structure was solved via molecular replacement to 2.71 Ǻ using the published Am. 
Ts-1-60 NAAAR:N-acetyl-methionine structure (PDB:1SJA) as a model
[100]
. 
4.5.1, Screening of conditions for NAAAR crystallisation:  
 Screening for suitable crystallisation conditions began with testing the 
conditions published by Gerlt et al used to crystallise the WT Am. Ts-1-60 NAAAR 
protein. In the published work, NAAAR was crystallised with N-acetyl-methionine 
(2.3 Ǻ, 1SJA), N-succinyl-methionine (2.1 Ǻ, 1SJC), OSB (2.2 Ǻ, 1SJB), and N-
succinyl-phenylglycine (1.9 Ǻ, 1SJD). These conditions (8 mg ml
-1
 NAAAR, 8% 
PEG 8K, 10 mM MgCl2, 100 mM HEPES (pH 8.0), 10 mM N-acetyl-DL-methionine) 
gave large crystals which formed overnight. However, two commercial screens (CSS 
and Index) were also used to check for other conditions that may give better-quality 
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crystals. From these screens, CSS gave four conditions that gave improved crystals 
(form and size) over the published conditions (Table 14).  
Table 14. The crystallisation conditions for NAAAR G291D F323Y. 
Condition Buffer precipitant co-precipitant 
A1 100 mM HEPES (pH 8.0) 25% PEG 2K MME 300 mM Na acetate 
A12 100 mM Tris-HCl (pH 8.0) 25% PEG 2K MME 800 mM Na formate 
B12 100 mM Tris-HCl (pH 8.0) 15% PEG 4K 800 mM Na formate 
C7 100 mM Tris-HCl (pH 8.0) 10% PEG 8K/1K 300 mM Na acetate 
Large scale hanging drop screens of these four conditions were performed with a ± 1 
% spread in polyethylene glycol (PEG)/ polyethylene glycol monomethyl ether (PEG 
MME) along the plate. Crystals formed overnight at 20°C in both apo- and holo- 
samples with no discernable differences between either. Samples from B12 gave the 
lowest diffraction (3.0 Ǻ) with no cryo-protectant. Four crystals from these 
conditions were flash cooled in liquid nitrogen prior to data collection at the 
synchrotron. 
4.5.2, Processing and refinement of NAAAR G291D F323Y data: 
All structural processing and refinement was performed by Dr Gideon 
Grogan (YSBL, The University of York). 
4.5.3, Structure of NAAAR G291D F323Y: 
The crystal structure of NAAAR G291D F323Y (PDB code: 4A6G) revealed 
two new, intra-molecular interactions between the introduced side groups of D291 
and Y323 with the native R299 (Figure 66). The electron density map of ligand (N-
acetyl-L-methionine), Y323, D291, and R299 is shown below (Figure 67). Due to the 
lower resolution of the data compared to the published structure (2.7 Ǻ compared to 
2.3 Ǻ), conclusions regarding any protein:ligand interactions which may occur in the 
variant structure are hard to draw. However the substrate did appear to be slightly 
displaced towards the Mg
2+
. No significant differences were noted between the 
quaternary and tertiary structures of NAAAR G291D F323Y and 1SJA. The 
asymmetric unit contained four monomers, half of the octameric structure observed 
by size exclusion chromatography. 
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Figure 66. Active site of Am. Ts-1-60 NAAAR G291D F323Y showing new salt bridge interaction 
between D291 and R229 and H-bond interaction between Y323 and D291. Mg
2+
 ion shown as 
magenta sphere. 
 
Figure 67. Electron density (2.7 Ǻ) in cyan, for of D291, R299 and Y323 of NAAAR D291 Y323 
and ligand electron density shown in pink, corresponding to the omit map (Fo-Fc map). 
The major impact of the G291D and F323Y mutations has been the formation 
of two new intra-molecular interactions. These are a 3.0 Ǻ salt bridge between the 
carboxylate side group of D291 and the guanidinium of R299, along with a 2.9 Ǻ H-
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Aspartic acid may be a better fit for the R299 interaction than glutamic acid, 
explaining the earlier observation that NAAAR G291D is a superior catalyst to 
G291E. The mutations appear to have a minimal effect on ligand binding with no 
immediate protein:ligand interactions being visible. There are clear comparisons 
between the WT NAAAR:N-succinyl-D-methionine and G291D F323Y NAAAR:N-
acetyl-L-methionine with both structures showing interactions between R299 and 
either the succinyl substrate (via two H2O molecules) or D291. Given that NAAAR 
is most activity on N-succinyl substrates, this interaction would appear to be required 
for high NAAAR activity. The G291D mutation would appear to be replacing the 
missing propanoic acid moiety from in the acetyl structure. The aspartic side group 
can almost be thought of as chemically complementing the substrate by replacing the 
missing carboxylate which is binding with R229 (Figure 68). Values for kcat also 
increase more with introduction of G291E/D than they do when F323Y is introduced. 
The occurrence of NAAAR enzymes in which F323 is naturally tyrosine (e.g. G. 
kaustophilus) is now understandable as, the D291-Y323 H-bond could also form 
Y323 to the succinyl substrate carboxylate.  
 
Figure 68. Comparison of NAAAR G291D F323Y: N-acetyl-L-methionine and WT NAAAR: N-
succinyl-D-methionine. H2O molecules shown as red crosses in WT NAAAR:N-succinyl-D-
methionine structure (PBD:1SJC)
[100]
. All bonding interactions ~3 Ǻ. 
D291 G291 R299 R299 
Y323 F323 
N-succinyl-D-methionine N-acetyl-L-methionine 
NAAAR G291D F323Y: NAAAR WT: 
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The introduction of salt bridges, like the D291-R299 interaction, has been shown to 
have an effect on catalytic performance
[264]
. To determine the effect of these 
mutations on protein stability, the melting temperatures (Tm) of each NAAAR variant 
and the WT was determined. 
4.5.4, Melting temperatures (Tm) of WT and variant NAAARs: 
The Tm of a protein is point at which half the protein molecules are folded 
and half un-folded
[265]
. The temperature at which this occurs is taken as a measure of 
how thermostable that protein is. Tm is determined by measuring the florescence 
signal of a dye (SYPRO orange) as a function of temperature
[266]
. When the protein is 
fully folded and in its native state, the fluorescence signal is quenched by the 
aqueous environment, but as temperature increases and the protein unfolds, the 
internal hydrophobic patches are revealed. These bind the dye and increase SYPRO 
orange fluorescence. Tm was determined for each NAAAR variant in both the apo- 
and holo- state to measure the effects of the new interactions introduced into the 
NAAAR active site. This was performed on a BioRad iQ5 rtPCR Thermocycler at 
the Edinburgh Protein Production Facility. Tm was calculated with 0.5 mg mL
-1
 
NAAAR in both the apo- and holo-form with 100 and 200 mM N-acetyl-DL-
methionine. The calculated Tm for each enzyme and Tm differential curves for apo- 
and holo- (100 and 200 mM ligand) shown is shown below (Figure 69, Figure 70, Figure 
71, and Table 15). 




Apo 100 mM ligand 200 mM ligand 
WT 67 68 69 
G291E 70 71 72 
G291D 71 72 73 
G291D F323Y 72 75 76 
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Figure 69. Differential graph of fluroescence response against temperature for apo-NAAAR. 









































Figure 70. Differential graph of fluroescence response against temperature for holo-NAAAR 
(100 mM N-acetyl-DL-methionine). 









































Figure 71. Differential graph of fluroescence response against temperature for holo-NAAAR 
(200 mM N-acetyl-DL-methionine). 
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The Tm data shows a clear increase in stability on going from WT → G291E 
→ G291D → G291D F323Y. This increase follows the earlier observed trend of 
increasing activity. The extent of ΔTm appears to be dependent on the presence of 
substrate in NAAAR G291D F323Y. Upon addition of ligand, NAAAR G291D 
F323Y undergoes a 3°C increase in Tm compared to only a 1°C in the WT, G291E 
and G291D NAAAR proteins. This may be due to Y323 having introduced the 
possibility of protein:ligand interactions that cannot occur in the F323 proteins. 
There is an increase in stability upon addition of ligand in all NAAAR variants, even 
though the crystal structure of the WT shows no strong protein:ligand interactions. 
This is likely due to the prediction that the lid/capping domain remains un-ordered in 
the absence of ligand, and hence is less stable
[98-100]
. The increase in Tm would also 
explain why NAAAR G291D F323Y shows no drop in activity after five hours at 
60°C, whereas the WT has reported thermostability of 30 mins at 55°C. Time and 
resources did not allow for determination of Tm for NAAAR WT with N-succinyl-
DL-methionine as a ligand to see if it is increased towards that of NAAAR G291D or 
even NAAAR G291D F323Y. This would further justify the hypothesis that D291 
performing the same role as the propanoic acid moiety of the N-succinyl substrate. It 
is possible that the rise in Tm is purely an artefact from the introduction of this R299 
interaction and the increase in stability is playing no role in the increase in enzyme 
efficiency.  
 It should be kept in mind that these mutations have been selected for during a 
genetic selection process performed at 37°C. There appears to be no reason why a 
series of mutations, which increase stability >69°C, would be selected for unless they 
can also exert an effect at 37°C. The introduced mutations must also be having a 
positive effect of activity at the lower temperature. The link between protein stability 
and activity has been well studied, particularly in proteins from psychrophilic 
bacteria
[267, 268]
. It is thought that residues which are important for function are 
detrimental to stability and vice versa. Removal of active site residues from T4 
Lysozyme resulted in a general decease in activity and an increase in stability
[269]
. 
The opposite process of introducing stability with a salt bridge was shown to increase 
thermostability at elevated temperatures, but then decrease activity at lower 
temperatures, of an Acylphosphatase (PhAcP, EC 3.6.1.7) from Pyrococcus 
horikoshii
[264]
. The literature would suggest that in general, an increase in stability of 
an active site will lower its activity at lower temperature (37°C). Clearly this is not 
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the case here as all three mutations show an increase in activity at both 37°C (in vivo 
screen) and 60°C (in vitro and in vivo assays), along with an increase in stability 
above 69°C (Tm measurements). These would appear to be in contrast with the 
general trend observed considering mutations that affect stability and activity. 
4.6, Conclusions: 
 Using a genetic selection system directed evolution techniques have been 
successfully used to increase the activity of NAAAR from Am. Ts-1-60. 
Improvements in the genetic selection method, such as a change in minimal media 
and expression plasmid removed a sizable variation in colony size that had been 
hindering selection and generating a large number of false positives. Although 
activity was evolved against N-acetyl-D-methionine, an increase in activity was 
observed towards both enantiomers of this substrate, along with several other natural 
and non-natural N-acetyl-amino acids.  
A double NAAAR variant containing G291D and F323Y was found to have a 
4.7 fold increase in kcat for N-acetyl-DL-methionine, although no major change in Km 
was observed. Saturation mutagenesis at these positions highlighted that they were 
the most effective mutations. Analysis of the NAAAR WT crystal structure revealed 
that both mutations are found within the acyl binding pocket, in close proximity to 
the substrate. To decipher the molecular basis of the increase in activity, the NAAAR 
G291D F323Y variant was crystallised. The structure was solved to 2.71 Ǻ with 
molecular replacement using the published WT structure. The variant structure 
showed two new intramolecular interactions that introduced a 3.0 Ǻ salt bridge 
between D291 and R229 and a 2.9 Ǻ H-bonding interaction between Y323 and 
D291. These interactions suggested that the enzyme has been stabilised and that this 
may be source of increased catalytic activity. Literature evidence suggested that this 
could be the case given the lack of obvious protein:ligand interactions. The change in 
protein stability was measured by determining the Tm for the WT and variant 
NAAARs. A 7°C increase in Tm was measured for NAAAR G291D F323Y 
compared to the WT (69°C) in the presence of 200 mM ligand (N-acetyl-DL-
methionine). As the increase in Tm between the WT and the G291D F323Y variant 
was greater in the presence of substrate (only 5°C in the apo- form), this would 
suggest that ligand:D291/Y323 interactions have also been introduced, although 
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these are not immediately clear in the solved structure. This may be due to the 
relatively low resolution of the crystals (2.71 Ǻ).  
4.7, Future work: 
 The 4.7 fold increase in activity shown by the G291D and F323Y mutations 
could likely be built upon by further mutagenesis. Whether this should target 
protein:ligand interactions or look to further increase the protein’s stability is 
unclear. An obvious target for mutagenesis is M50 and its surrounding neighbours 
which appear to be responsible for amino acid substrate specificity. Mutagenesis of 
these residues will require a different screening/selection strategy than the SET21 
genetic selection employed here which is specific for N-acetyl-D-methionine. High 
throughput chiral HPLC screening was successfully performed to carry out saturation 
mutagenesis at F323 confirming that F323Y was the most active residue – applying 
this approach these residues would be relatively simple to implement with the correct 
equipment and assays. As NAAAR has a very broad substrate range, accepting most 
amino acids with varying levels of activity, the substrate R-group binding pocket 
could likely be optimised to suit a specific amino acid if a mutagenesis program was 
focused on this area of the protein. Changes in the N-acyl pocket could be easily 
accessed by synthesis of the appropriate methionine derivatives, i.e. N-benzoyl-D-
methionine for evolution of an N-benzoyl amino acid racemase. 
 Although not characterised fully in this project, two further NAAAR enzymes 
for Geobacillus have also been cloned from G. kaustophilus and G. 
thermodenitrificans. These enzymes may provide a more active NAAAR starting 
point for mutagenesis, or have different substrate preferences to the Am. Ts-1-60 
NAAAR used here. Interestingly, both Geobacillus NAAARs are Y323, which may 
be forming H-bonds between the succinyl carboxylate and Y323 like the D291-Y332 
H-bond observed with NAAAR G291D F323Y:N-acetyl-L-methionine. To determine 
whether N-succinyl racemase activity has been affected, and to support the 
hypothesis regarding the molecular role of these mutations, the activity of NAAAR 
containing the F323Y and G291D mutations should be measured with an N-succinyl 
amino acid. Given that Geobacillus NAAARs already contain F323Y, it may be that 
this mutation increases activity with N-succinyl substrates as it can interact with the 
succinyl carboxylate as it does with the aspartic carboxylate. If the D291 side group 
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is acting as a mimic for the succinyl carboxylate, variants with this mutation may no 
longer accept the N-succinyl substrate. 
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Chapter 5, Industrial applications of Amycolatopsis Ts-1-60 


















- 113 - 
5.1, Industrial application of Amycolatopsis NAAAR G291D F323Y: 
The goal of this project was to generate a cost effective racemase biocatalyst 
that would fit in to the established D/L-acylase process for production of enantiopure 
α-amino acids. Given the promise shown by the coupled NAAAR G291D F323Y/L-
acylase whole cell biocatalyst DKR of N-acetyl-DL-methionine (See section 3.3.3), 
and the marked increase in activity of NAAAR G291D F323Y compared to the WT, 
there was strong reason to think that NAAAR G291D F323Y would meet these 
criteria. To study the performance of NAAAR G291D F323Y under industrial 
conditions, the enzyme was first prepared by fermentation, and the resulting 
biocatalyst tested under various reaction conditions including NAAAR/D-acylase 
DKRs of several N-acetylated amino acids. 
5.1.1, Fermentation of Amycolatopsis NAAAR G291D F323Y:  
Biocatalysts are routinely produced by fermentation to allow for high cell 
densities and large volumes of enzyme. E. coli grown in a shake flask will reach an 
OD600 of the range 5-10, whereas a fermentation of the same host will reach 100-150 
in the same time scale. Some exceptional fermentation expression hosts, such as 
Pseudomonas fluorescens, marketed as the Pfenex expression system, will generate 
an OD600 of >400.  
A 1 L fermentation of BL21(DE3) expressing NAAAR G291D F323Y was 
carried out over 48 hours at 30°C. Similar to shake flask expression for protein 
purification no IPTG was added (See section 3.3.2.1). The fermentation process 
started with a 50 mL overnight culture of BL21(DE3) pET20b NAAAR G291D 
F323Y in E. coli seed media. This was then used to inoculate 700 mL of E. coli 
fermentation media. After 19.5 hours, E. coli feed media was dripped in at a rate of 
14 mL hour
-1
. Expression of NAAAR was monitored by measuring NAAAR activity 
and SDS-PAGE analysis (Figure 72). After 48 hours, the fermentation was harvested 
with centrifugation (5,000 g, 30 mins, 4°C), giving a yield of 92 g of wet cells (16.2 
g dry cells) from 1 L of media.  
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Figure 72. SDS-PAGE analysis of BL21(DE3) pET20b NAAAR G291D F323Y fermentation. 
NAAAR (Mr = 39.4 kDa) expression highlighted in red box. M= Marker, 1= fermentation after 
17 hours, 2 = fermentation after 18.5 hours, 3 = fermentation after 20 hours, 4 = fermentation 
after 21 hours, 5 = fermentation after 22 hours, 6 = fermentation after 23 hours, 7 = 
fermentation after 24 hours, 8 = fermentation after 40 hours. 
The total NAAAR activity was calculated by means of the standard NAAAR activity 
assay. This involved incubation of a 10 fold dilution (with 50 mM Tris-HCl (pH 
8.0)) of fermentation broth with 150 mM N-acetyl-L-methionine in 50 mM Tris-HCl 
(pH 8.0), 5 mM CoCl2. Again, the substrate was dissolved in 100 mM Tris-HCl (pH 
8.0) to control pH. The reaction was run at 60°C with agitation for 60 mins before 
termination and 1000 fold dilution with HPLC running buffer (75:25 0.01% 
TEAA:MeOH). Chiral HPLC was used to measure racemase activity, which was 
then converted in to a specific activity per mL of broth. One unit (U) of NAAAR 
activity was defined as the amount of enzyme required to racemise 1 μmole of N-
acetyl-L-methionine in 60 minutes at 60°C. The specific and total activity were 
calculated for samples taken throughout the fermentation process indicating that 
specific activity (per OD600) reached a maximum after 24 hours, with total activity 
reaching a maximum after 40 hours (Figure 73 and Figure 74). The fermentation was 
harvested after 40 hours at an OD600 of 96. The total NAAAR activity present in the 
92 g of cells was approx. 10,000,000 units. Specific NAAAR activity dropped after 
24 hours, this may be due to the loss of antibiotic selection (100 μg mL
-1
 ampicillin). 
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Figure 73. Specific NAAAR activity of fermentation broth at differing time points. Note that 






Figure 74. Total NAAAR activity present in BL21(DE3) pET20b NAAAR G291D F323Y 
fermentation broth. 
5.1.2, Downstream processing (DSP) of Amycolatopsis NAAAR G291D F323Y 
biocatalyst:  
BL21(DE3) pET20b NAAAR G291D F323Y fermentation broth was 
processed into a CFE from wet cells to allow it to be tested for industrial use. This 
was carried out by sonication (15 s on/ 15 s off) for 15 minutes at 2°C and then 
clarified by centrifugation (12,000 g, 30 mins, 4°C). The extract was tested for 
NAAAR activity using the standard NAAAR activity assay. 50 mL of CFE was 
generated from 10 g of wet cell paste, which had a specific activity 6615 (± 660) U 
mL
-1
, where 1 U = the amount of enzyme required to racemise 1 μmole of N-acetyl-
L-methionine in 1 hour at 60°C. DSP of all 92 g of wet cells would generate 460 mL 
of CFE with a total activity of 3,043,000 (± 304,000) U. This DSP was non-
- 116 - 
optimised and represents a 70% loss of activity from the fermentation broth. Further 
mutagenesis of NAAAR may result in an increase in activity; however a more 
obvious and simpler approach would be to optimise the NAAAR DSP and 
fermentation to recover more activity. 
5.1.3, Substrate profiling of NAAAR G291D F323Y: 
 The activity towards a range of proteinogenic and synthetically useful N-
acetyl-amino acids was tested with NAAAR G291D F323Y CFE. Activity was tested 
by measuring the number of units required to racemise 300 mM (30 μmoles) of a 
single enantiomer of various substrates in 8 hours. These reactions were carried out 
at 60°C with agitation in 50 mM Tris-HCl (pH 8.0) with 5 mM CoCl2, and again the 
substrate was dissolved in 100 mM Tris-HCl (pH 8.0). The required NAAAR 
loading and final % e.e. are listed below (Figure 75).   
  
Figure 75. The required substrate loading for racemisation/partial racemisation of various 
substrates at 300 mM concentration. 
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The most active substrates were found to be three non-natural amino acids, N-
acetyl-allylglycine, N-acetyl-phenylglycine, and N-acetyl-(4-fluoro)phenylglycine 
followed by N-acetyl-methionine. N-acetyl-D-allylglycine proved to be the best 
substrate with only 30 kU L
-1
 of NAAAR required to take the substrate to <1% e.e. 
N-acetyl-phenylalanine and N-acetyl-(2-amino)butyric acid proved to be poor 
substrates that did not form a racemate with 200 kU L
-1
 NAAAR. NAAAR activity 
towards N-benzoyl-DL-phenylalanine was also tested but no activity was measured 
with either enantiomer. No activity was detected towards N-acetyl-D-naphthylalanine 
or N-acetyl-L-orthinine. 
5.1.4, Temperature studies of NAAAR G291D F323Y: 
 WT Am. Ts-1-60 NAAAR is known to be a thermostable protein with 
reported activity up to 55°C
[95]
. This was further investigated by activity 
measurements from 35 to 80°C. The standard NAAAR activity assay was carried out 
in 50 μL PCR tubes and the temperature controlled by a PCR thermal cycler. The 
reaction was terminated and diluted 1000 fold in HPLC running buffer (75:25 0.01% 
TEAA:MeOH). The activity was calculated by chiral HPLC and plotted relative to 
that at 51°C, which was designated as 100% activity. Activity remained above 90% 
between the range of 40 and 62°C, suggesting a wide range of applicable temperature 
uses for NAAAR. Importantly, NAAAR shows high activity with the temperatures 
required for both L-acylase (60°C) and D-acylase (40°C) (Figure 76). 
 The thermal stability of NAAAR G291D F323Y was investigated by 
incubating NAAAR at 60°C for varying time periods and then measuring the residual 
activity via the standard NAAAR activity assay. No drop in activity was seen after 
five hours incubation at 60°C. These measurements back-up literature reports of high 
thermal stability, but also show that NAAAR G291D F323Y has higher stability than 
that reported for the WT (30 mins at 55°C) as suggested by Tm measurements (See 
section 3.4.4). 
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Figure 76. Relative NAAAR activity between 30°C and 80°C with N-acetyl-L-methionine.  
5.2, NAAAR/D-acylase DKR processes: 
 NAAAR G291D F323Y was coupled to a D-acylase (Chirotech Technology 
Ltd) to measure the possible yields of D-amino acids using these enzymes. Both 
these enzymes require only CoCl2 as a cofactor. A whole cell DKR process using 
NAAAR G291D F323Y/L-acylase had already been shown to work efficiently over 5 
hours with 30 mM of N-acetyl-DL-methionine, however, this substrate concentration 
is too low to make this an economical process. To address this, industrially relevant 
substrate concentrations of 300 mM were used. This equates to roughly 50 g L
-1
 for 
an average N-acetylated amino acid. NAAAR/D-acylase DKRs were performed on 
N-acetyl-DL-serine, N-acetyl-DL-allylglycine, N-acetyl-DL-methionine, and N-acetyl-
DL-phenylglycine (Figure 77).  
 
Figure 77. N-acetyl substrates for NAAAR/D-acylase coupled DKRs. 
The D-acylase process represents a simple method to generate D-amino acids 
which cannot be fermented in the same manner as their L-enantiomers. The 
efficiency of NAAAR G291D F323Y would be judged by its ability to improve this 
reaction above the inherent 50% limitation. To mimic an industrial process, 300 mM 
substrate was used with the fermentation CFE, and reactions ran for 24 hours at 
40°C. As D-serine and D-allylglycine lack a natural chromophore for UV detection, it 
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was necessary for these products to be derivatised to aid their detection. These 
reactions were terminated by careful dilution in a series of buffers to facilitate a final 





Figure 78. Dansylation of primary amines. 
To allow the dansylation to be performed, the biotransformation was first terminated 
and diluted tenfold in H2O:ACN (75:25) containing 10 mM DL-phenylalanine as an 
internal standard (I.S.) to monitor the efficiency of the dansylation process. The I.S. 
was used to generate the correction factor. Phenylalanine was selected as the internal 
standard as it was likely to have a different retention time to the amino acids being 
analysed. This tenfold diluted sample was then diluted tenfold again in H2O:ACN 
(75:25), before a final tenfold dilution with 100 mM sodium carbonate buffer (pH 
9.8). Dansyl derivatisation was performed by addition of 100 μL dansyl-Cl (3 mg 
mL
-1
) in 100% acetone solution to the carbonate buffered biotransformation. The 
reaction was then incubated at 37°C for three hours before termination with 100 μL 
of glacial acetic acid. A standard curve was generated by derivatisation of known 
concentrations of amino acid product under the same conditions. The resulting 
dansylated amino acids were analysed by Luna C8(2) (Phenomenex) RP-HPLC and 
monitored at 330 nm. The elution of the dansylated amino acids was found to be 
straightforward, with a 15 minute isocratic elution of H2O:ACN being effective at 
eluting all reaction species with excellent separation. Reactions were carried out on a 
1 mL scale with varying amounts of NAAAR G291D F323Y CFE, typically between 
30 kU L
-1
 and 120 kU L
-1
, in 50 mM Tris-HCl with 5 mM CoCl2. As always, 
substrate was prepared in 100 mM Tris-HCl (pH 8.0), giving a final Tris-HCl 
concentration of 100 mM.  
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5.2.4.1, NAAAR/D-acylase DKR of N-acetyl-DL-allylglycine: 
 NAAAR G291D F323Y coupled with D-acylase was found to be very 
efficient at producing D-allylglycine with only 30 kU L
-1
 of NAAAR required to take 
the reaction to completion (>99% D-allylglycine) in 24 hours. An equivalent D-
acylase kinetic resolution gave only a 48% yield (Table 16). 
Table 16. Final yields of N-dansyl-D-allylgylycine in D-acylase KR and NAAAR/D-acylase DKR. 
#
 Concentration = (peak area * correction factor) / 0.2218 
RP-HPLC analysis of N-dansyl-D-allylglycine was performed with an isocratic 
elution (75:25 H2O:ACN (0.01%TFA)). Un-reacted dansyl-Cl and the hydrolysis 
product dansyl-OH, eluted at 1 min. N-dansyl-D-allylglycine eluted at 4.15 mins and 
of N-dansyl-DL-phenylalanine eluted at 6.7 mins (Figure 79). A standard curve of N-
dansyl-D-allylglycine was generated by dansylation of L-allylglycine standards 
(Figure 80). 
 
Figure 79. HPLC analysis (column = C8 Luna) of N-dansyl-D-allylglycine product from both D-
acylase KR and NAAAR/D-acylase DKR. 




















72.1 0.92 298.65 99.5% 
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Figure 80. A Standard curve of N-dansyl-L-allylglycine (after 1000 fold dilution) response at 330 
nm, and HPLC traces of standards (column = C8 Luna). 
If all 3 million NAAAR units generated from DSP of a 1 litre fermentation 
were committed to a NAAAR/D-acylase resolution of N-acetyl-DL-allylglycine (100 
L at 300 mM), 4.9 kg of N-acetyl-DL-allylglycine could be resolved to give a 
theoretical 3.6 kg of D-allylglycine in a 24 hour time frame. Of this, 1.8 kg would 
come from racemisation of N-acetyl-L-allylglycine before hydrolysis. This would 
represent an excellent economical yield with acetic acid as the only major by-
product.  
5.2.4.2, NAAAR/D-acylase DKR of N-acetyl-DL-serine: 
 Using the same reaction conditions (40 kU L
-1
 D-acylase, 40°C, 24 hours), 60 
kU L
-1
 of NAAAR G291D F323Y was found to give an 81% yield of D-serine from 
300 mM N-acetyl-DL-serine. Using 120 kU L
-1
 resulted in 99% yield, and a kinetic 
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Table 17. The final yields of N-dansyl-D-serine from D-acylase KR and NAAAR/D-acylase 
DKRs. 
#
 Concentration = (peak area * correction factor) / 0.0703 
RP-HPLC analysis of N-dansyl-D-serine was performed with an isocratic elution 
(80:20 H2O:ACN (0.01% TFA)). Un-reacted dansyl-Cl and hydrolysis product 
dansyl-OH, eluted at 1.5 mins. N-dansyl-D-serine eluted at 2.0 mins and N-dansyl-
DL-phenylalanine eluted at 14.75 mins (Figure 81). A standard curve of N-dansyl-D-
serine was generated by dansylation of D-serine standards (Figure 82).  
 
Figure 81. HPLC analysis (column = C8 Luna) of N-dansyl-D-serine product from both D-
acylase KR and NAAAR/D-acylase DKR. 












 D-acylase 11.2 0.92 146.67 48.9 
40 kU L
-1





15.8 1.08 243.20 81.1 
40 kU L
-1





20.7 1.01 297.12 99.0 
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Figure 82. A Standard curve of N-dansyl-D-serine (after 1000 fold dilution) response at 330 nm, 
and HPLC traces of standards (column = C8 Luna). 
Chiral HPLC was also carried out on the starting material to visualise the loss of the 
L-enantiomer upon addition of NAAAR. The hydrolysis of only N-acetyl-D-serine 
can be seen in the D-acylase KR, and hydrolysis of both enantiomers in the 
NAAAR/D-acylase DKR (Figure 83). 
 
Figure 83. Chiral HPLC analysis (column = Chirobiotic T) of N-acetyl-DL-serine starting 
materials (L-2 mins, D-2.4 mins), and chiral HPLC of D-Acylase and NAAAR/D-Acylase 
reactions after 24 hours.   
A coupled NAAAR/D-acylase process, if scaled up accordingly using all 3 million 
units from a 1 L fermentation, could resolve 2.2 kg of N-acetyl-DL-serine (50 L at 
300 mM) in to 1.3 kg of D-serine in 24 hours with 60 kU L
-1
 NAAAR. Using 120 kU 
L
-1
 NAAAR, only 800 g of D-serine could be resolved (25 L at 300 mM). Increasing 
the time scale of the 60 kU L
-1
 NAAAR resolution to 30 hours would likely take the 
reaction to completion and allow 1.6 kg of D-serine to be resolved with 99% yield. 
Of this, 800 g would come from racemisation of N-acetyl-L-serine before hydrolysis.  
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5.2.4.3, NAAAR/D-acylase DKR of N-acetyl-DL-methionine: 
 N-acetyl-DL-methionine was only partially resolved using 120 kU L
-1
 
NAAAR with 40 kU L
-1
 D-acylase giving a 79 % yield of D-methionine. A D-acylase 
KR gave only a 50% yield (Table 18).  
Table 18. Final yields of N-dansyl-D-methionine from D-acylase KR and NAAAR/D-acylase 
DKRs. 
#
 Concentration = (peak area * correction factor) / 0.0703 
After 24 hours, only 60 % of N-acetyl-L-methionine had been racemized and 
hydrolysed to D-methionine. The decrease in N-acetyl-L-methionine can be seen at 
2.25 mins in the HPLC trace below (Figure 84). D-methionine eluted at 5.5 mins. No 
N-acetyl-D-methionine was observed in the HPLC traces. No L-methionine was 
observed at the expected elution of 4.5 mins confirming that the product had an e.e. 
of >99 %. The HPLC elution was run at 1 mL min
-1
 causing a change in retention 
times compared to earlier HPLC work (See section 3.2.4.2). 
 
Figure 84. Chiral HPLC analysis (column = Chirobiotic T) of NAAAR/D-acylase DKR and D-
acylase KR of N-acetyl-DL-methionine. 












 D-acylase 358 1.00 149.2 49.7 
40 kU L
-1





585 0.97 236.4 78.8 
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5.3.4.4, NAAAR/D-acylase DKR of N-acetyl-DL-phenylglycine: 
 NAAAR/D-acylase DKRs and D-acylase KRs of N-acetyl-DL-phenylglycine 
were attempted as this appeared to be a highly active substrate in earlier assays. This 
would also be an excellent industrial substrate as phenylglycines are useful synthetic 
building blocks and are also known to be potent ligands for Glutamate receptors in 
the central nervous system
[271]
. However, due to the highly insoluble nature of the D-
phenylglycine product it proved difficult to effectively carry out these processes. The 
reactions would inevitably be almost entirely solid after 24 hours. Analysis of this 
solid showed the reaction was incomplete (~40% complete for D-acylase KRs, and 
~70% for NAAAR/D-acylase DKRs). HPLC analysis of the NAAAR reaction 
indicated that although N-acetyl-L-phenylglycine concentration was dropping by 
30%, D-phenylglycine was only increasing by 10%. This would suggest that some D-
phenylglycine was being lost during the work up and skewing the final yield. Even 
using only the soluble N-acetyl-L-phenylglycine peak (elution time = 2.2 mins) to 
estimate final yield, the process would reach only ~80% yield, however, the reaction 
is possibly failing to reach 100% completion due to the formation of insoluble 
product. No L-phenylglycine was measured during analysis (elution time = 6.6 mins) 
giving the product an e.e. >99% (Figure 85). 
 
Figure 85. Chiral HPLC analysis (column = Chirobiotic T) of NAAAR/D-acylase DKR and D-
acylase KR of N-acetyl-DL-phenylglycine. 
5.3, Conclusions: 
 The industrial promise of NAAAR G291D F323Y has been successfully 
shown by small scale NAAAR/D-acylase DKRs of several N-acetylated amino acids. 
These reactions were conducted in the presence of 300 mM substrate over 24 hours – 
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typical industrial conditions. The final yield of D-amino acids in the NAAAR G291D 
F323Y/D-acylase DKRs was pushed towards 100%, a large improvement over the 
previous 50% maximum that was possible with a D-acylase KR. The e.e. of final 
product was measured by chiral HPLC to be >99%. The most active substrate, N-
acetyl-DL-allylglycine, could be theoretically resolved on a multi kg scale using the 
total NAAAR biocatalyst from a 1 L fermentation and an appropriate acylase. This 
could possibly be a very effective method of producing enantiopure allylglycine. N-
acetyl-DL-phenylglycine had shown promise in earlier assays but the resolution 
processes proved to be difficult to carry out and analyse due to the highly insoluble 
nature of the D-phenylglycine product. 
 NAAAR G291D F323Y has been shown to be a stable enzyme that can be 
produced by fermentation in high volume and recovered in reasonable yield (30% 
after DSP). Further optimisation of this and the DSP may be more beneficial than 
further mutagenesis for improving the cost efficiency of using NAAAR. Using a 
specialised fermentation host, such as Pseudomonas fluorescens would likely reduce 
the operating cost even further. Importantly for industrial processes, NAAAR has 
been shown to be stable at elevated temperatures for several hours and retains >90% 
activity over a range of 40 to 60°C. The lack of organic cofactor in both NAAAR 
and D/L-acylase removes the need for complex cofactor recycling systems which add 
extra cost. The NAAAR G291D F323Y/acylase DKR would appear to be a simple 
and cost effective means to produce enatiopure amino acids with high yields and e.e. 
 An application for a patent covering the use of NAAAR G291D F323Y in the 
production of enantiopure amino acids has been filed with US Patent and Trademark 
Office (Application number: 61/474,455). The enzyme has been used in the 
production of a sample amino acid on multi-gram scale by Chirotech Technology Ltd 
for customer evaluation, with the possibility of a multi kg order being placed. 
5.4, Future work: 
 Future work on the industrial use of NAAAR will involve scale up and 
testing the reactions displayed here. The DKR of N-acetyl-DL-allylglycine looks like 
it may be the most successful biotransformation to come out of this work. The 
activity towards this substrate is pleasing as allylglycine is a precursor for pipeloic 
acid which is a chiral building block for Palinavir, a HIV protease inhibitor
[272]
. N-
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acetyl-phenylglycines also look like they would be good substrates but further work 
and expertise is needed to test these adequately. 
 The D-acylase coupled to NAAAR has its highest activity with N-acetylated 
amino acids which is ideal for NAAAR. However, even though the L-acylase will 
accept N-acetylated amino acids, it has higher activity with N-benzoyl derivatives
[86]
. 
Although NAAAR is reported to have low, but measurable activity with N-benzoyl-
amino acids, no activity was measured with N-benzoyl-D-phenylalanine when tested. 
Directed evolution could be applied to NAAAR using N-benzoyl-D-methionine 
(assuming SET21 can hydrolyse N-benzoyl amino acids, otherwise it will need 
complemented with L-acylase) as a source of L-methionine. If successful, this novel 
N-benzoyl-amino acid racemase would be an ideal enzyme to improve the yield of L-
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6.1, Materials and reagents: 
 All general materials and reagents were purchased from Sigma-Aldrich or 
Fisher unless otherwise stated. Amino acid substrates were purchased from Sigma-
Aldrich, Alfa Aesar, or provided by Chirotech Technology Ltd. All competent cells 
were purchased from Invitrogen or Promega. All oligos were purchased from Sigma-
Genosys.  
 The SET21 cell line and pTTQ18 NAAAR WT plasmid were provided by Dr 
Ian Fotheringham (Ingenza Ltd).  
6.2, Cell lines: 
Cell line (supplier) Genotype Application 
DH5α (Invitrogen) F
-
 endA1 glnV44 thi-1 recA1 












Top10 (Invitrogen) F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 nupG 








JM109 (Promega) endA1 glnV44 thi-1 relA1 gyrA96 
recA1 mcrB
+





















) λ(DE3 [lacI lacUV5-T7 gene 
1 ind1 sam7 nin5]) 
Protein expression 






rpoS396(Am), rph-1, Δ (rhaD-
RhaB)568, rrnB-4, hsdR514, 
ΔmetB, ΔdadA..dadX 
NAAAR selection host 
SET21(DE3)  
(this work) 
As SET21 plus λ(DE3) T7 promoter compatible 
NAAAR selection host 
6.3, Microbiology reagents: 
6.3.1, Agar: 
All agars were dissolved in ddH2O before being autoclaved (15 mins at 121°C).  
LB agar: 35 g L
-1
 LB agar (Sigma). 
S-gal agar: 38 g L
-1
 S-gal/LB agar mix (Invitrogen). 
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6.3.2, Broth: 
All broths were dissolved in ddH2O before being autoclaved (15 mins at 121°C). 
LB broth: 10 g L
-1
 peptone, 5 g L
-1
 yeast extract, 10 g L
-1
 NaCl. 
SOC broth: 10 g L
-1
 peptone, 5 g L
-1
 yeast extract, 0.88 g L
-1





MgCl2, 1.36 g L
-1
 MgSO4, 3.6 g L
-1
 glucose. 
6.4, General techniques: 
6.4.1, Heat shock transformation: 
Chemical competent cells were mixed with 2 μL of chilled DNA and 
incubated for 20 minutes on ice. After a 45 second heat shock at 42°C, cells were 
mixed with 80 μL SOC and incubated at 37°C for 1 hour with agitation. 50 μL of this 
was spread on an LB agar plate supplemented with appropriate antibiotics. For 
cloning steps, e.g. ligations or mutagenesis, the entire transformation mixture was 
spread. 
6.4.2, Electroporation: 
 Electrocompetent cells were mixed with 2 μL of DNA in a 0.2 cm gap 
electrocuvette (BioRad) and immediately electroporated with a single pulse of 2.5 
kV, set to a capacitance of 25 μF and a resistance of 200 Ω. Cells were immediately 
resuspended in 1 mL of SOC preheated to 37°C. This was incubated at 37°C with 
agitation before 50 μL was spread on an LB agar plate supplemented with 
appropriate antibiotics. For SET21 selection assays, the 1 mL was washed repeatedly 
before spreading to remove exogenous L-methionine (See section 6.5.5). 
6.4.3, Plasmid DNA isolation: 
 Plasmid DNA was isolated from a 5 mL LB broth overnight culture 
(supplemented with either 30 μg mL
-1
 kanamycin or 100 μg mL
-1
 ampicillin) using a 
QIAprep Spin Miniprep Kit (Qiagen) kit following the manufacturers protocol. DNA 
was eluted in 100 μL ddH2O and stored at -20°C. 
6.4.4, Big Dye sequencing method: 
 Plasmid DNA was sequenced using the Sanger dideoxy chain-termination 
method. Two sequencing PCRs were performed, one with the forward sequencing 
primer, and one with the reverse as follows: 
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5 µL plasmid 
 2 µL Terminator 3.1 buffer 
 2 µL Big Dye 
 1 µL primer 
The following thermal cycle was used: 94°C for 30s, (94°C for 30s, 50°C for 20s, 
60°C for 20s) x24. The DNA was sequenced using an ABI prisim 377 DNA 
sequencer using the Sanger dideoxy chain termination method by the Genepool at the 
Ashworth Laboratories. Sequencing primers used were standard pET forward/pET 
reverse, pGEM forward/pGEM reverse, M13for and pTTQ18rev (5’-GCC AGT 
GCC AAG CTT CTA-3’) 
6.5, SET21 Microbiology: 
6.5.1, SET21 host growth conditions: 
 Non-transformed SET21 cells (from a 20% glycerol stock) were washed three 
times with sterile ddH2O and streaked on replica DMA plates (with no antibiotic 
selection) containing either; 2 mM L-methionine, 2 mM D-methionine, 2 mM N-
acetyl-L-methionine, or 2 mM N-acetyl-D-methionine. SET21(DE3) transformed 
with pET20b NAAAR WT cells (from overnight LB broth (100 μg mL
-1
 ampicillin) 
cultures) were washed three times with sterile ddH2O and streaked on replica DMA 
plates (with no antibiotic selection) containing either; 2 mM L-methionine, 2 mM D-
methionine, 2 mM N-acetyl-L-methionine, or 2 mM N-acetyl-D-methionine Plates 
contained 2 mg mL
-1 
2,3,5-triphenyltetrazolium chloride (TTC) as a growth contrast 
agent. Plates were incubated at 37°C for 24 hours to allow for cell growth. 
6.5.2, SET21(DE3) lysogenization: 
 SET21 were made λ(DE3) lysogens using a commercial kit and the 
manufacturer’s instructions (Merck). Lysogenation was confirmed by over 
expression of NAAAR from pET28a NAAAR WT. 
6.5.3, Minimal media: 
6.5.3.1, M9 minimal agar: 
M9 salts (10x): 
Na2HPO4.7H2O          128 g L
-1 
KH2PO4                       30 g L
-1
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NaCl                             5 g L
-1
 
NH4Cl                          10 g L
-1
 
Autoclaved for 15 minutes at 121°C. 
1 M MgSO4 – filter sterilised. 
1 M CaCl2 – filter sterilised. 
20% glucose – filter sterilised. 
1 M IPTG – filter sterilised. 
60 mM CoCl2 – filter sterilised. 
100 mM methionine derivative – filter sterilised. 
No trace metal or vitamin solution was added to minimal media. 
To 270 mL of autoclaved agar number 1, the following were added: 
720 μL MgSO4 
36 μL CaCl2 
7.2 mL 20% Glucose 
36 mL M9 Salts (10x) 
300 - 600 μL appropriate antibiotics 
300 μL IPTG 
1.5 mL CoCl2 
Methionine derivative added as required. 
6.5.3.2, Davis minimal agar: 
26.6 g L
-1
 Davis Minimal agar (autoclaved for 15 minutes at 121°C). 
100 mM methionine derivative – filter sterilised. 
To 100 mL of autoclaved Davis minimal agar, the following were added: 
100 - 200 μL appropriate antibiotics. 
Methionine derivative added as required. 
This was then aliquoted as 25 mL into sterile Petri dishes. 
6.5.3.3, Davis minimal broth: 
11.6 g L
-1
 Davis Minimal broth (autoclaved for 15 minutes at 121°C). 
100 - 200 μL appropriate antibiotics. 
100 mM methionine derivative – filter sterilised. 
To 100 mL of autoclaved Davis minimal broth, the following were added: 
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100 - 200 μL appropriate antibiotics. 
Methionine derivative added as required. 
6.5.4, SET21(DE3) cell competency: 
6.5.4.1, CaCl2 chemical competent cells: 
 SET21 and SET21(DE3) were made chemically competent by first streaking 
a strain glycerol stock on LB agar (30 μg mL
-1
 chloramphenicol) and picking a single 
colony into 5 mL LB broth (30 μg mL
-1
 chloramphenicol). This was incubated 
overnight at 37°C before back dilution into 100 mL LB broth (30 μg mL
-1
 
chloramphenicol) to an OD600 of 0.1. This was allowed to grow at 37°C with 
agitation until the OD600 reached 0.5, at which point the culture was chilled on ice for 
60 minutes. All following steps were performed in a cold room at 4°C with a chilled 
centrifuge and ice cold buffers. Cells were pelleted (2,000 g, 15 mins, 4°C) and 
resuspended with 100 mL of autoclaved 100 mM CaCl2. These were incubated on ice 
for 30 minutes followed by another centrifugation (2,000 g, 15 mins, 4°C) and 
resuspension with 10 mL of 100 mM CaCl2. This step was repeated before a final 
centrifugation (2,000 g, 15 mins, 4°C) and resuspension in 2 mL 100 mM CaCl2 15% 
glycerol. Cells were stored as 200 μL aliquots at -80°C.  
6.5.4.2, Electrocompetent cells: 
SET21 and SET21(DE3) were made electrocompetent by first streaking a 
glycerol on LB agar (30 μg mL
-1
 chloramphenicol) and picking a single colony into 5 
mL LB broth (minus NaCl) (30 μg mL
-1
 chloramphenicol). This was incubated 
overnight at 37°C before back dilution into 100 mL LB broth (minus NaCl) (30 μg 
mL
-1
 chloramphenicol) to an OD600 of 0.1. This was allowed to grow at 37°C until 
the OD600 reached 0.5-0.6, at which point the culture was chilled on ice for 60 
minutes. All following steps were performed in a cold room at 4°C with a chilled 
centrifuge and ice cold buffers. Cells were pelleted (2,000 g, 15 mins, 4°C) and 
resuspended with 25 mL autoclaved ddH2O. These were incubated on ice for 30 
minutes followed by another centrifugation (2,000 g, 15 mins, 4°C) and resuspension 
with 25 mL ddH2O. Cells were pelleted again (2,000 g, 15 mins, 4°C) and 
resuspension in 5 mL 20% glycerol, before a final centrifugation (2,000 g, 15 mins, 
4°C) and resuspension in 500 μL 20% glycerol, 150 mM trehalose. Cells were stored 
as 50 μL aliquots at -80°C.   
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6.5.4.3, Calculating transformation efficiency: 
 Both electro and chemically competent cells were measured for 
transformation efficiency by transforming with 0.01 ng of pUC18 (Invitrogen) using 
the standard transformation protocols. After 1 hour of phenolic outgrowth, four LB 
agar plates (100 μg mL
-1
 ampicillin) were spread with 10% of cells with no dilution, 
1/10 dilution, 1/100 dilution, or 1/1000 dilution. The dilutions were performed as the 
neat and 1/10 dilution typically gave >10
2-3
 colonies making counting impossible. 
Transformation efficiency, in c.f.u. per μg pUC18, was calculated using Eqn (5). 






6.5.5, SET21 genetic selection: 
6.5.5.1, SET21 pTTQ18 G293x saturation mutagenesis selection: 
SET21 cells electroporated with a mutagenic the pTTQ18 NAAAR G293x 
library were incubated at 37°C with agitation for 1 hour and then washed three times 
with 0.2 μm filtered ddH2O to remove exogenous media containing L-methionine. 
The final resuspension was in 100 μL ddH2O. 95 μL of this was spread on Davis 
minimal agar (100 μg mL 
-1
 ampicillin, 30 μg mL
-1
 chloramphenicol) supplemented 
with 2.5 mM N-acetyl-D-methionine for selection, and the remaining 5 μL was 
spread on LB agar (100 μg mL 
-1
 ampicillin, 30 μg mL
-1
 chloramphenicol) to check 
cloning efficiency. Colony size was judged by eye and those thought to be the largest 
on a selection plate were re-streaked onto a replica Davis minimal agar plate (100 μg 
mL
-1
 ampicillin, 30 μg mL
-1
 chloramphenicol, 2.5 mM N-acetyl-D-methionine). 
These were incubated at 37°C overnight and growth compared to a SET21 pTTQ18 
NAAAR G293E standard. Those colonies that appeared to outgrow the parental 





 chloramphenicol). The plasmid DNA from these was isolated and 
sequenced using the Big dye method (See section 6.4.4). 
6.5.5.2, SET21(DE3) pET20b G291D epPCR selection: 
SET21(DE3) cells electroporated with a pET20b NAAAR G291D epPCR 
mutagenic library were incubated at 37°C with agitation for 1 hour and then washed 
three times with 0.2 μm filtered ddH2O to remove exogenous media containing L-
methionine. The final resuspension was in 100 μL. 95 μL of this was spread on Davis 
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minimal agar (100 μg mL 
-1
 ampicillin, 30 μg mL
-1
 chloramphenicol, 500 μM N-
acetyl-D-methionine) and the remaining 5 μL was spread on LB agar (100 μg mL
-1
 
ampicillin) to check cloning efficiency. Colony size was judged by eye and those 
thought to be the largest on a selection plate were picked into LB broth (100 μg mL
-1
 
ampicillin, 30 μg mL
-1
 chloramphenicol). These cultures were incubated at 37°C 
overnight with agitation before being sub-cultured to an OD600 ~0.1 in Davis 
minimal broth (100 μg mL
-1
 ampicillin, 30 μg mL
-1
 chloramphenicol, 500 μM N-
acetyl-D-methionine). The OD600 of these culture was monitored over the next 8 
hours at 37°C and compared to growth of SET21(DE3) pET20b G291D NAAAR 
grown in the same media. 
6.6, Cloning of pET28a and pET20b NAAAR: 
pET28a and pET20b NAAAR WT was cloned using the WT NAAAR gene 
from pTTQ18 NAAAR WT with primers NAAAR NdeI F that encoded an 5’- NdeI 
site and NAAAR HindIII R encoding a 3’- HindIII site. The restriction sites are 
underlined and tha start codon mutation shown below in bold. The reaction 
contained: 
       125ng NAAAR NdeI F 5’-CAT ATG AAA CTC AGC GGT GTG GAA CTG-3’ 
       125 ng NAAAR HindIII R 5’-AAG CTT CTA CGA ACC GAT CCA-3’ 
       50 ng pTTQ18 NAAAR WT 
       5 µL dNTP (50x, 200 µM final concentration of each) 
       2 µL MgSO4 (25x, 1 mM final concentration) 
       5 µL KOD polymerase buffer (10x) 
       1 µL KOD polymerase (1 U µL
-1
) 
       Up to 50 µL with ddH2O 
The following thermal cycle was used: 95°C for 5 mins, (95°C for 1 min, 50°C for 1 
min, 72°C for 2 mins) x30, 72°C for 2 mins. A’ overhangs were added by adding 1 
Pure Taq Ready to Go bead (GE healthcare) to the finished PCR reaction and using 
the following thermal cycle: 95°C for 5 minutes, 72°C for 10 minutes. The PCR 
product (1116 bp) was gel purified using the standard protocol found in the Qiagen 
QAIquick® Gel extraction kit. This was then ligated into pGEM-Teasy using the 
following protocol: 
 1 µL pGEM-Teasy plasmid 
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 3 µL NAAAR WT PCR product  
 1 µL T4 DNA ligase 
 5 µL Rapid ligation buffer (2x) 
The reaction was left at 4°C overnight before being used to transform JM109 using 
the standard heat shock transformation protocol. Transformants were spread on S-gal 
LB agar plates (100 µg mL
-1
 ampicillin) and incubated at 37°C overnight. White 
colonies were selected against black/blue colonies and used to culture 5 mL LB broth 
(100 µg mL
-1
 ampicillin). Cultures were incubated at 37°C overnight and the plasmid 
DNA isolated. The presence of an insert was checked by a restriction digest with 
EcoRI and HindIII. Digestion products were run on 1% agarose gel. Plasmids which 
gave the correct bands (double cut – 1120bp & 3000bp; single cut – 4120bp) were 
checked by sequencing with the Big Dye method (See section 6.4.4). 
 Sequence confirmed pGEM T-easy NAAAR WT plasmids were digested 
with NdeI and HindIII to give a sticky ended fragment which was ligated as above, 
into pET28a or pET20b cut with the same restriction enzymes. The transformation 
was performed in DH5α and spread on LB agar (30 µg mL
-1
 kanamycin for pET28a 
or 100 µg mL
-1
 ampicillin for pET20b). Transformants were picked into 5 mL LB 
(30 µg mL
-1
 kanamycin for pET28a or 100 µg mL
-1
 ampicillin for pET20b) and 
grown overnight at 37°C. The plasmid DNA was isolated from these cultures and 
checked for the presence of an insert with an NdeI/HindIII restriction digest. 
Plasmids with confirmed inserts were stored at -20°C. This generated the plasmids 
pET28a NAAAR WT and pET20b NAAAR WT. To generate pET28a NAAAR 
G291E and pET20b NAAAR G291E, this procedure was repeated with pTTQ 
NAAAR G293E as the initial PCR template (See section 6.7.1). 
6.7, Mutagenesis: 
6.7.1, Site directed mutagenesis of pTTQ18 NAAAR G293E: 
pTTQ18 NAAAR WT was used as a template for SDM at position G293 
using primers G293E for and G293E rev which encode a G293E mutation. The 
introduced DNA mutation is shown below in bold. The reaction contained: 
125 ng G291E for – 5’-GG TGC GGC GAG ATG ATC GAG ACC G-3’ 
125 ng G291E rev – 5’-CC GGT CTC GAT CAT CTC GCC GCA C-3’ 
50 ng pTTQ18 NAAAR WT 
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1 µL dNTPS (50x, 200 µM final concentration of each) 
5 µL Pfu reaction buffer (10x) 
1 µL Pfu turbo (2.5 U µL
-1
) 
Up to 50 µL with ddH2O 
The following thermal cycle was used: 94°C for 30s, (94°C for 30s, 50°C for 20s, 
72°C for 2 mins) x24. 10 μL of PCR product was digested for 5 hour at 37°C with 1 
μL DpnI (1 U μL
-1
) to remove the methylated parental plasmid. 2 µl of the digested 
PCR product was then used to transform 50 µl of Top10 cells by heat shock and 
spread on LB agar (100 µg mL
-1
 ampicillin). Several transformants were used to 
culture separate 5 mL LB (100 µg mL
-1
 ampicillin) overnights at 37°C. The plasmid 
DNA from these cultures was isolated and sequenced using the Big Dye method (See 
section 6.4.4). 
6.7.2, Saturation mutagenesis of pTTQ18 NAAAR G293: 
 Site directed saturation mutagenesis of G293 was performed on pTTQ18 
NAAAR WT using primers G293x for and G293x rev. The degenerate NNK codon is 
shown below in bold. The reaction contained:  
125 ng G293x for: 5’-C CCG GTG TGG TGG TGC GGC NNK ATG-3’ 
125 ng G293x rev: 5’-CC GGT CTC GAT CAT MNN GCC G-3’ 
50 ng pTTQ18 NAAAR WT 
1 µL dNTPS (50x, 200 µM final concentration of each) 
5 µL Pfu reaction buffer (10x) 
1 µL Pfu turbo (2.5 U µL
-1
) 
Up to 50 µL with ddH2O 
The following thermal cycle was used: 94°C for 30s, (94°C for 30s, 50°C for 20s, 
72°C for 2 mins) x24. 10 μL of PCR product was digested for 5 hour at 37°C with 1 
μL DpnI (1 U μL
-1
) to remove the methylated parental plasmid. This product was 
used to transform SET21 for selection of improved variant NAAARs (See section 
6.5.5.1). 
6.7.3, Error prone PCR of pET20b NAAAR G291D: 
A mutagenic pET20b G291D NAAAR library was constructed using pET20b 
Fm and pET20b Rm which terminated on the 3’ end with either the ATG start codon 
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or CTA stop codon reverse compliment. The start and stop codons are shown below 
in bold and the restriction sites underlined. The reaction contained: 
    250 ng pET20b Fm 5’-GTT TAA CTT TAA GAA GGA GAT ATA CAT ATG-3’ 
    250 ng pET20b Rm 5’-GTG CTC GAG TGC GGC CGC AAG CTT CTA-3’ 
    500 ng pET20b NAAAR G291D 
    1 µL dNTPS (50x, 200 µM final concentration of each) 
    5 µL mutazyme reaction buffer (10x) 
    1 µL mutazyme (2.5 U µL
-1
) 
    Up to 50 µL with ddH2O 
The following thermal cycle was used: 98°C for 2 mins, (98°C for 30s, 55°C for 30s, 
72°C for 2 mins) x24, 72°C for 10 mins. 2 µL of this PCR product was used in a 
second, high fidelity PCR to increase the amount of mutagenic PCR product. The 
reaction contained: 
    250 ng pET20b Fm 5’-GTT TAA CTT TAA GAA GGA GAT ATA CAT ATG-3’ 
    250 ng pET20b Rm 5’-GTG CTC GAG TGC GGC CGC AAG CTT CTA-3’ 
    1 µL pET20b NAAAR G291D epPCR product 
    1 µL dNTPS (50x, 200 µM final concentration of each) 
    5 µL Pfu turbo reaction buffer (10x) 
    1 µL Pfu turbo (2.5 U µL
-1
) 
    Up to 50 µL with ddH2O 
The following thermal cycle was used: 98°C for 2 mins, (98°C for 30s, 55°C for 30s, 
72°C for 2 mins) x24, 72°C for 10 mins. This PCR product (1152 bp) was gel 
purified before cloning into a pET20b plasmid using a MEGAWHOP PCR 
containing: 
    >300 ng gel purified high fidelity epPCR product (megaprimer) 
    50 ng pET20b NAAAR WT 
    1 µL dNTPS (50x, 200 µM final concentration of each) 
    5 µL Pfu turbo reaction buffer (10x) 
    1 µL Pfu turbo (2.5 U µL
-1
) 
    Up to 50 µL with ddH2O 
The following thermal cycle was used: 98°C for 2 mins, (98°C for 20s, 55°C for 20s, 
68°C for 2 mins) x25. 10 μL of PCR product was digested for 5 hour at 37°C with 1 
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μL DpnI (1 U μL
-1
) to remove the methylated parental plasmid. This product was 
used to transform SET21(DE3) for selection of improved variant NAAARs (See 
section 6.5.5.2). 
6.7.4, Saturation mutagenesis of pET20b NAAAR G291D F323: 
 Saturation mutagenesis of F323 was performed by creating a megaprimer 
from pET20b NAAAR G291D using primers pET20b Fm and F323x rev. This 
megaprimer was incorporated into pET20b NAAAR G291D using a MEGAWHOP 
PCR. The degenerate NNK codon is shown below in bold, with the NdeI restriction 
site underlined. 
     1 μg pET20b Fm: 5’- GTT TAA CTT TAA GAA GGA GAT ATA CAT ATG -3’ 
     1 μg F323x rev: 5’- GGT TTT GTG MNN CCG GTC C -3’         
     50 ng pET20b NAAAR G291D 
     1 µL dNTPS (50x, 200 µM final concentration of each) 
     5 µL Pfu turbo reaction buffer (10x) 
     1 µL Pfu turbo (2.5 U µL
-1
) 
     Up to 50 µL with ddH2O 
The following thermal cycle was used: 98°C for 30s, (98°C for 30s, 55°C for 30s, 
72°C for 2 mins) x40) 72°C for 10 mins. This PCR product was gel purified before 
cloning into a pET20b plasmid using a MEGAWHOP PCR containing: 
    >300 ng gel purified high fidelity G291x PCR product (megaprimer) 
    50 ng pET20b NAAAR G291D 
    1 µL dNTPS (50x, 200 µM final concentration of each) 
    5 µL Pfu turbo reaction buffer (10x) 
    1 µL Pfu turbo (2.5 U µL
-1
) 
    Up to 50 µL with ddH2O 
The following thermal cycle was used: 98°C for 2 mins, (98°C for 20s, 55°C for 20s, 
68°C for 2 mins) x25. 10 μL of PCR product was digested for 5 hour at 37°C with 1 
μL DpnI (1 U μL
-1
) to remove the methylated parental plasmid. This product was 
used to transform BL21(DE3) for high-throughput, chiral HPLC screening of 
improved variant F323x NAAARs (See section 6.8). 
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6.8, High-throughput HPLC screening of pET20b NAAAR G291D F323x 
libraries: 
2 µL of digested pET20b G291D F323x saturation mutagenesis product was 
used to transform BL21(DE3) and this spread on LB agar (100 µg mL
-1
 ampicillin). 
After an overnight incubation at 37°C, 96 random colonies were picked into 1 ml of 
LB broth (100 µg mL
-1
 ampicillin) in two 2.2 mL 48 well plates. These were 
incubated at 37°C overnight with agitation and a gas permeable sealed top. These 
cells were then used in a small scale biotransformation of N-acetyl-L-methionine to 
look for variants with improved racemase activity. The reaction was carried out by 
adding 10 µL cells to 90 µL reaction buffer (final concentrations upon addition of 
cells: 100 mM Tris-HCl (pH 8.0), 5 mM CoCl2, 150 mM N-acetyl-L-methionine). 
These reactions, incubated at 60°C for 60 minutes, were carried out in 2.2 mL 96 
well plates. The reactions were terminated with addition of 900 µL of 0.01% 
TEAA:MeOH (75:25), and diluted a further 100 fold with the same buffer. Reactions 
were then analysed by chiral HPLC
[256]
 (See section 6.12). Conversion of N-acetyl-L-
methionine to N-acetyl-D-methionine was used to assess enzyme activity. The 
plasmid DNA from the most active wells was isolated from the master growth plates 
and sequenced.  
6.9, his-NAAAR and native NAAAR expression: 
6.9.1, Expression of his-NAAAR: 
WT and G291E hexa-histidine tagged NAAAR (his-NAAAR) was expressed 
in BL21(DE3) transformed with pET28a NAAAR WT/G291E. A single 
transformant from an LB agar plate (30 µg mL
-1
 kanamycin) was used to inoculate 
two 250 mL seed cultures of LB broth (30 µg mL
-1
 kanamycin). One of these of 
these was used to sub-culture 4.5 L of sterile LB broth (30 µg mL
-1
 kanamycin) to an 
OD600 ~0.1 and aliquoted into ten sterile 500 mL baffle flasks. These were incubated 
with agitation at 37°C until the OD600 reached 0.6, at which point expression was 
induced with 1 mM IPTG. Cells were harvested after 5 hours at 37°C (5,000 g, 20 
mins, 4°C) and stored at -20°C.  
6.9.2, Expression of native NAAAR: 
Native NAAAR (WT and all variants) was expressed in BL21(DE3) 
transformed with pET20b expressing the NAAAR of interest. A single transformant 
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from an LB agar plate (100 µg mL
-1
 ampicillin) was used to inoculate 500 mL of 
sterile LB broth (100 µg mL
-1
 ampicillin). This was incubated at 37°C for 24 hours 
with no IPTG induction. Cells were then harvested (5,000 g, 20 mins, 4°C) and often 
used immediate for NAAAR purification (See section 6.10.2). If not used 
immediately, pellets were stored at -20°C. 
6.10, his-NAAAR and native NAAAR purification: 
6.10.1, Purification of his-NAAAR: 
His-tagged NAAAR was purified using Ni-affinity chromatography, with all 
steps performed at 4°C or on ice. A BL21(DE3) cell pellet expressing his-NAAAR 
was re-suspended in 10 mL lysis buffer (50 mM Tris-HCl (pH 7.5), 20 mM 
imidazole, 1 complete mini EDTA free protease inhibitor tablet(Roche)) and lysed 
using 30 s on/30 s off sonication (Soniprep150). The resulting cell free extract was 
then clarified by centrifugation (18,000 g, 30 mins, 4°C), after which the supernatant 
was removed, 0.45 μm filtered, and gently mixed with 1 mL of Ni:NTA beads 
(Invitrogen) for 60 mins at 4°C. Ni:NTA beads were previously washed and 
equilibrated with lysis buffer.  
  The protein bound Ni:NTA beads were loaded into a 1 mL polypropylene 
column (Qiagen) using a peristaltic pump and eluted using a step wise gradient of 
imidazole (20 cv of 50 mM, 10 cv of 100 mM, and 10 cv of 250 mM). Fractions 
were tested for the presence of his-NAAAR by SDS-PAGE analysis. The 100 mM 
and 250 mM imidazole fractions, both of which usually contained his-NAAAR were 
dialysed three times against 1 L of 50 mM Tris-HCl (pH 7.5) with an 8 kDa MWCO 
membrane. Protein concentration was estimated from Abs280 measured on a Varian 





Protein yield was roughly 10 mg L
-1
 of growth media and judged to be at least 95% 
pure. Protein concentration was adjusted to 1 mg mL
-1
 and frozen as 20% glycerol at 
-20°C.  
6.10.2, Purification of native NAAAR: 
Native NAAAR was purified using Anion Exchange and Size Exclusion 
chromatography, all steps performed at 4°C or on ice. After 24 hours of expression, 
500 mL of LB broth (100 μg mL
-1
 ampicillin) containing BL21(DE3) pET20b 
NAAAR was harvested (6,000 g, 20 mins, 4°C) and then resuspended in 10 mL lysis 
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buffer (50 mM Tris-HCl (pH 8.0) 100 mM NaCl, 2 mg mL
-1
 Lysozyme, 1 mini 
complete EDTA free protease inhibitor tablet (Roche) and left for 30 minutes on ice. 
Cells were lysed by sonication (30s on/ 30s off) and the cell free extract clarified by 
centrifugation (18,000 g, 60 mins, 4°C). The supernatant was removed and 0.45 µm 
filtered before loading onto a HiPrep 16/10 FF Q column (GE healthcare) 
equilibrated with 50 mM Tris-HCl (pH 8.0), 100 mM NaCl. NAAAR was then 
eluted using a 2 stage gradient (0 to 45% over 9 column volumes, 45 to 100% over 3 
column volume) of 50 mM Tris-HCl (pH 8.0), 1 M NaCl. Fractions judged to contain 
the highest purity and concentration of NAAAR were pooled and concentrated to 
less than to 1 mL using a 30 kDa cut off spin filter (Vivaspin). The concentrated 
sample was then loaded on to an HiPrep 26/60 Sephacryl S-300 HR (GE healthcare) 
equilibrated with 50 mM Tris-HCl (pH 8.0), 100 mM NaCl. NAAAR was eluted 
over an isocratic elution at 1 mL min
-1
. WT NAAAR, and all variants, eluted as 
octamers at roughly 135 mL. Protein concentration was calculated using Abs280 (Mr 
WT = 39,407 g, Mr G291E = 39,479 g, Mr G291D = 39,463 g, Mr G291D F323Y = 39,481 g, ε 




). Protein samples were submitted to 
SIRCAMS (The University of Edinburgh) at a concentration of 1 mg mL
-1
 in size 
exclusion elution buffer for ESI-MS analysis. The Sephacryl S-300 column was 
calibrated with Carbonic Anhydrase (Mr = 29 kDa), Conalbumin (75 kDa), Aldolase 
(158 kDa), and Thyroglobulin (669 kDa), all eluted in 50 mM Tris-HCl (pH 8.0), 
100 mM NaCl. The void volume was found to be 92.101 mL with Blue Dextran (Mr 
>2,000 kDa) and the column volume was 320 mL. This gave Eqn (6) and Eqn (7) 
which were used to calculate molecular weight: 

















6.11, In vitro NAAAR assays: 
Purified his-NAAAR and native NAAAR were both assayed using chiral 
HPLC. Purified enzyme was incubated with a single N-acetyl-amino acid enantiomer 
in the following reaction. 
100 μL purified NAAAR (0.1 mg mL
-1
 final concentration) 
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100 μL CoCl2 (10x, 5 mM final concentration) 
100 μL Tris-HCl (10x, 50 mM final concentration) 
500 μL N-acetyl amino acid in 100 mM Tris-HCl (pH 8.0) (2x) 
200 μL ddH2O 
Substrates were made up in 100 mM Tris-HCl and the pH adjusted to 8.0 at 60°C. 
Substrate solutions were 2x stocks giving an overall final Tris-HCl concentration of 
100 mM. 
Reactions were terminated and diluted 20 fold with 50 mM HCl and boiled for 3 
minutes to precipitate protein. These were clarified by centrifugation (11,000 g, 5 
mins, rt) and the supernatant 0.45 μm filtered before analysis using an Agilent 1100 
or 1200 HPLC system (Ingenza, Roslin Biocentre). HPLC conditions were as 
follows: 
Column: Chirobiotic™ T (5 µm, 250 mm x 4.6 mm) 
Flow rate: 0.5 mL min
-1 
Mobile phase: 15 minute isocratic elution of 75:25 0.01% TEAA: MeOH. TEAA 
was a 1:1 (v/v) of glacial acetic acid and triethylamine. 
Detection λ: 210 nm 
Injection volume: 5 μL 
Temperature: 40°C 
Elution times: N-acetyl-L-methionine 4.5 mins, N-acetyl-D-methionine 6.1 mins, L-
methionine 8.5 mins, and D-methionine 10.0 mins. 
6.12, In vivo NAAAR assays: 
Biotransformations were carried out by transforming BL21(DE3) cells with 
pET20b NAAAR WT and G291E, G291D, or G291D F323Y variants. These were 
used to inoculate 5 mL of LB (100 µg mL
-1
 ampicillin) and grown overnight at 37°C 
with agitation. No IPTG was added to these cultures. To generate a range of NAAAR 
concentrations these cells were diluted by factors of 1.0 (no dilution), 0.75, 0.5 and 
0.25, and 10 µL of each diluted culture was incubated with 50 µL substrate (final 
concentration, 150 mM), 10 µL Tris-HCl (stock concentration, 500 mM, pH 8.0 at 
60°C), 10 µL CoCl2 (stock concentration, 50 mM) and 20 µL dH2O (final volume 
100 µL). The substrates were suspended in 100 mM Tris-HCl and the pH adjusted to 
8.0 at 60°C. This gave a final concentration of 100 mM Tris-HCl in each reaction. 
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The reactions were incubated at 60°C for 1 hour with agitation in a 2.2 mL 96 deep 
well plate. The reactions were terminated and diluted with three 10 fold dilutions in 
0.01% TEAA:MeOH (75:25). The enantiomeric excess was measured by chiral 
HPLC as follows: 
Column: Chirobiotic™ T (5 µm, 250 mm x 4.6 mm) 
Mobile phase: isocratic elution of 75:25 0.01% TEAA: MeOH. TEAA was a 1:1 
(v/v) of glacial acetic acid and triethylamine. 
Flow rate: 0.5 mL min
-1 
Injection volume: 20 μL 
Detection λ: 210 nm 
Temperature: 40°C 
Elution times: N-acetyl-L-methionine 4.4 mins, N-acetyl-D-methionine 6.9 mins, N-
acetyl-L-phenylalanine 4.8 mins, N-acetyl-D-phenylalanine 18.9 mins, N-acetyl-(2-
aminobutyric acid), N-acetyl-L-allylgylcine 4.2 mins, N-acetyl-D-allylgylcine 5.8 
mins, N-acetyl-L-(4-fluorophenylglycine) 5.1 mins, N-acetyl-D-(4-
fluorophenylglycine) 18.0 mins, and N-acetyl-L-phenylglycine 5.0 mins, N-acetyl-D-
phenylglycine 18.5 mins. The column was calibrated with single enantiomers of N-
acetyl derivatives. 
Rate constants were calculated using Eqn (1), Eqn (2), and Eqn (3), where D = 
proportion of D-enantiomer, and L = proportion of L-enantiomer: 
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Specific activities were then calculated for 1 OD600 unit for each pET20b NAAAR 
BL21(DE3) strain using Eqn (4): 
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6.13, Whole cell DKRs with NAAAR and an L-acylase: 
6.13.1, Expression of NAAAR: 
 NAAAR WT, G291E, G291D, and G291D F323Y were expressed in 
BL21(DE3) from the appropriate pET20b plasmid in LB broth (100 µg mL
-1
 
ampicillin) over 24 hours with no IPTG. 
6.13.2, Expression of L-acylase: 
 L-acylase was expressed from a propriety plasmid (Chirotech Technology 
Ltd) under the control of a lac promoter. Expression was in auto-induction media (10 
g L
-1
 peptone, 5 g L
-1
 yeast extract, 50 mM (NH4)2SO4, 100 mM KH2PO4, 100 mM 
Na2HPO4, 0.5% glycerol, 0.05% glucose, 0.2% lactose, 1 mM MgSO4, 100 µg mL
-1
 
ampicillin, pH 7.5) for 24 hours at 37°C. No IPTG was added to this culture. 
6.13.3, L-acylase kinetic resolution: 
 Kinetic resolution were started by adding 0.2 OD600 units of BL21(DE3) 
expressing L-acylase to a 5 mL reaction buffer containing 100 mM Tris-HCl (pH 8.0) 
5 mM CoCl2, 30 mM N-acetyl-DL-methionine. 50 μL samples were taken at regular 
time points to monitor reaction progress. These samples were terminated and diluted 
20 fold in 50 mM HCl, before boiling for three minutes and being centrifuged 
(11,000 g, 5 mins, rt). The supernatant was then 0.45 μm filtered and analysed by 
chiral HPLC (See section 6.11). 
6.13.4, NAAAR/L-acylase dynamic kinetic resolution: 
 A dynamic kinetic resolution was carried out exactly the same as the kinetic 
resolution above, but 0.2 OD600 units of BL21(DE3) expressing each NAAAR 
variant was also included. Samples were taken and analysed by chiral HPLC (See 
section 6.11). 
6.14, Fermentation of BL21(DE3) pET20b NAAAR G291D F323Y: 
 The following fermentation was carried out at Chirotech Technology Ltd 
with the help of Dr Ian Taylor. BL21(DE3) were transformed with pET20b G291D 
F323Y NAAAR and spread on LB agar (100 µg mL
-1
 ampicillin). A single 
- 146 - 
transformant from this plate was used to inoculate a shake flask containing 50 mL of 
E. coli seed media (40 g L
-1 
Amisoy, 5 g L
-1
 HiYeast, 0.5 g L
-1 
MgSO4.7H2O, 0.5 g 
L
-1 
NaCl, 5 g L
-1 
KH2PO4, 100 µg mL
-1
 ampicillin, pH 7.0). This was cultured at 
30°C for 8 hours before 2.5 mL was used to inoculate a 1 L fermentor containing 700 
mL of E. coli fermentation media (15 g L
-1 
Amisoy, 15 g L
-1
 HiYeast, 4 g L
-1
 
(NH4)2SO4, 8 g L
-1
 KH2PO4, 7 g L
-1
 K2HPO4, 1 g L
-1
 MgSO4.7H2O, 1 mL L
-1
 trace 
elements solution (Dow), 2 mL L
-1
 antifoam, 50 mL L
-1
 glycerol, 100 µg mL
-1
 
ampicillin, pH 7.0). After 19.5 hours, E. coli feed media (40 g L
-1
 Amisoy, 20 g L
-1
 
HiYeast, 5 g L
-1
 (NH4)2SO4, 1 g L
-1
 MgSO4.7H2O, 208 g L
-1
 glycerol, 1.25 mL L
-1
 
trace elements solution, 100 µg mL
-1
 ampicillin, pH 7.0) was fed in at a rate of 14 
mL hour
-1
. After 40 hours at 30°C, the cells were harvested (6,000 g, 30 mins, 4°C) 
to give a wet weight of 90.8 g (16.2 g dry cells) from a total of 1.05 L media. 
Samples were taken throughout the fermentation process to monitor NAAAR 
activity. Total NAAAR activity present in the fermentation broth and specific 
activities were calculated by testing the fermentation broth under standard NAAAR 
assay conditions (150 mM N-acetyl-L-methionine in 100 mM Tris-HCl (pH 8.0), 5 
mM CoCl2, for 1 hour at 60°C, in a reaction volume of 100 µL. The decrease in e.e. 
was measured as above using chiral HPLC (See section 6.12). The specific activity 
was determined by calculating the activity per OD600 of each fermentation sample. 
Total activity was calculated by measuring the total OD600 of the fermentation. 
6.15, BL21(DE3) pET20b NAAAR G291D F323Y downstream processing 
(DSP): 
 10 g of fermented wet cells were resuspended in 50 mL of 50 mM Tris-HCl 
(pH 8.0), 100 mM NaCl and lysed with sonication (20 s on/ 20 s off, 15 mins, 2°C). 
This was clarified by centrifugation (12,000 g, 20 mins, 4°C) and the supernatant 
stored at -20°C. The cell free extract (50 mL) was assayed under standard NAAAR 
assay conditions (150 mM N-acetyl-L-methionine in 100 mM Tris-HCl (pH 8.0), 5 
mM CoCl2, for 1 hour at 60°C, in a reaction volume of 100 µL and found to contain 
6615 (± 660) U mL
-1
, where 1 U = the amount of enzyme required to racemise 1 
μmole of N-acetyl-L-methionine in 60 minutes at 60°C. This reaction was analysed 
by chiral HPLC (See section 6.12). 
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6.16, Substrate profiling of NAAAR G291D F323Y cell free extract: 
The CFE generated from the BL21(DE3) NAAAR G291D F323Y 
fermentation DSP was used to test substrate specificity with a variety of amino acids. 
The reactions were run for 1 hour at 60°C on a 100 µL scale. The reaction contained, 
50 mM Tris-HCl (pH 8.0), 5 mM CoCl2, 300 mM substrate in 100 mM Tris-HCl (pH 
8.0), and an appropriate volume of NAAAR G291D F323Y CFE. The final 
concentration of Tris-HCl was 100 mM. The reaction was terminated with addition 
of 900 µL 0.01% TEAA:MeOH (75:25). This was then diluted a further 100 fold in 
the same buffer to give a final 1000 fold dilution of the reaction. The rate of 
racemisation was measured by chiral HPLC (See section 6.12). 
The following amino acids were tested: N-acetyl-DL-methionine, N-acetyl-D-
allylglycine, and N-acetyl-DL-phenylglycine, N-acetyl-D-(4-fluoro)phenylglycine, N-
acetyl-DL-phenylalanine, N-acetyl-DL-(2-amino)butyric acid, N-acetyl-L-orthinine, 
N-acetyl-D-naphthylalanine, N-benzoyl-DL-phenylalanine. 
6.17, Thermal studies of NAAAR G291D F323Y CFE: 
6.17.1, Thermal stability of NAAAR G291D F323Y CFE: 
 5 μL NAAAR G291D F323Y CFE was incubated with 150 mM N-acetyl-L-
methionine in reaction buffer (100 mM Tris-HCl, 5 mM CoCl2, final reaction volume 
= 50 µL) in a 12 well PCR strip. This was then incubated in a PCR thermal cycler 
running a well temperature gradient increasing ~2.5°C per well (30 to 55°C) for 60 
minutes before termination and 1000 fold dilution with HPLC running buffer 0.01% 
TEAA:MeOH (75:25). The samples were analysed by chiral HPLC (See section 
6.12). This process was repeated with the thermal cycler running a well gradient 
between 55 and 80°C. 
6.17.2, Thermal activity profiling of NAAAR G291D F323Y CFE: 
 NAAAR G291D F323Y CFE was incubated at 60°C for 5 hours, and tested 
for NAAAR activity under standard NAAAR assay conditions (150 mM N-acetyl-L-
methionine in 100 mM Tris-HCl (pH 8.0), 5 mM CoCl2, for 1 hour at 60°C, in a 
reaction volume of 100 µL. Samples were terminated and diluted 1000 fold in HPLC 
running buffer 0.01% TEAA:MeOH (75:25) and samples were analysed by chiral 
HPLC (See section 6.12). 
- 148 - 
6.18, NAAAR/D-acylase dynamic kinetic resolutions and D-acylase 
kinetic resolutions: 
Reactions (1 mL) were prepared containing 100 mM Tris-HCl (pH 8.0), 5 
mM CoCl2, 300 mM N-acetyl-DL-amino acid (pH 8.0), 40 U D-acylase (Chirotech 
Technology Ltd), and 30-120 U NAAAR G291D F323Y (or buffer in place of this 
for kinetic resolutions). These reactions were incubated at 40°C for 24 hours with 
agitation. After this time, the N-acetyl-DL-serine and N-acetyl-DL-allylglycine 
reactions were terminated and diluted 10 fold in HPLC running buffer (75:25 
H2O:ACN) containing 10 mM DL-phenylalanine as an internal standard (I.S). This 
reaction was then diluted a further 10 fold in HPLC running buffer before a final 10 
fold dilution in 50 mM sodium carbonate buffer (pH 9.8). To this 100 μL of 3 mg 
mL
-1
 5-(dimethylamino)naphthalene-1-sulfonyl chloride (dansyl-Cl) in 100% 
acetone was added. This was incubated at 37°C for three hours before the reaction 
was terminated with 100 μL of glacial acetic acid. The conversion of N-acetyl-DL-
allylglycine/N-acetyl-DL-serine to N-dansyl-D-allylglycine/N-dansyl-D-serine was 
measured by RP-HPLC using the following isocratic conditions: 
Column: Luna (Phenomenex) C8(2) (5 µm, 150 mm x 4.6 mm) 
Mobile phase (N-dansyl-serine): isocratic elution of 80:20 H2O:MeOH (0.01% TFA) 
Mobile phase (N-dansyl-allylglycine): isocratic elution of 75:25 H2O:MeOH (0.01% 
TFA) 
Flow rate: 2.0 mL min
-1
 
Detection λ: 330 nm 
Injection volume: 50 μL 
Temperature: rt 
Elution times: N-dansyl-serine 2.0 mins, N-dansyl-allylglycine 4.15 mins, N-dansyl-
phenylalanine 14.75 mins under N-dansyl-serine conditions and 6.7 mins under N-
dansyl-allylglycine conditions. 
N-acetyl-DL-serine, N-acetyl-DL-methionine, and N-acetyl-DL-phenylglycine 
reactions were terminated and diluted 1000 fold in HPLC running buffer. These were 
analysed by chiral HPLC using the following conditions. 
Column: Chirobiotic™ T (5 µm, 250 mm x 4.6 mm) 
Flow rate: 1 mL min
-1 
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Mobile phase: 15 minute isocratic elution of 75:25 0.01% TEAA: MeOH. TEAA 
was a 1:1 (v/v) of glacial acetic acid and triethylamine. 
Detection λ: 210 nm 
Injection volume: 50 μL 
Temperature: rt 
 
Elution times: N-acetyl-L-methionine 2.25 mins, N-acetyl-D-methionine 3.05 mins, 
N-acetyl-L-serine 2.0 mins, N-acetyl-D-serine 2.4 mins, N-acetyl-L-phenylglycine 2.2 
mins, N-acetyl-D-phenylglycine 3.0 mins. 
6.19, Melting temperature determination of NAAAR WT, G291E, 
G291D, and G291D F323Y: 
The melting temperatures (Tm) of NAAAR WT, NAAAR G291E, NAAAR 
G291D and NAAAR G291D F323Y were determined using a BioRad iQ5 rtPCR 
Thermocycler at the Edinburgh Protein Production Facility. Each NAAAR variant 
was purified by Anion Exchange and Size Exclusion Chromatography (See section 
6.10.1). Final NAAAR concentration was 0.5 mg mL
-1
. Tm for apo- and holo-forms 
was determined without ligand or at concentrations of either 100 or 200 mM N-
acetyl-DL-methionine. SYPRO orange was the fluorescent dye. Tm was determined in 
triplicate in 1°C min
-1
 steps from 20 to 95°C.  
6.20, X-ray crystallography of NAAAR G291D F323Y: 
6.20.1, Data collection:  
Pure NAAAR G291D F323Y (See section 6.10.2) which had been complexed 
previously with 10 mM N-acetyl-DL-methionine, was subjected to crystallization 
trials using a range of commercially available screens in 96-well plates using 300 nL 
drops at a range of protein concentrations. The ligand:protein complex was formed 
by mixing NAAAR with 100 mM ligand (100 mM Tris-HCl (pH 8.0)) to give a final 
concentration of 10 mM ligand. The best crystals were obtained overnight using CSS 
A1, A12, B12, and C7 at 20°C, and at a protein concentration of 8 mg mL
-1
. Larger 
crystals for diffraction analysis were prepared using the hanging-drop vapour 
diffusion method in 24-well plate Linbro dishes and using crystallisation drops of 2 
L, with a protein concentration of 8 mg mL
-1 
that had been incubated previously 
with 10 mM N-acetyl-DL-methionine. The best crystals were routinely obtained in 
crystal drops containing 100 mM Tris-HCl (pH 8.0) 15% PEG 4K, 800 mM sodium 
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formate. Crystals were tested for diffraction using a Rigaku Micromax-007HF fitted 
with Osmic multilayer optics and a MARRESEARCH MAR345 imaging plate 
detector. Those crystals that diffracted to greater than 3 Å resolution were flash-
cooled in liquid nitrogen in a cryogenic solution containing the mother liquor and no 
other cryopotectant, prior to data collection at the synchrotron. 
6.20.2, Data collection and processing, structure solution and refinement: 
All data collection, processing, structure solutions, and refinement were 
performed by Dr Gideon Grogan, The University of York. A complete dataset was 
collected on beamline io-4 at the Diamond Light Source Synchrotron in Oxford on 
11
th
 July 2011. Data were processed on the beamline using the expert data processing 
system Xia2 and the data collection statistics are given in (Table 19)
[273]
. The crystals 
had the space group H32, the same as that described for the WT NAAAR crystals 
(1SJA)
[100]
. Coordinates for one monomer of the NAAAR tetramer, derived from 
PDB file 1SJA were used as a molecular replacement model for structure solution of 
the G291D F323Y variant using PHASER The solution contained four molecules in 
the asymmetric unit, the same as for 1SJA
[100, 274]
. The model was improved using 
iterative rounds of building in Coot and refinement using REFMAC
[275, 276]
. In 
refinement, non-crystallographic symmetry (NCS) restraints were applied for chains 
B, C and D against chain A. After building the protein and water molecules, clear 
electron density was observed to persist throughout refinement in the active site of 
the enzyme, as observed in the Fo-Fc map at a level of 4. A coordinate file for N-
acetyl methionine was derived from 1SJA and this ligand was successfully modelled 
into the density in each subunit and refined using an occupancy level of 1.0. The 
final ligand-bound structure exhibited Rcryst and Rfree values of 14.8 and 20.3% 
respectively and was finally validated using PROCHECK
[277]
. Refinement statistics 
are presented in (Table 19). The Ramachandran plot showed 95.3% of residues to be 
situated in the most favoured regions, 3.8% in additional allowed and 0.9% in 
generously allowed regions.  
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Table 19, Data collection and refinement statistics for NAAAR G291D F323Y variant. Figures 
in brackets refer to the highest resolution shell. 
 NAAAR G291D F323Y 
complexed with N-
acetyl methionine 
Beamline Diamond io-3 
Wavelength (Å) 0.97630 Å 
Space Group H32 
Unit cell (Å) a = b = 216.71; c = 
261.10 
Resolution 88.31-2.71 (2.78-2.71) 
Unique Reflections 60693 
Completeness (%) 100 (100) 
Rmerge 0.085 (0.503) 
Rp.i.m. 0.041 (0.241) 
Multiplicity 10.2 (10.4) 
<I/(I)> 18.6 (4.8) 
Protein atoms 10967 
Rcryst/Rfree (%) 14.8/20.3 
r.m.s.d. 1-2 bonds (Å) 0.020 
r.m.s.d. 1-3 bonds (°) 2.12 
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6.21 Protein sequences and alignments: 
6.21.1, N-acetyl amino acid racemase (Amycolatopsis Ts-1-60): 
GenBank: BAA06400.1 
Accession: BAA06400 
Protein sequence with G291 and F323 shown in red: 
1   MKLSGVELRR VQMPLVAPFR TSFGTQSVRE LLLLRAVTPA GEGWGECVTM AGPLYSSEYN 
61  DGAEHVLRHY LIPALLAAED ITAAKVTPLL AKFKGHRMAK GALEMAVLDA ELRAHERSFA 
121 AELGSVRDSV PCGVSVGIMD TIPQLLDVVG GYLDEGYVRI KLKIEPGWDV EPVRAVRERF 
181 GDDVLLQVDA NTAYTLGDAP QLARLDPFGL LLIEQPLEEE DVLGHAELAR RIQTPICLDE 
241 SIVSARAAAD AIKLGAVQIV NIKPGRVGGY LEARRVHDVC AAHGIPVWCG GMIETGLGRA 
301 ANVALASLPN FTLPGDTSAS DRFYKTDITE PFVLSGGHLP VPTGPGLGVA PIPELLDEVT 
361 TAKVWIGS* 
6.21.2, Sequence alignment of N-acetyl amino acid racemase and L-Ala-D/L-
Glu epimerase from Amycolatopsis mediterranei U32. 
 The five conserved catalytic residues (K163, K263, D189, E214, and D239, 
numbering is relative to Am. Ts-1-60 NAAAR) are shown in yellow. 
 
NAAAR_          --------MKLTGVELLRVRMPLVAPFRTSFGTQAER--ELLLLRAVTSEGEGWGECGAM 50 
AEE_            MTGAPSAGDRADPAEFVVDRVEAWAIALPAVRSLERRTAPRILVKVTAGGVTGWGEA--- 57 
                         :   .*::  *:   *   .:. :  .*    :*::..:.   ****.    
 
NAAAR_          AGPLYSAEYIDGVEHVLQAFLVPALLAAGDLTAHKVAPLLAKFK------GHRMAKAALE 104 
AEE_            -TPARTCETAESILATIRYHLAPALVGRSAWDLDGITSAFDRAVNCGFTIGAPPAKAAVD 116 
                  *  :.*  :.:  .:: .*.***:. .    . ::. : :        *   ****:: 
 
NAAAR_          MAVLDAELRAHGLSFGTALGS-TSDSVPCGVSVGIMDSIPQLVDVVGGYLDAGYLRIKLK 163 
AEE_            MAVHDLLGRALGLSLGVLWGARRTDRLELGWTVAGR-SAAEAADSVAEGLDHGYRAFKVD 175 
                *** *   ** ***:*.  *:  :* :  * :*.   * .: .* *.  ** **  :*:. 
 
NAAAR_          IEPGWDVEPVRAVRER--FGDDILLQVDANTAYTLSDVPQLQR-LDPFGLLLIEQPLEEE 220 
AEE_            LGGLGRREDAGIVEAVRAAASDAVLWADGNQSYTVDSALRVAGPLADVGATVFEQPLPAN 235 
                :      * .  *.     ..* :* .*.* :**:... ::   *  .*  ::****  : 
 
NAAAR_          DVLGHAELARHLRTPICLDETVVSAASAAAAIRLGACRIVNIKPSRVGGYLEARRVHDVC 280 
AEE_            DIAGLKRLRDASPVPIALDEGLPHPSDLATLVRLDAVDVVVAKVQRSGGLTLSRRLCGFA 295 
                *: *  .*     .**.*** :  .:. *: :**.*  :*  * .* **   :**: ... 
 
NAAAR_          AAHGIPVWCGGMLETGLGRAANVALASLPGFTLPGDTSASDRFYRTDIT-EPFVLEAGRL 339 
AEE_            EDCGTRLMGSGLADSDLGLAASLHLFAAYDIGTPVDLAGRQFVRSPYATGRTVTVVDGAA 355 
                   *  :  .*: ::.** **.: * :  .:  * * :. : .  .  * ....:  *   
 
NAAAR_          PVPSGPGLGVTPIPERLAEVTTAKSWLA 367 
AEE_            EVPTGPGLGVDVDEQVVRSLAVDLPG-- 381 









- 153 - 
6.21.3, Sequence NAAAR from Am. Azurea, Am. Lurida, Am. Ts-1-60, Am. 
Mediterranei, and G. kaustophilus. 
 The five conserved catalytic residues (K163, K263, D189, E214, and D239, 
numbering is relative to Am. Ts-1-60 NAAAR) are shown in yellow. The location of 
G291, R299 and F323 are shown in cyan. 
Azurea_         --MKLSGVELRRVRMPLVAPFRTSFGTQSERELMLVRAVTPAGE-GWGECVTMAAPVYSS  57 
Lurida_         --MKLSGVELRRVRMPLVAPFRTSFGTQSERELLLVRAVTPAGE-GWGECVAMEAPLYSS  57 
Ts-1-60_        --MKLSGVELRRVQMPLVAPFRTSFGTQSVRELLLLRAVTPAGE-GWGECVTMAGPLYSS  57 
Med_            --MKLTGVELLRVRMPLVAPFRTSFGTQAERELLLLRAVTSEGE-GWGECGAMAGPLYSA  57 
Geo_            MAINIEYVILRHLQMELKAPFTTSFGTFQTKEFILVEVVDCDGVSGWGESVAFSVPWYSE  60 
                  :::  * * :::* * *** *****   :*::*:..*   *  ****. ::  * **  
 
Azurea_         EYNDAAEHVLRNHLIPALLAADDVTAYKVTPLLAKFKGHRMAKGALEMAVLDAELRAHER 117 
Lurida_         EYNDAAEHVLRNHLIPALLAAEDVTAHKVTPLLAKFKGHRMAKGALEMAVLDAELRAHDR 117 
Ts-1-60_        EYNDGAEHVLRHYLIPALLAAEDITAAKVTPLLAKFKGHRMAKGALEMAVLDAELRAHER 117 
Med_            EYIDGVEHVLQAFLVPALLAAGDLTAHKVAPLLAKFKGHRMAKAALEMAVLDAELRAHGL 117 
Geo_            ETVKTNWHMLEEFLVPLLFSKPLRHPAELPERFAAIRQNNMAKAALEGAVWDLYAKRLGV 120 
                *  .   *:*. .*:* *::     . ::.  :* :: :.***.*** ** *   :     
 
Azurea_         SFAAELGSTRDSVACGVSVGIMDSIPQLLDVVGDYLDEGYVRIKLKIEPGWDIEPVRQVR 177 
Lurida_         SFAAELGSTRDSVACGVSVGIMDSIPHLLDVVGGYLDEGYVRIKLKIEPGWDVEPVRQVR 177 
Ts-1-60_        SFAAELGSVRDSVPCGVSVGIMDTIPQLLDVVGGYLDEGYVRIKLKIEPGWDVEPVRAVR 177 
Med_            SFGTALGSTSDSVPCGVSVGIMDSIPQLVDVVGGYLDAGYLRIKLKIEPGWDVEPVRAVR 177 
Geo_            PLCQALGGTKKEIEVGVSIGIQPTVDDLLQVIERYVAQGYRRIKVKIKPGWDVDVIRDVR 180 
                .:   **.. ..:  ***:**  :: .*::*:  *:  ** ***:**:****:: :* ** 
 
Azurea_         ERFGDDVLLQVDANTAYTLGDAPLLARLDPFDLLLIEQPLEEEDVHGHAELAKRIRTPIC 237 
Lurida_         ERFGDDVLLQVDANTAYTLGDAPLLSRLDPFDLLLIEQPLEEEDVLGHAELAKRIRTPIC 237 
Ts-1-60_        ERFGDDVLLQVDANTAYTLGDAPQLARLDPFGLLLIEQPLEEEDVLGHAELARRIQTPIC 237 
Med_            ERFGDDILLQVDANTAYTLSDVPQLQRLDPFGLLLIEQPLEEEDVLGHAELARHLRTPIC 237 
Geo_            RAFP-DVPLMADANSAYTLADAKRLQALDEFGLMMIEQPLAADDLVDHARLQPLLKTPIC 239 
                . *  *: * .***:****.*.  *  ** *.*::*****  :*: .**.*   ::**** 
 
Azurea_         LDESIVSAKAAADAIKLGACQIVNIKPGRVGGYLEARRVHDVCAAHGVAVWCGGMIETGL 297 
Lurida_         LDESIVSAKAAADAIKLGACQIVNIKPGRVGGYLEARRVHDVCAAHGIAVWCGGMIETGL 297 
Ts-1-60_        LDESIVSARAAADAIKLGAVQIVNIKPGRVGGYLEARRVHDVCAAHGIPVWCGGMIETGL 297 
Med_            LDETVVSAASAAAAIRLGACRIVNIKPSRVGGYLEARRVHDVCAAHGIPVWCGGMLETGL 297 
Geo_            LDESIRSYDDARKALDLGSCRIINIKIGRVGGLWEAKRIHDLCAERGVPVWCGGMLEAGV 299 
                ***:: *   *  *: **: :*:*** .****  **:*:**:** :*:.******:*:*: 
 
Azurea_         GRAANVALASLPGFTLPGDTSASGRFYRTDITEPFVLEA-GHLPVPTGPGLGVTPIPDIL 356 
Lurida_         GRAANVALASLPGFTLPGDTSASGRFYRTDITEPFVLDA-GHLPVPTGPGLGVTPIPDLL 356 
Ts-1-60_        GRAANVALASLPNFTLPGDTSASDRFYKTDITEPFVLSG-GHLPVPTGPGLGVAPIPELL 356 
Med_            GRAANVALASLPGFTLPGDTSASDRFYRTDITEPFVLEA-GRLPVPSGPGLGVTPIPERL 356 
Geo_            GRAHNIAITTLENFALPGDTAASSHYWERDIITPEVEVHNGLIRVPNAPGIGYDVDRRQV 359 
                *** *:*:::* .*:*****:**.:::. **  * *    * : **..**:*       : 
 
Azurea_         DDFTTEKVWIGS---- 368 
Lurida_         DEVTTEKAWIGS---- 368 
Ts-1-60_        DEVTTAKVWIG----- 367 
Med_            AEVTTAKSWLA----- 367 
Geo_            ERYTQFAKLFHRTATA 375 







- 154 - 
7.1, References: 
[1] D. Cavalieri, P. E. McGovern, D. L. Hartl, R. Mortimer, M. Polsinelli, J. Mol. Evol. 
2003, 57 Suppl 1, S226. 
[2] A. Ghamen, Tetrahedron 2007, 63, 1721. 
[3] M. K. Turner, Trends Biotechnol. 1995, 13, 173. 
[4] A. L. Demain, J. Ind. Microbiol. Biotechnol. 2001, 27, 352. 
[5] S. J. Chiang, J. Ind. Microbiol. Biotechnol. 2004, 31, 99. 
[6] J. B. van Beilen, Z. Li, Curr. Opin. Biotechnol. 2002, 13, 338. 
[7] L. Hilterhaus, A. Liese, Adv. Biochem. Eng. Biotechnol. 2007, 105, 133. 
[8] M. Alcalde, M. Ferrer, P. F. J., A. Ballesteros, Trends Biotechnol. 2006, 24, 281. 
[9] N. Ran, L. Zhao, Z. Chen, J. Tao, Green Chem. 2008, 10, 361. 
[10] C. Delhomme, D. Weuster-Botz, F. E. Kuhn, Green Chem. 2008, 11, 13. 
[11] R. McKenna, D. R. Nielsen, Metab. Eng. 2011, 13, 544. 
[12] T. Willke, K.-D. Vorlop, Appl. Microbiol. Biotechnol. 2004, 66, 131. 
[13] A. J. Straathof, S. Panke, A. Schmid, Curr. Opin. Biotechnol. 2002, 13, 548. 
[14] T. Nagasawa, H. Shimizu, H. Yamada, Appl. Microbiol. Biotechnol. 1993, 40, 189. 
[15] H. Yamada, M. Kobayashi, Biosci. Biotechnol. Biochem. 1996, 60, 1391. 
[16] F. H. Arnold, A. A. Volkov, Curr. Opin. Chem. Biol. 1999, 3, 54. 
[17] N. J. Turner, Nat. Chem. Biol. 2009, 5, 567. 
[18] C. K. Savile, J. M. Janey, E. C. Mundorff, J. C. Moore, S. Tam, W. R. Jarvis, J. C. 
Colbeck, A. Krebber, F. J. Fleitz, J. Brands, P. N. Devine, G. W. Huisman, G. J. Hughes, 
Science 2010, 329, 305. 
[19] R. Singh, R. Sharma, N. Tewari, D. S. Rawat, Chem. Biodivers. 2006, 3, 1279. 
[20] L. Martinkova, V. Kren, Curr. Opin. Chem. Biol. 2010, 14, 130. 
[21] J. A. Chaplin, M. D. Levin, B. Morgan, N. Farid, J. Li, Z. Zhu, J. McQuaid, L. W. 
Nicholson, C. A. Rand, M. J. Burk, Tetrahedron: Asymmetry 2004, 15, 2793. 
[22] Y. Asano, Y. Kato, C. Levy, P. Baker, D. Rice, Biocatal. Biotransfor. 2004, 22, 131. 
[23] N. J. Turner, Curr. Opin. Chem. Biol. 2011, 15, 234. 
[24] M. J. van der Werf, W. J. van den Tweel, J. Kamphuis, S. Hartmans, J. A. de Bont, 
Trends Biotechnol. 1994, 12, 95. 
[25] B. Weiner, G. J. Poelarends, D. B. Janssen, B. L. Feringa, Chemistry 2008, 14, 10094. 
[26] S. Yamada, K. Nabe, N. Izuo, K. Nakamichi, I. Chibata, Appl. Environ. Microbiol. 1981, 
42, 773. 
[27] T. F. Schwede, J. Retey, G. E. Schulz, Biochemistry 1999, 38, 5355. 
[28] N. P. Botting, M. Akhtar, M. A. Cohen, D. Gani, Biochemistry 1988, 27, 2953. 
[29] M. T. Reetz, Curr. Opin. Chem. Biol. 2002, 6, 145. 
[30] A. Zaks, A. M. Klibanov, Proc. Natl. Acad. Sci. U. S. A. 1985, 82, 3192. 
[31] J. Y. Houng, M. L. Wu, S. T. Chen, Chirality 1996, 8, 418. 
[32] S. V. Malhotra, H. Zhao, Chirality 2005, 17 Suppl., S240. 
[33] Y. K. Choi, Y. Kim, K. Han, J. Park, M. J. Kim, J. Org. Chem. 2009, 74, 9543. 
[34] N. J. Turner, Curr. Opin. Chem. Biol. 2004, 8, 114. 
[35] M. Alexeeva, R. Carr, N. J. Turner, Org. Biomol. Chem. 2003, 1, 4133. 
[36] R. Carr, M. Alexeeva, A. Enright, T. S. Eve, M. J. Dawson, N. J. Turner, Angew. Chem. 
Int. Ed. Engl. 2003, 42, 4807. 
[37] P. D. Pawelek, J. Cheah, R. Coulombe, P. Macheroux, S. Ghisla, A. Vrielink, The 
EMBO journal 2000, 19, 4204. 
[38] S. Umhau, L. Pollegioni, G. Molla, K. Diederichs, W. Welte, M. S. Pilone, S. Ghisla, 
Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 12463. 
[39] V. I. Tishkov, S. V. Khoronenkova, Biochemistry (Mosc) 2005, 70, 40. 
[40] F. R. Alexandre, D. P. Pantaleone, P. P. Taylor, I. G. Fotheringham, D. J. Ager, N. J. 
Turner, Tetrahedron Letters 2002, 43, 707. 
[41] R. Fernández-Lafuente, V. Rodriguez, J. M. Guisán, Enzyme Microb. Technol. 1998, 
23, 28. 
- 155 - 
[42] H. Luo, Q. Li, H. Yu, Z. Shen, Biotechnol. Lett. 2004, 26, 939. 
[43] S. K. Mujawar, Hindustan. Antibiot. Bull. 1999, 41, 1. 
[44] L. Pollegioni, L. Caldinelli, G. Molla, S. Sacchi, M. S. Pilone, Biotechnol. Prog. 2004, 
20, 467. 
[45] D. Monti, G. Carrea, S. Riva, E. Baldaro, G. Frare, Biotechnol. Bioeng. 2000, 70, 239. 
[46] S. M. De Wildeman, T. Sonke, H. E. Schoemaker, O. May, Acc. Chem. Res. 2007, 40, 
1260. 
[47] F. Paradisi, P. A. Conway, A. R. Maguire, P. C. Engel, Org. Biomol. Chem. 2008, 6, 
3611. 
[48] K. Vedha-Peters, M. Gunawardana, J. D. Rozzell, S. J. Novick, J. Am. Chem. Soc. 
2006, 128, 10923. 
[49] A. Menzel, H. Werner, J. Altenbuchner, H. Groger, Eng. Life Sci. 2004, 4, 573. 
[50] W. Hummel, M. Kuzu, B. Geueke, Org. Lett. 2003, 5, 3649. 
[51] D. Koszelewski, K. Tauber, K. Faber, W. Kroutil, Trends Biotechnol. 2010, 28, 324. 
[52] J. E. Ayling, H. C. Dunathan, E. E. Snell, Biochemistry 1968, 7, 4537. 
[53] M. D. Truppo, J. D. Rozzell, J. C. Moore, N. J. Turner, Org. Biomol. Chem. 2009, 7, 
395. 
[54] K. Yonaha, S. Toyama, H. Kagamiyama, J. Biol. Chem. 1983, 258, 2260. 
[55] M. D. Truppo, N. J. Turner, J. D. Rozzell, Chem. Comm. (Camb) 2009, 2127. 
[56] P. Tufvesson, J. Lima-Ramos, J. S. Jensen, N. Al-Haque, W. Neto, J. M. Woodley, 
Biotechnol. Bioengin. 2011, 108, 1479. 
[57] D. Koszelewski, I. Lavandera, D. Clay, G. M. Guebitz, D. Rozzell, W. Kroutil, Angew. 
Chem. Int. Ed. Engl. 2008, 47, 9337. 
[58] T. Eguchi, Y. Kuge, K. Inoue, N. Yoshikawa, K. Mochida, T. Uwajima, Biosci. 
Biotechnol. Biochem. 1992, 56, 701. 
[59] J. M. Clemente-Jimenez, S. Martinez-Rodriguez, F. Rodriguez-Vico, F. J. Heras-
Vazquez, Recent. Pat. Biotechnol. 2008, 2, 35. 
[60] D. C. Lee, G. J. Kim, Y. K. Cha, C. Y. Lee, H. S. Kim, Biotechnol. Bioeng. 1997, 56, 449. 
[61] J. Altenbuchner, M. Siemann-Herzberg, C. Syldatk, Curr. Opin. Biotechnol. 2001, 12, 
559. 
[62] C. H. Kao, H. H. Lo, S. K. Hsu, W. H. Hsu, J. Biotechnol. 2008, 134, 231. 
[63] H. H. Lo, C. H. Kao, D. S. Lee, T. K. Yang, W. H. Hsu, Chirality 2003, 15, 699. 
[64] M. Battilotti, U. Barberini, J .Mol. Catal. 1988, 43, 343. 
[65] D. C. Lee, H. S. Kim, Biotechnol. Bioeng. 1998, 60, 729. 
[66] S.-K. Hsu, H.-H. Lo, W.-D. Lin, I.-C. Chen, C.-H. Kao, W.-H. Hsu, Process Biochem. 
2007, 42, 856. 
[67] M. Kobayashi, M. Goda, S. Shimizu, FEBS Lett. 1998, 439, 325. 
68] G. Volpato, R. C. Rodrigues, R. Fernandez-Lafuente, Curr. Med. Chem. 2010, 17, 
3855. 
[69] J. M. Hamilton-Miller, Int. J. Antimicrob. Agents 2008, 31, 189. 
[70] M. Arroyo, I. de la Mata, C. Acebal, M. P. Castillon, Appl. Microbiol. Biotechnol. 
2003, 60, 507. 
[71] J. Rajendhran, P. Gunasekaran, J. Biosci. Bioeng. 2004, 97, 1. 
[72] Y. Kim, W. G. Hol, Chem. Biol. 2001, 8, 1253. 
[73] A. K. Chandel, L. Venkateswar Rao, M. Lakshmi Narasu, O. V. Singh, Enzyme Micro. 
Tech. 2008, 42, 199. 
[74] R. V. Ulijn, L. De Martin, P. J. Halling, B. D. Moore, A. E. Janssen, J. Biotechnol. 2002, 
99, 215. 
[75] M. I. Youshko, L. M. van Langen, E. de Vroom, F. van Rantwijk, R. A. Sheldon, V. K. 
Svedas, Biotechnol. Bioeng. 2002, 78, 589. 
[76] Y. Asano, S. Yamaguchi, J Am Chem Soc 2005, 127, 7696. 
[77] S. Yamaguchi, H. Komeda, Y. Asano, Appl. Environ. Microbiol. 2007, 73, 5370. 
[78] K. Plhackova, V. Vojtisek, J. Plachy, Folia. Microbiol. (Praha) 1982, 27, 382. 
- 156 - 
[79] T. Sonke, S. Ernste, R. F. Tandler, B. Kaptein, W. P. Peeters, F. B. van Assema, M. G. 
Wubbolts, H. E. Schoemaker, Appl. Environ. Microbiol. 2005, 71, 7961. 
[80] C. Carboni, H. G. T. Kierkels, L. Gardossi, K. Tamiola, J. D. B., P. J. L. M. Quaedfliega, 
Tetrahedron: Asymmetry 2006, 17, 245. 
[81] D. H. Baek, S. J. Kwon, S. P. Hong, M. S. Kwak, M. H. Lee, J. J. Song, S. G. Lee, K. H. 
Yoon, M. H. Sung, Appl. Environ. Microbiol. 2003, 69, 980. 
[82] A. S. Bommarius, K. Drauz, H. Klenk, C. Wandrey, Ann. N. Y. Acad. Sci. 1992, 672, 
126. 
[83] L. A. Mounter, L. T. Dien, F. E. Bell, J. Biol. Chem. 1958, 233, 903. 
[84] F. E. Bell, L. A. Mounter, J. Biol. Chem. 1958, 233, 900. 
[85] H. K. Chenault, J. Dahmer, G. M. Whitesides, J. Am. Chem. Soc. 1989, 111, 6354. 
[86] H. S. Toogood, E. J. Hollingsworth, R. C. Brown, I. N. Taylor, S. J. C. Taylor, R. 
McCague, J. A. Littlechild, Extremophiles 2002, 6, 111. 
[87] K. Sakai, T. Obata, K. Ideta, M. Moriguchi, J. Ferment. Bioeng. 1991, 71, 79. 
[88] S. V. Story, A. M. Grunden, M. W. Adams, J. Bacteriol. 2001, 183, 4259. 
[89] O. May, S. Verseck, A. Bommarius, K. Drauz, Org. Process. Res. Dev. 2002, 6, 452. 
[90] T. C. Stadtman, P. Elliott, J. Biol. Chem. 1957, 228, 983. 
[91] S. Tokuyama, K. Hatano, Appl. Microbiol. Biotechnol. 1996, 44, 774. 
[92] S. K. Hsu, H. H. Lo, C. H. Kao, D. S. Lee, W. H. Hsu, Biotechnol. Prog. 2006, 22, 1578. 
[93] S. Tokuyama, K. Hatano, T. Takahashi, Biosci. Biotech. Bioch. 1994, 58, 24. 
[94] S. Tokuyama, K. Hatano, Appl. Microbiol. Biotechnol. 1995, 42, 884. 
[95] S. Tokuyama, K. Hatano, Appl. Microbiol. Biotechnol. 1995, 42, 853. 
[96] S. Shiun-Cheng, L. Chia-Yin, Enzyme Micro Tech 2002, 30, 647. 
[97] S. Verseck, A. Bommarius, M. R. Kula, Appl. Microbiol. Biotechnol. 2001, 55, 354. 
[98] W. C. Wang, W. C. Chiu, S. K. Hsu, C. L. Wu, C. Y. Chen, J. S. Liu, W. H. Hsu, J. Mol. 
Biol. 2004, 342, 155. 
[99] M. Hayashida, S. H. Kim, K. Takeda, T. Hisano, K. Miki, Proteins 2008, 71, 519. 
[100] J. B. Thoden, E. A. Taylor Ringia, J. B. Garrett, J. A. Gerlt, H. M. Holden, I. Rayment, 
Biochemistry 2004, 43, 5716. 
[101] E. A. Taylor Ringia, J. B. Garrett, J. B. Thoden, H. M. Holden, I. Rayment, J. A. Gerlt, 
Biochemistry 2004, 43, 224. 
[102] P. C. Babbitt, M. S. Hasson, J. E. Wedekind, D. R. Palmer, W. C. Barrett, G. H. Reed, I. 
Rayment, D. Ringe, G. L. Kenyon, J. A. Gerlt, Biochemistry 1996, 35, 16489. 
[103] D. R. Palmer, J. B. Garrett, V. Sharma, R. Meganathan, P. C. Babbitt, J. A. Gerlt, 
Biochemistry 1999, 38, 4252. 
[104] V. A. Klenchin, E. A. Taylor Ringia, J. A. Gerlt, I. Rayment, Biochemistry 2003, 42, 
14427. 
[105] M. E. Glasner, N. Fayazmanesh, R. A. Chiang, A. Sakai, M. P. Jacobson, J. A. Gerlt, P. 
C. Babbitt, J. Mol. Biol. 2006, 360, 228. 
[106] A. Sakai, D. F. Xiang, C. Xu, L. Song, W. S. Yew, F. M. Raushel, J. A. Gerlt, 
Biochemistry 2006, 45, 4455. 
[107] S. D. Brown, J. A. Gerlt, J. L. Seffernick, P. C. Babbitt, Genome Biol. 2006, 7, R8. 
[108] J. A. Gerlt, P. C. Babbitt, Annu. Rev. Biochem. 2001, 70, 209. 
[109] J. A. Gerlt, P. C. Babbitt, I. Rayment, Arch. Biochem. Biophys. 2005, 433, 59. 
[110] P. C. Babbitt, G. T. Mrachko, M. S. Hasson, G. W. Huisman, R. Kolter, D. Ringe, G. A. 
Petsko, G. L. Kenyon, J. A. Gerlt, Science 1995, 267, 1159. 
[111] J. Gerlt, Biochemistry 2009. 
[112] T. G. Spring, F. Wold, J. Biol. Chem. 1971, 246, 6797. 
[113] C. W. Levy, P. A. Buckley, S. Sedelnikova, Y. Kato, Y. Asano, D. W. Rice, P. J. Baker, 
Structure 2002, 10, 105. 
[114] J. A. Gerlt, F. M. Raushel, Curr. Opin. Chem. Biol. 2003, 7, 252. 
[115] J. F. Rakus, A. A. Fedorov, E. V. Fedorov, M. E. Glasner, J. E. Vick, P. C. Babbitt, S. C. 
Almo, J. A. Gerlt, Biochemistry 2007, 46, 12896. 
- 157 - 
[116] D. M. Schmidt, E. C. Mundorff, M. Dojka, E. Bermudez, J. E. Ness, S. Govindarajan, P. 
C. Babbitt, J. Minshull, J. A. Gerlt, Biochemistry 2003, 42, 8387. 
[117] J. E. Vick, D. M. Schmidt, J. A. Gerlt, Biochemistry 2005, 44, 11722. 
[118] J. E. Vick, J. A. Gerlt, Biochemistry 2007, 46, 14589. 
[119] D. Reardon, G. K. Farber, Faseb. J. 1995, 9, 497. 
[120] A. R. Raine, N. S. Scrutton, F. S. Mathews, Protein Sci. 1994, 3, 1889. 
[121] K. M. Fox, P. A. Karplus, Structure 1994, 2, 1089. 
[122] M. Henn-Sax, B. Hocker, M. Wilmanns, R. Sterner, Biol. Chem. 2001, 382, 1315. 
[123] D. M. Schmidt, B. K. Hubbard, J. A. Gerlt, Biochemistry 2001, 40, 15707. 
[124] J. Pozo-Dengra, A. I. Martínez-Gómeza, S. Martínez-Rodrígueza, J. M. Clemente-
Jiméneza, F. Rodríguez-Vicoa, L. H.-V. F.J., Process Biochem. 2009, 44, 835. 
[125] J. Pozo-Dengra, S. Martinez-Rodriguez, L. M. Contreras, J. Prieto, M. Andujar-
Sanchez, J. M. Clemente-Jimenez, F. J. Las Heras-Vazquez, F. Rodriguez-Vico, J. L. 
Neira, Biopolymers 2009, 91, 757. 
[126] T. J. Lupoli, H. Tsukamoto, E. H. Doud, T. S. Wang, S. Walker, D. Kahne, J. Am. Chem. 
Soc. 2011, 133, 10748. 
[127] S. K. Hsu, H. H. Loc, W. D. Lina, I. C. Chena, C. H. Kaoe, W. H. Hsu, Process. Biochem. 
2007, 42, 856. 
[128] T. B. Thompson, J. B. Garrett, E. A. Taylor, R. Meganathan, J. A. Gerlt, I. Rayment, 
Biochemistry 2000, 39, 10662. 
[129] J. A. Gerlt, P. G. Gassman, Biochemistry 1993, 32, 11943. 
[130] F. Cava, H. Lam, M. A. de Pedro, M. K. Waldor, Cell. Mol. Life Sci. 2011, 68, 817. 
[131] V. S. Lamzin, Z. Dauter, K. S. Wilson, Curr. Opin. Struc. Bio. 1995, 5, 830. 
[132] T. Yoshimura, M. Goto, FEBS J. 2008, 275, 3527. 
[133] J. Lee, D. G. Lee, Exp. Mol. Med. 2008, 40, 370. 
[134] M. L. Mangoni, N. Papo, J. M. Saugar, D. Barra, Y. Shai, M. Simmaco, L. Rivas, 
Biochemistry 2006, 45, 4266. 
[135] M. R. Levengood, C. C. Kerwood, C. Chatterjee, W. A. van der Donk, Chembiochem 
2009, 10, 911. 
[136] H. E. Umbarger, Annu. Rev. Biochem. 1978, 47, 532. 
[137] A. Watanabe, T. Yoshimura, B. Mikami, H. Hayashi, H. Kagamiyama, N. Esaki, J. Biol. 
Chem. 2002, 277, 19166. 
[138] S. Y. Choi, N. Esaki, T. Yoshimura, K. Soda, J. Biochem. 1992, 112, 139. 
[139] S. Glavas, M. E. Tanner, Biochemistry 1999, 38, 4106. 
[140] T. Yamauchi, S. Y. Choi, H. Okada, M. Yohda, H. Kumagai, N. Esaki, K. Soda, J. Biol. 
Chem. 1992, 267, 18361. 
[141] K. Y. Hwang, C. S. Cho, S. S. Kim, H. C. Sung, Y. G. Yu, Y. Cho, Nat. Struct. Biol. 1999, 
6, 422. 
[142] M. A. Spies, J. G. Reese, D. Dodd, K. L. Pankow, S. R. Blanke, J. Baudry, J. Am. Chem. 
Soc. 2009, 131, 5274. 
[143] A. Buschiazzo, M. Goytia, F. Schaeffer, W. Degrave, W. Shepard, C. Gregoire, N. 
Chamond, A. Cosson, A. Berneman, N. Coatnoan, P. M. Alzari, P. Minoprio, Proc. 
Natl. Acad. Sci. U. S. A. 2006, 103, 1705. 
[144] M. Kanda, K. Hori, T. Kurotsu, S. Miura, Y. Saito, J. Biochem. 1989, 105, 653. 
[145] C. L. Chen, L. K. Chang, Y. S. Chang, S. T. Liu, J. S. Tschen, Mol. Gen. Genet. 1995, 
248, 121. 
[146] S. G. Laland, O. Froyshov, C. Gilhuus-Moe, T. L. Zimmer, Nat. New. Biol. 1972, 239, 
43. 
[147] B. Marrs, S. Delagrave, D. Murphy, Curr. Opin. Microbiol .1999, 2, 241. 
[148] J. D. Rozzell, Bioorg. Med. Chem. 1999, 7, 2253. 
[149] D. Georlette, V. Blaise, T. Collins, S. D'Amico, E. Gratia, A. Hoyoux, J. C. Marx, G. 
Sonan, G. Feller, C. Gerday, FEMS Microbiol. Rev. 2006, 28, 25. 
[150] J. L. Jestin, S. Vichier-Guerre, Res. Microbiol. 2005, 156, 961. 
- 158 - 
[151] K. A. Powell, S. W. Ramer, S. B. Del Cardayre, W. P. Stemmer, M. B. Tobin, P. F. 
Longchamp, G. W. Huisman, Angew. Chem. Int. Ed. Engl. 2001, 40, 3948. 
[152] O. Khersonsky, C. Roodveldt, D. S. Tawfik, Curr. Opin. Chem. Biol. 2006, 10, 498. 
[153] H. Kunz, Angew. Chem. Int. Ed. Engl. 2002, 41, 4439. 
[154] M. Adamczak, S. H. Krishna, Food Technol. Biotechnol. 2004, 42, 251. 
[155] A. Glieder, E. T. Farinas, F. H. Arnold, Nat. Biotechnol. 2002, 20, 1135. 
[156] R. Fasan, Y. T. Meharenna, C. D. Snow, T. L. Poulos, F. H. Arnold, J. Mol. Biol. 2008, 
383, 1069. 
[157] C. Neylon, Nucleic Acids Res. 2004, 32, 1448. 
[158] M. T. Reetz, D. Kahakeaw, R. Lohmer, Chembiochem 2008, 9, 1797. 
[159] J. M. Smith, Nature 1970, 225, 563. 
[160] M. T. Reetz, L. W. Wang, M. Bocola, Angew. Chem. Int. Ed. Engl. 2006, 45, 1236. 
[161] T. S. Rasila, M. I. Pajunen, H. Savilahti, Anal. Biochem. 2009, 388, 71. 
[162] T. W. Wang, H. Zhu, X. Y. Ma, T. Zhang, Y. S. Ma, D. Z. Wei, Mol. Biotechnol. 2006, 
34, 55. 
[163] A. Greener, M. Callahan, B. Jerpseth, Methods Mol. Biol. 1996, 57, 375. 
[164] R. D. Sleator, C. G. Gahan, C. Hill, Appl. Environ. Microbiol. 2001, 67, 4560. 
[165] P. L. Foster, Methods Enzymol. 1991, 204, 114. 
[166] E. O. McCullum, B. A. Williams, J. Zhang, J. C. Chaput, Methods Mol. Biol. 2010, 634, 
103. 
[167] J. H. Spee, W. M. de Vos, O. P. Kuipers, Nucleic Acids. Res. 1993, 21, 777. 
[168] M. Zaccolo, D. M. Williams, D. M. Brown, E. Gherardi, J. Mol. Biol. 1996, 255, 589. 
[169] T. Vanhercke, C. Ampe, L. Tirry, P. Denolf, Anal. Biochem. 2005, 339, 9. 
[170] T. S. Wong, D. Roccatano, M. Zacharias, U. Schwaneberg, J. Mol. Biol. 2006, 355, 
858. 
[171] H. Murakami, T. Hohsaka, M. Sisido, Nat. Biotechnol. 2002, 20, 76. 
[172] F. H. Crick, L. Barnett, S. Brenner, R. J. Watts-Tobin, Nature 1961, 192, 1227. 
[173] D. H. Ardell, G. Sella, J. Mol. Evol. 2001, 53, 269. 
[174] T. S. Wong, D. Roccatano, U. Schwaneberg, Biocatal. Biotransform. 2007, 25, 229. 
[175] W. P. Stemmer, Nature 1994, 370, 389. 
[176] W. P. Stemmer, Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 10747. 
[177] W. M. Coco, W. E. Levinson, M. J. Crist, H. J. Hektor, A. Darzins, P. T. Pienkos, C. H. 
Squires, D. J. Monticello, Nat. Biotechnol. 2001, 19, 354. 
[178] G. S. Roeder, Genes Dev. 1997, 11, 2600. 
[179] Y. An, J. Ji, A. Lv, R. Huang, Z. Xiu, Mol. Biol. (Mosk) 2006, 40, 546. 
[180] H. Zhao, F. H. Arnold, Nucleic Acids Res. 1997, 25, 1307. 
[181] A. Crameri, E. A. Whitehorn, E. Tate, W. P. Stemmer, Nat. Biotechnol. 1996, 14, 315. 
[182] L. Zheng, U. Baumann, J. L. Reymond, Nucleic Acids Res. 2004, 32, e115. 
[183] D. L. Steffens, J. G. W. Williams, J. Biomol. Tech. 2007, 18, 147. 
[184] M. T. Reetz, D. Kahakeaw, J. Sanchis, Mol. Biosyst. 2009, 5, 115. 
[185] J. Sanchis, L. Fernandez, J. D. Carballeira, J. Drone, Y. Gumulya, H. Hobenreich, D. 
Kahakeaw, S. Kille, R. Lohmer, J. J. Peyralans, J. Podtetenieff, S. Prasad, P. Soni, A. 
Taglieber, S. Wu, F. E. Zilly, M. T. Reetz, Appl. Microbiol. Biotechnol. 2008, 81, 387. 
[186] K. Miyazaki, Methods Enzymol. 2011, 498, 399. 
[187] D. Wei, M. Li, X. Zhang, L. Xing, Anal. Biochem. 2004, 331, 401. 
[188] M. T. Reetz, S. Prasad, J. D. Carballeira, Y. Gumulya, M. Bocola, J. Am. Chem. Soc. 
2010, 132, 9144. 
[189] M. T. Reetz, S. Wu, Chem. Commun. (Camb) 2008, 5499. 
[190] M. T. Reetz, J. D. Carballeira, Nat. Protoc. 2007, 2, 891. 
[191] M. T. Reetz, M. Bocola, J. D. Carballeira, D. Zha, A. Vogel, Angew. Chem. Int. Ed. 
Engl. 2005, 44, 4192. 
[192] Y. P. Lai, J. Huang, L. F. Wang, J. Li, Z. R. Wu, Biotechnol. Bioeng. 2004, 86, 622. 
- 159 - 
[193] J. Nelms, R. M. Edwards, J. Warwick, I. Fotheringham, Appl. Environ. Microbiol. 
1992, 58, 2592. 
[194] U. Mohan, U. C. Banerjee, Chembiochem 2008, 9, 2238. 
[195] J. L. Guenet, Genetica 2004, 122, 9. 
[196] Y. An, W. Wu, A. Lv, Biochimie 2010, 92, 1081. 
[197] W. C. Tseng, J. W. Lin, T. Y. Wei, T. Y. Fang, Anal. Biochem. 2008, 375, 376. 
[198] Y. L. Boersma, M. J. Droge, A. M. van der Sloot, T. Pijning, R. H. Cool, B. W. Dijkstra, 
W. J. Quax, Chembiochem 2008, 9, 1110. 
[199] M. T. Reetz, H. Hobenreich, P. Soni, L. Fernandez, Chem. Commun. (Camb) 2008, 
5502. 
[200] M. T. Reetz, Angew. Chem. Int. Ed. Engl. 2011, 50, 138. 
[201] T. Yano, S. Oue, H. Kagamiyama, Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 5511. 
[202] S. Delagrave, D. J. Murphy, J. L. Pruss, A. M. Maffia, 3rd, B. L. Marrs, E. J. Bylina, W. 
J. Coleman, C. L. Grek, M. R. Dilworth, M. M. Yang, D. C. Youvan, Protein Eng. 2001, 
14, 261. 
[203] M. Gabler, M. Hensel, L. Fischer, Enzyme Microb. Technol. 2000, 27, 605. 
[204] S. Bershtein, D. S. Tawfik, Curr. Opin. Chem. Biol. 2008, 12, 151. 
[205] C. Heddle, S. L. Mazaleyrat, Protein Eng. Des. Sel. 2007, 20, 327. 
[206] Y. Ikenaka, H. Nanba, K. Yajima, Y. Yamada, M. Takano, S. Takahashi, Biosci. 
Biotechnol. Biochem. 1998, 62, 1672. 
[207] H. Kaltwasser, H. G. Schlegel, Anal. Biochem. 1966, 16, 132. 
[208] S. Fong, T. D. Machajewski, C. C. Mak, C. Wong, Chem. Biol. 2000, 7, 873. 
[209] K. Kiianitsa, J. A. Solinger, W. D. Heyer, Anal. Biochem. 2003, 321, 266. 
[210] S. van den Berg, P. A. Lofdahl, T. Hard, H. Berglund, J. Biotechnol. 2006, 121, 291. 
[211] S. Becker, H. U. Schmoldt, T. M. Adams, S. Wilhelm, H. Kolmar, Curr. Opin. 
Biotechnol. 2004, 15, 323. 
[212] S. Becker, H. Hobenreich, A. Vogel, J. Knorr, S. Wilhelm, F. Rosenau, K. E. Jaeger, M. 
T. Reetz, H. Kolmar, Angew. Chem. Int. Ed. Engl. 2008, 47, 5085. 
[213] A. Zanghellini, L. Jiang, A. M. Wollacott, G. Cheng, J. Meiler, E. A. Althoff, D. 
Rothlisberger, D. Baker, Protein Sci. 2006, 15, 2785. 
[214] M. Hohne, S. Schatzle, H. Jochens, K. Robins, U. T. Bornscheuer, Nat. Chem. Biol. 
2010, 6, 807. 
[215] K. A. Dill, S. B. Ozkan, T. R. Weikl, J. D. Chodera, V. A. Voelz, Curr. Opin. Struct. Biol. 
2007, 17, 342. 
[216] K. A. Dill, S. B. Ozkan, M. S. Shell, T. R. Weikl, Annu. Rev. Biophys. 2008, 37, 289. 
[217] M. A. Dwyer, L. L. Looger, H. W. Hellinga, Science 2004, 304, 1967. 
[218] M. A. Dwyer, L. L. Looger, H. W. Hellinga, Science 2008, 319, 569. 
[219] W. J. Albery, J. R. Knowles, Biochemistry 1976, 15, 5627. 
[220] J. B. Siegel, A. Zanghellini, H. M. Lovick, G. Kiss, A. R. Lambert, J. L. St Clair, J. L. 
Gallaher, D. Hilvert, M. H. Gelb, B. L. Stoddard, K. N. Houk, F. E. Michael, D. Baker, 
Science 2010, 329, 309. 
[221] D. Rothlisberger, O. Khersonsky, A. M. Wollacott, L. Jiang, J. DeChancie, J. Betker, J. 
L. Gallaher, E. A. Althoff, A. Zanghellini, O. Dym, S. Albeck, K. N. Houk, D. S. Tawfik, 
D. Baker, Nature 2008, 453, 190. 
[222] K. Auclair, A. Sutherland, J. Kennedy, D. J. Witter, J. P. Van den Heever, C. R. 
Hutchinson, J. C. Vederas, J. Am. Chem. Soc. 2000, 122, 11519. 
[223] C. R. Guimaraes, M. Udier-Blagovic, W. L. Jorgensen, J. Am. Chem. Soc. 2005, 127, 
3577. 
[224] D. Hilvert, K. W. Hill, K. D. Nared, M. T. M. Auditor, J. Am. Chem. Soc. 1989, 111, 
9261. 
[225] A. A. Desai, Angew. Chem. Int. Ed. Engl. 2011, 50, 1974. 
[226] A. Iwasaki, Y. Yamada, N. Kizaki, Y. Ikenaka, J. Hasegawa, Appl. Microbiol. 
Biotechnol. 2006, 69, 499. 
- 160 - 
[227] B. K. Cho, H. Y. Park, J. H. Seo, J. Kim, T. J. Kang, B. S. Lee, B. G. Kim, Biotechnol. 
Bioeng. 2008, 99, 275. 
[228] J.-S. Shin, B.-G. Kim, J. Org. Chem. 2002, 67, 2848. 
[229] S. Royer, PhD, The University of Edinburgh, UK (2005). 
[230] M. M. Kaplan, M. Flavin, Biochim. Biophys. Acta. 1965, 104, 390. 
[231] M. M. Kaplan, M. Flavin, J. Biol. Chem. 1966, 241, 5781. 
[232] M. M. Kaplan, M. Flavin, J. Biol. Chem. 1966, 241, 4463. 
[233] J. Wild, T. Klopotowski, Mol. Gen. Genet. 1981, 181, 373. 
[234] J. Wild, M. Filutowicz, T. Klopotowski, Arch. Microbiol. 1978, 118, 71. 
[235] K. A. Datsenko, B. L. Wanner, Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 6640. 
[236] O. Kuchner, F. H. Arnold, Trends Biotechnol. 1997, 15, 523. 
[237] M. J. Stark, Gene 1987, 51, 255. 
[238] P. R. Jensen, H. V. Westerhoff, O. Michelsen, Eur. J. Biochem. 1993, 211, 181. 
[239] L. Robert, G. Paul, Y. Chen, F. Taddei, D. Baigl, A. B. Lindner, Mol. Syst. Biol. 2010, 6, 
357. 
[240] R. S. Donovan, C. W. Robinson, B. R. Glick, J. Ind. Microbiol. 1996, 16, 145. 
[241] T. Baba, T. Ara, M. Hasegawa, Y. Takai, Y. Okumura, M. Baba, K. A. Datsenko, M. 
Tomita, B. L. Wanner, H. Mori, Mol. Syst. Biol. 2006, 2, 2006 0008. 
[242] R. B. Roberts, P. H. Abelson, D. B. Crowie, E. T. Bolton, R. J. Britten, Carnegie Inst. 
Washington Publ. 1955, article 607. 
[243] J. Lederberg, Methods Med. Res. 1950, 3, 5. 
[244] M. Mandel, A. Higa, J. Mol. Biol. 1970, 53, 159. 
[245] W. J. Dower, J. F. Miller, C. W. Ragsdale, Nucleic Acids Res. 1988, 16, 6127. 
[246] X. Shi, T. Karkut, M. Alting-Mees, M. Chamankhah, S. M. Hemmingsen, D. D. 
Hegedus, Anal. Biochem. 2003, 320, 152. 
[247] S. B. Leslie, E. Israeli, B. Lighthart, J. H. Crowe, L. M. Crowew, Appl. Enviorn. Mirco. 
1995, 61, 3592. 
[248] B. T. Storey, E. E. Noiles, K. A. Thompson, Cryobiology 1998, 37, 46. 
[249] S. N. Ho, H. D. Hunt, R. M. Horton, J. K. Pullen, P. L. R., Gene 1989, 77, 51. 
[250] Y. Nakamura, T. Gojobori, T. Ikemura, Nucleic Acids Res. 2000, 28, 292. 
[251] G. von Heijne, J. Mol. Biol. 1991, 218, 499. 
[252] J. Pozo-Dengra, A. I. Martınez-Gomez, S. Martınez-Rodrıguez, J. M. Clemente-
Jimenez, F. Rodrıguez-Vico, F. J. Las Heras-Vazquez, Process Biochem. 2009, 44, 835. 
[253] Y. Okamoto, T. Ikai, Chem. Soc. Rev. 2008, 37, 2593. 
[254] D. W. Aswad, Anal. Biochem. 1984, 137, 405. 
[255] D. W. Armstrong, Y. Youbang Liu, K. H. Ekborgott, Chirality 1995, 7, 474. 
[256] Y. P. Yu, S. H. Wu, Chirality 2001, 13, 231. 
[257] C. N. Pace, F. Vajdos, L. Fee, G. Grimsley, T. Gray, Protein Sci. 1995, 4, 2411. 
[258] A. Narmandakh, S. L. Bearne, Protein Expr. Purif. 2010, 69, 39. 
[259] J. Kiraga, P. Mackiewicz, D. Mackiewicz, M. Kowalczuk, P. Biecek, N. Polak, K. 
Smolarczyk, M. R. Dudek, S. Cebra, BMC Genomics 2007, 8. 
[260] S. C. Su, C. Y. Lee, Enzyme Microb. Tech. 2002, 30, 647. 
[261] J. L. Bada, Naturwissenschaften 1975, 62, 71. 
[262] L. Canoira, M. J. Garcia-martinez, J. F. Llamas, O. J. E., T. D. Torres, Int. J. Chem. 
Kinet. 2003, 35, 576. 
[263] R. S. Ward, Tetrahedron: Asymmetry 1995, 6, 1475. 
[264] S. Y. Lam, R. C. Yeung, T. H. Yu, K. H. Sze, K. B. Wong, PLoS Biol. 2011, 9, e1001027. 
[265] K. M. Polizzi, A. S. Bommarius, J. M. Broering, J. F. Chaparro-Riggers, Curr. Opin. 
Chem. Biol. 2007, 11, 220. 
[266] U. B. Ericsson, B. M. Hallberg, G. T. Detitta, N. Dekker, P. Nordlund, Anal. Biochem. 
2006, 357, 289. 
[267] S. D'Amico, J. C. Marx, C. Gerday, G. Feller, J. Biol. Chem. 2003, 278, 7891. 
[268] P. A. Fields, G. N. Somero, Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 11476. 
- 161 - 
[269] B. K. Shoichet, W. A. Baase, R. Kuroki, M. B. W., Proc. Natl. Acad. Sci. U. S. A. 1995, 
92, 452. 
[270] S. Heimbecher, Y. C. Lee, S. E. Tabibi, Y. S. H., J. Chromatogr. B. 1997, 691, 173. 
[271] E. F. Birse, S. A. Eaton, D. E. Jane, P. L. St J. Jones, R. H. P. Porter, P. C. K. Pook, D. C. 
Sunter, P. M. Udvarhely, B. Wharton, P. J. Roberts, T. F. Salt, J. C. Watkins, 
Neuroscience 1993, 52, 481. 
[272] R. C. Lloyd, M. C. Lloyd, M. E. B. Smith, K. E. Holt, J. P. Swift, P. A. Keene, S. J. C. 
Taylor, R. McCague, Tetrahedron 2004, 60, 717. 
[273] J. Winter, J. Appl. Cryst 2010, 43, 186. 
[274] A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, R. J. 
Read, J. Appl. Crystallogr. 2007, 40, 658. 
[275] P. Emsley, K. Cowtan, Acta. Crystallogr. D. Biol. Crystallogr. 2004, 60, 2126. 
[276] G. N. Murshudov, A. A. Vagin, E. J. Dodson, Acta. Crystallogr. D. Biol. Crystallogr. 
1997, 53, 240. 
[277] R. A. Laskowski, M. W. MacArthur, D. S. Moss, J. M. Thornton, J. Appl. Cryst. 1993, 
26, 283. 
 
 
 
 
